antimycobacterial drug - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	antimycobacterial drug	go back to main search page
Accession:	CHEBI:64912	browse the term
Definition:	A drug used to treat or prevent infections caused by Mycobacteria, a genus of actinobacteria. Aerobic and nonmotile, members of the genus include the pathogens responsible for causing tuberculosis and leprosy.
Synonyms:	related_synonym:	antimycobacterial agent; antimycobacterial agents; antimycobacterial drugs; antimycobacterials; antimycobacterium

show annotations for term's descendants Sort by:
Rat (1265 ) Mouse (1327 ) Human (1308 ) Chinchilla (0 ) Bonobo (0 ) Dog (2 ) Squirrel (0 ) Pig (1 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (1265)

3-nitropropanoic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions
increases activity

EXP

saroglitazar inhibits the reaction [3-nitropropionic acid results in increased activity of ACHE protein]; thymoquinone inhibits the reaction [3-nitropropionic acid results in increased activity of ACHE protein]; trandolapril inhibits the reaction [3-nitropropionic acid results in increased activity of ACHE protein]

PMID:25445565 PMID:27206696 PMID:39326639

NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

EXP

3-nitropropionic acid results in decreased phosphorylation of AKT1 protein
methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased phosphorylation of AKT1 protein]]; N(6)-cyclohexyladenosine inhibits the reaction [3-nitropropionic acid results in decreased phosphorylation of AKT1 protein]; Topiramate inhibits the reaction [3-nitropropionic acid results in decreased phosphorylation of AKT1 protein]; Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased phosphorylation of AKT1 protein]

PMID:29753867 PMID:36509115 PMID:38513929

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

BCL2-associated agonist of cell death

multiple interactions
increases expression

EXP

naringin inhibits the reaction [3-nitropropionic acid results in increased expression of BAD mRNA]

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

BCL2 associated X, apoptosis regulator

affects localization
increases expression
multiple interactions

EXP

3-nitropropionic acid affects the localization of BAX protein
3-nitropropionic acid results in increased expression of BAX mRNA; 3-nitropropionic acid results in increased expression of BAX protein
[Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BAX protein; Ginkgo biloba extract inhibits the reaction [3-nitropropionic acid results in increased expression of BAX mRNA]; methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of BAX protein]]; naringin inhibits the reaction [3-nitropropionic acid results in increased expression of BAX mRNA]; Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of BAX protein]; ursodoxicoltaurine inhibits the reaction [3-nitropropionic acid affects the localization of BAX protein]

PMID:11080188 PMID:15571979 PMID:21827809 PMID:21945202 PMID:38513929

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

EXP
ISO

[Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BCL2 protein; BCL2 protein promotes the reaction [BDNF protein results in decreased susceptibility to 3-nitropropionic acid]; methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased expression of BCL2 protein]]; naringin inhibits the reaction [3-nitropropionic acid results in decreased expression of BCL2 mRNA]; Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased expression of BCL2 protein]
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]]
3-nitropropionic acid results in decreased expression of BCL2 mRNA; 3-nitropropionic acid results in decreased expression of BCL2 protein

PMID:15571979 PMID:19428112 PMID:21945202 PMID:37308051 PMID:38513929

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

decreases expression
multiple interactions

EXP
ISO

3-nitropropionic acid results in decreased expression of BCL2L1 mRNA
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein]]
Ginkgo biloba extract inhibits the reaction [3-nitropropionic acid results in decreased expression of BCL2L1 mRNA]

PMID:21827809 PMID:37308051

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

brain-derived neurotrophic factor

decreases response to substance
decreases expression
multiple interactions

EXP

BDNF protein results in decreased susceptibility to 3-nitropropionic acid
3-nitropropionic acid results in decreased expression of BDNF protein
BCL2 protein promotes the reaction [BDNF protein results in decreased susceptibility to 3-nitropropionic acid]; Dinitrochlorobenzene inhibits the reaction [BDNF protein results in decreased susceptibility to 3-nitropropionic acid]; KT 5823 inhibits the reaction [BDNF protein results in decreased susceptibility to 3-nitropropionic acid]; N(6)-cyclohexyladenosine inhibits the reaction [3-nitropropionic acid results in decreased expression of BDNF protein]; saroglitazar inhibits the reaction [3-nitropropionic acid results in decreased expression of BDNF protein]; Topiramate inhibits the reaction [3-nitropropionic acid results in decreased expression of BDNF protein]

PMID:19428112 PMID:29753867 PMID:36509115 PMID:39326639

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657

G

caspase 2

increases activity

EXP

3-nitropropionic acid results in increased activity of CASP2 protein

NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:72,116,246...72,134,022

G

caspase 3

increases activity
increases expression
multiple interactions
increases cleavage

EXP
ISO

3-nitropropionic acid results in increased activity of CASP3 protein
3-nitropropionic acid results in increased expression of CASP3 protein
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]]
3-nitropropionic acid results in increased cleavage of CASP3 protein
methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of CASP3 protein]]; naringin inhibits the reaction [3-nitropropionic acid results in increased cleavage of CASP3 protein]; Tacrolimus inhibits the reaction [3-nitropropionic acid results in increased activity of CASP3 protein]; Topiramate inhibits the reaction [3-nitropropionic acid results in increased activity of CASP3 protein]; Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of CASP3 protein]

PMID:15571979 PMID:21945202 PMID:29753867 PMID:37308051 PMID:38513929

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

increases activity

EXP

3-nitropropionic acid results in increased activity of CASP8 protein

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

increases activity

EXP

3-nitropropionic acid results in increased activity of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

catalase

multiple interactions
decreases activity
decreases expression

EXP

3-nitropropionic acid affects the reaction [[lead acetate results in increased abundance of Lead] affects the reaction [Ethanol affects the expression of CAT protein]]; 3-nitropropionic acid affects the reaction [[lead acetate results in increased abundance of Lead] which affects the expression of CAT protein]; 3-nitropropionic acid affects the reaction [Ethanol affects the expression of CAT protein]; Cyclosporine inhibits the reaction [3-nitropropionic acid results in decreased expression of CAT protein]; naringin inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]; Nitric Oxide promotes the reaction [Sertraline inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]]; Nitric Oxide promotes the reaction [Venlafaxine Hydrochloride inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]]; Sertraline inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]; thymoquinone analog inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]; trandolapril inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]; Venlafaxine Hydrochloride inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]

PMID:20305041 PMID:20448265 PMID:21945202 PMID:25445565 PMID:27206696 More...

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

cyclin D1

increases expression

EXP

3-nitropropionic acid results in increased expression of CCND1 protein

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin-dependent kinase 4

increases expression

EXP

3-nitropropionic acid results in increased expression of CDK4 protein

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163

G

chromosome transmission fidelity factor 18

decreases expression

ISO

3-nitropropionic acid results in decreased expression of CHTF18 mRNA

NCBI chr10:15,247,525...15,255,573
Ensembl chr10:15,246,362...15,255,685

G

cannabinoid receptor 1

affects expression

EXP

3-nitropropionic acid affects the expression of CNR1 mRNA

NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252

G

cytochrome c oxidase subunit 4i1

decreases expression

ISO

3-nitropropionic acid results in decreased expression of COX4I1 mRNA

NCBI chr19:65,630,383...65,636,623
Ensembl chr19:65,630,432...65,636,624

G

cytochrome c oxidase subunit 4i2

increases response to substance
increases expression

ISO

COX4I2 mRNA results in increased susceptibility to 3-nitropropionic acid
3-nitropropionic acid increases expression of Cox4i2 mRNA in primary astrocytes
3-nitropropionic acid results in increased expression of COX4I2 mRNA

CTD
RGD

PMID:19306371 PMID:19306371

NCBI chr 3:161,686,193...161,699,605
Ensembl chr 3:161,689,017...161,699,602

G

cAMP responsive element binding protein 1

multiple interactions
decreases expression
decreases phosphorylation

EXP

N(6)-cyclohexyladenosine inhibits the reaction [3-nitropropionic acid results in decreased phosphorylation of CREB1 protein]; saroglitazar inhibits the reaction [3-nitropropionic acid results in decreased expression of CREB1 protein]; Topiramate inhibits the reaction [3-nitropropionic acid results in decreased phosphorylation of CREB1 protein]

PMID:29753867 PMID:36509115 PMID:39326639

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

cysteine-rich with EGF-like domains 1

decreases expression

ISO

3-nitropropionic acid results in decreased expression of CRELD1 mRNA

NCBI chr 4:148,187,510...148,197,120
Ensembl chr 4:148,187,265...148,197,116

G

dynamin 1-like

increases expression

EXP

3-nitropropionic acid results in increased expression of DNM1L protein

NCBI chr11:98,084,049...98,135,663
Ensembl chr11:98,085,397...98,137,420

G

energy homeostasis associated

decreases expression

ISO

3-nitropropionic acid results in decreased expression of ENHO mRNA

NCBI chr 5:61,596,860...61,598,657
Ensembl chr 5:61,596,860...61,598,657

G

enolase 2

decreases expression
multiple interactions

EXP

3-nitropropionic acid results in decreased expression of ENO2 mRNA
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of ENO2 mRNA]

NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220

G

fibrinogen C domain containing 1

decreases expression

ISO

3-nitropropionic acid results in decreased expression of FIBCD1 mRNA

NCBI chr 3:35,490,459...35,524,142
Ensembl chr 3:35,490,459...35,524,142

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions
increases expression

EXP

Ginkgo biloba extract inhibits the reaction [3-nitropropionic acid results in increased expression of GAPDH mRNA]

NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

EXP

[naringin co-treated with 3-nitropropionic acid] results in increased expression of GCLC mRNA

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

G protein-coupled receptor 37-like 1

decreases expression

ISO

3-nitropropionic acid results in decreased expression of GPR37L1 mRNA

NCBI chr13:49,150,355...49,157,204
Ensembl chr13:49,150,359...49,157,204

G

glutamate ionotropic receptor AMPA type subunit 2

decreases expression
multiple interactions

EXP

3-nitropropionic acid results in decreased expression of GRIA2 mRNA
topiramate inhibits the reaction [3-nitropropionic acid results in decreased expression of GRIA2 mRNA]

NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:168,247,496...168,367,616

G

glutamate ionotropic receptor NMDA type subunit 2B

increases response to substance

EXP

GRIN2B protein results in increased susceptibility to 3-nitropropionic acid

NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:170,322,617...170,773,570

G

glycogen synthase kinase 3 beta

decreases phosphorylation
multiple interactions

EXP

3-nitropropionic acid results in decreased phosphorylation of GSK3B protein
topiramate inhibits the reaction [3-nitropropionic acid results in decreased phosphorylation of GSK3B protein]

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

glutathione-disulfide reductase

multiple interactions
decreases activity

EXP

naringin inhibits the reaction [3-nitropropionic acid results in decreased activity of GSR protein]; thymoquinone analog inhibits the reaction [3-nitropropionic acid results in decreased activity of GSR protein]; thymoquinone inhibits the reaction [3-nitropropionic acid results in decreased activity of GSR protein]

PMID:21945202 PMID:27206696 PMID:37116597

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

glutathione S-transferase pi 1

multiple interactions

EXP

[naringin co-treated with 3-nitropropionic acid] results in increased expression of GSTP1 mRNA

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

H2A.X variant histone

increases expression

ISO

3-nitropropionic acid results in increased expression of H2AX protein

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

heme oxygenase 1

multiple interactions
decreases activity

EXP

[naringin co-treated with 3-nitropropionic acid] results in increased expression of HMOX1 mRNA; methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased activity of HMOX1 protein]]; Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased activity of HMOX1 protein]

PMID:22871521 PMID:38513929

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heat shock protein family A (Hsp70) member 5

increases expression

EXP

3-nitropropionic acid results in increased expression of HSPA5 protein

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

heat shock protein family A (Hsp70) member 9

increases expression

EXP

3-nitropropionic acid results in increased expression of HSPA9 protein

NCBI chr18:26,810,004...26,832,958
Ensembl chr18:26,804,774...26,828,398

G

insulin-like growth factor binding protein 4

decreases expression

ISO

3-nitropropionic acid results in decreased expression of IGFBP4 mRNA

NCBI chr10:84,491,471...84,503,487
Ensembl chr10:84,485,775...84,503,473

G

interleukin 1 beta

multiple interactions
increases expression

EXP

methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of IL1B protein]]; Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of IL1B protein]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

increases expression
multiple interactions

ISO
EXP

3-nitropropionic acid results in increased expression of IL6 mRNA
saroglitazar inhibits the reaction [3-nitropropionic acid results in increased expression of IL6 protein]
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of IL6 mRNA]

PMID:28853159 PMID:39326639

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

inositol 1,4,5-trisphosphate receptor, type 1

decreases expression

EXP

3-nitropropionic acid results in decreased expression of ITPR1 protein

NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:142,743,334...143,066,504

G

Janus kinase 2

increases phosphorylation
multiple interactions

EXP

3-nitropropionic acid results in increased phosphorylation of JAK2 protein
methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in increased phosphorylation of JAK2 protein]]; Tropisetron inhibits the reaction [3-nitropropionic acid results in increased phosphorylation of JAK2 protein]

NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762

G

kelch repeat and BTB domain containing 12

increases expression

ISO

3-nitropropionic acid results in increased expression of KBTBD12 mRNA

NCBI chr 4:122,571,903...122,645,895
Ensembl chr 4:122,573,526...122,645,810

G

L1 cell adhesion molecule

decreases expression

ISO

3-nitropropionic acid results in decreased expression of L1CAM mRNA

NCBI chr X:156,748,597...156,775,116
Ensembl chr X:156,748,597...156,775,077

G

leukocyte receptor tyrosine kinase

decreases expression

ISO

3-nitropropionic acid results in decreased expression of LTK mRNA

NCBI chr 3:127,188,479...127,195,356
Ensembl chr 3:127,188,480...127,197,402

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

ISO

3-nitropropionic acid inhibits the reaction [Curcumin results in increased localization of MAP1LC3B protein]

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen activated protein kinase 1

decreases phosphorylation
multiple interactions

EXP

3-nitropropionic acid results in decreased phosphorylation of MAPK1 protein
N(6)-cyclohexyladenosine inhibits the reaction [3-nitropropionic acid results in decreased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

EXP

N(6)-cyclohexyladenosine inhibits the reaction [3-nitropropionic acid results in decreased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

microtubule-associated protein tau

affects localization

EXP

3-nitropropionic acid affects the localization of MAPT protein

NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108

G

mitofusin 1

increases expression

EXP

3-nitropropionic acid results in increased expression of MFN1 protein

NCBI chr 2:117,240,525...117,288,017
Ensembl chr 2:117,241,759...117,290,190

G

marker of proliferation Ki-67

decreases expression

EXP

3-nitropropionic acid results in decreased expression of MKI67 protein

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases expression
decreases expression

EXP

[naringin co-treated with 3-nitropropionic acid] affects the localization of NFE2L2 protein; methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased expression of NFE2L2 protein]]; saroglitazar inhibits the reaction [3-nitropropionic acid results in increased expression of NFE2L2 protein]; Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased expression of NFE2L2 protein]

PMID:22871521 PMID:38513929 PMID:39326639

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor kappa B subunit 1

decreases response to substance

ISO

NFKB1 results in decreased susceptibility to 3-nitropropionic acid

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

nitric oxide synthase 2

increases expression
multiple interactions

EXP
ISO

3-nitropropionic acid results in increased expression of NOS2 mRNA; 3-nitropropionic acid results in increased expression of NOS2 protein
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of NOS2 mRNA]; T 0070907 inhibits the reaction [delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of NOS2 mRNA]]
N(6)-cyclohexyladenosine inhibits the reaction [3-nitropropionic acid results in increased expression of NOS2 protein]; naringin inhibits the reaction [3-nitropropionic acid results in increased expression of NOS2 mRNA]

PMID:22871521 PMID:28853159 PMID:36509115

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

EXP

[naringin co-treated with 3-nitropropionic acid] results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

neurotrophic receptor tyrosine kinase 2

multiple interactions
decreases phosphorylation

EXP

N(6)-cyclohexyladenosine inhibits the reaction [3-nitropropionic acid results in decreased phosphorylation of NTRK2 protein]

NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,564,570...5,874,628

G

proenkephalin

decreases expression
multiple interactions

EXP

3-nitropropionic acid results in decreased expression of PENK mRNA
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of PENK mRNA]

NCBI chr 5:21,981,381...21,987,074
Ensembl chr 5:21,981,382...21,986,705

G

protein interacting with PRKCA 1

increases expression
multiple interactions

EXP

3-nitropropionic acid results in increased expression of PICK1 protein
topiramate inhibits the reaction [3-nitropropionic acid results in increased expression of PICK1 protein]

NCBI chr 7:112,676,890...112,697,275
Ensembl chr 7:112,677,322...112,697,257

G

protein kinase C, delta

multiple interactions

ISO

3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]]

NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,775,681...5,805,839

G

proline and serine rich 2

decreases expression

ISO

3-nitropropionic acid results in decreased expression of PROSER2 mRNA

NCBI chr17:77,061,371...77,096,788
Ensembl chr17:77,077,727...77,095,194

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

EXP

3-nitropropionic acid results in increased expression of PTGS2 mRNA
naringin inhibits the reaction [3-nitropropionic acid results in increased expression of PTGS2 mRNA]

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

RB transcriptional corepressor 1

decreases expression

EXP

3-nitropropionic acid results in decreased expression of RB1 protein

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

RELA proto-oncogene, NF-kB subunit

increases phosphorylation
multiple interactions

EXP

3-nitropropionic acid results in increased phosphorylation of RELA protein
methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in increased phosphorylation of RELA protein]]; N(6)-cyclohexyladenosine inhibits the reaction [3-nitropropionic acid results in increased phosphorylation of RELA protein]; Tropisetron inhibits the reaction [3-nitropropionic acid results in increased phosphorylation of RELA protein]

PMID:36509115 PMID:38513929

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

sirtuin 1

decreases expression

ISO
EXP

3-nitropropionic acid results in decreased expression of SIRT1 protein

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

superoxide dismutase 1

multiple interactions
decreases expression

EXP

Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of SOD1 mRNA]

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

superoxide dismutase 2

decreases expression
multiple interactions

EXP

3-nitropropionic acid results in decreased expression of SOD2 mRNA
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of SOD2 mRNA]

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

SRY-box transcription factor 4

decreases expression

ISO

3-nitropropionic acid results in decreased expression of SOX4 mRNA

NCBI chr17:35,876,298...35,881,004
Ensembl chr17:35,875,756...35,884,024

G

serine peptidase inhibitor, Kazal type 4

decreases expression

ISO

3-nitropropionic acid results in decreased expression of SPINK4 mRNA

NCBI chr 5:60,811,899...60,860,823
Ensembl chr 5:60,849,060...60,860,823

G

synaptophysin

multiple interactions
affects expression

EXP

Bezafibrate affects the reaction [3-nitropropionic acid affects the expression of SYP protein]

NCBI chr X:17,521,348...17,536,449
Ensembl chr X:17,521,348...17,536,984

G

tachykinin, precursor 1

decreases expression
multiple interactions

EXP

3-nitropropionic acid results in decreased expression of TAC1 mRNA
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of TAC1 mRNA]

NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546

G

tumor necrosis factor

increases expression
multiple interactions

EXP
ISO

3-nitropropionic acid results in increased expression of TNF mRNA; 3-nitropropionic acid results in increased expression of TNF protein
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of TNF mRNA]; T 0070907 inhibits the reaction [delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of TNF mRNA]]
methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of TNF protein]]; N(6)-cyclohexyladenosine inhibits the reaction [3-nitropropionic acid results in increased expression of TNF protein]; naringin inhibits the reaction [3-nitropropionic acid results in increased expression of TNF mRNA]; Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of TNF protein]

PMID:22871521 PMID:28853159 PMID:36509115 PMID:38513929

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

tubulin tyrosine ligase like 12

decreases expression

ISO

3-nitropropionic acid results in decreased expression of TTLL12 mRNA

NCBI chr 7:116,612,609...116,631,244
Ensembl chr 7:116,612,609...116,631,577

G

urocortin 2

increases expression

ISO

3-nitropropionic acid results in increased expression of UCN2 mRNA

NCBI chr 8:118,516,111...118,517,660
Ensembl chr 8:118,483,364...118,517,439

G

voltage-dependent anion channel 1

increases expression

EXP

3-nitropropionic acid results in increased expression of VDAC1 protein

NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541

4-aminosalicylic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

bone morphogenetic protein 6

increases expression

ISO

Aminosalicylic Acid results in increased expression of BMP6 mRNA

NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261

G

epiregulin

increases expression

ISO

Aminosalicylic Acid results in increased expression of EREG mRNA

NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,311,485...17,325,260

G

interleukin 24

increases expression

ISO

Aminosalicylic Acid results in increased expression of IL24 mRNA

NCBI chr13:44,905,362...44,910,760
Ensembl chr13:44,905,363...44,910,760

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

ISO

Aminosalicylic Acid results in increased expression of MET mRNA

NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821

G

N-acetyltransferase 1

increases acetylation

ISO

NAT1 protein results in increased acetylation of Aminosalicylic Acid

PMID:15627487 PMID:16003948

NCBI chr16:26,984,882...27,005,194
Ensembl chr16:26,982,625...26,986,527

G

N-acetyltransferase 2

multiple interactions

ISO

[Peroxynitrous Acid results in decreased activity of NAT2 protein] which results in decreased acetylation of Aminosalicylic Acid

NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304

G

phosphotyrosine interaction domain containing 1

increases expression

ISO

Aminosalicylic Acid results in increased expression of PID1 mRNA

NCBI chr 9:92,732,471...92,951,168
Ensembl chr 9:92,734,214...92,750,070

G

solute carrier family 7 member 11

increases expression

ISO

Aminosalicylic Acid results in increased expression of SLC7A11 mRNA

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

secretory leukocyte peptidase inhibitor

increases expression

ISO

Aminosalicylic Acid results in increased expression of SLPI mRNA

NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases activity

ISO

azadiradione results in increased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

increases activity

ISO

azadiradione results in increased activity of CASP8 protein

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

increases activity

ISO

azadiradione results in increased activity of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

heat shock protein family A (Hsp70) member 1A

increases expression

ISO

azadiradione results in increased expression of HSPA1A mRNA

NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

ISO

Clofazimine results in decreased activity of ABCB11 protein

PMID:20829430 PMID:23956101

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

acetyl-CoA carboxylase alpha

increases expression

EXP

Clofazimine results in increased expression of ACACA mRNA

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

CCAAT/enhancer binding protein alpha

increases expression

EXP

Clofazimine results in increased expression of CEBPA protein

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

diacylglycerol O-acyltransferase 1

decreases expression

EXP

Clofazimine results in decreased expression of DGAT1 mRNA

NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016

G

Fas cell surface death receptor

increases expression

EXP

Clofazimine results in increased expression of FAS mRNA

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

glutathione S-transferase pi 1

multiple interactions

ISO

Clofazimine inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

potassium voltage-gated channel subfamily H member 2

decreases activity

ISO

Clofazimine results in decreased activity of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

peroxisome proliferator-activated receptor gamma

increases expression

EXP

Clofazimine results in increased expression of PPARG mRNA; Clofazimine results in increased expression of PPARG protein

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

sterol regulatory element binding transcription factor 1

increases expression

EXP

Clofazimine results in increased expression of SREBF1 mRNA

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

zinc finger protein 423

increases expression

EXP

Clofazimine results in increased expression of ZFP423 mRNA

NCBI chr19:35,282,149...35,580,775
Ensembl chr19:35,282,110...35,580,773

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

ISO

Cycloserine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

DNA-damage inducible transcript 3

multiple interactions

ISO

Cycloserine inhibits the reaction [resveratrol results in increased expression of DDIT3 protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

early growth response 1

increases expression

EXP

Cycloserine results in increased expression of EGR1 protein

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

EXP

Cycloserine promotes the reaction [Clozapine results in increased expression of FOS mRNA]

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

homer scaffold protein 1

multiple interactions

EXP

Cycloserine inhibits the reaction [Clozapine results in increased expression of HOMER1 mRNA]; Cycloserine inhibits the reaction [Haloperidol results in increased expression of HOMER1 mRNA]

NCBI chr 2:26,279,012...26,388,279
Ensembl chr 2:26,278,105...26,381,657

G

mitogen activated protein kinase 1

multiple interactions

EXP

Cycloserine inhibits the reaction [Dronabinol results in increased activity of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions

EXP

Cycloserine inhibits the reaction [Dronabinol results in increased activity of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

poly (ADP-ribose) polymerase 1

multiple interactions

ISO

Cycloserine inhibits the reaction [resveratrol results in increased cleavage of PARP1 protein]

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

decreases expression

EXP

Dapsone metabolite results in decreased expression of ABCC2 protein

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

catalase

decreases activity

EXP

Dapsone results in decreased activity of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-C motif chemokine ligand 3

multiple interactions

ISO

Dapsone inhibits the reaction [Paraquat results in increased expression of CCL3 mRNA]

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-X-C motif chemokine receptor 4

multiple interactions

ISO

Dapsone analog inhibits the reaction [Metribolone results in increased expression of CXCR4 mRNA]

NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity

ISO

Dapsone results in increased activity of CYP1A1 protein

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

ISO

CYP2B6 protein results in increased metabolism of and results in increased susceptibility to Dapsone

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

ISO

CYP2C19 protein results in increased metabolism of and results in increased susceptibility to Dapsone

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

cytochrome P450, family 2, subfamily c, polypeptide 79

increases metabolic processing

ISO

CYP2C8 protein results in increased metabolism of Dapsone

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions

ISO

CYP2D6 protein results in increased metabolism of and results in increased susceptibility to Dapsone

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
affects metabolic processing

EXP
ISO

[SOD2 co-treated with CYP3A4] affects the susceptibility to Dapsone
CYP3A4 protein affects the metabolism of Dapsone
CYP3A4 protein results in increased metabolism of and results in increased susceptibility to Dapsone

PMID:12920490 PMID:15327588 PMID:19501153 PMID:19998329

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

endothelin 1

multiple interactions

ISO

Dapsone inhibits the reaction [Paraquat results in increased expression of EDN1 mRNA]

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

ETS transcription factor ELK4

multiple interactions

ISO

Dapsone analog inhibits the reaction [Metribolone results in increased expression of ELK4 mRNA]

NCBI chr13:46,004,145...46,027,206
Ensembl chr13:46,004,182...46,027,199

G

FKBP prolyl isomerase 5

multiple interactions

ISO

Dapsone analog inhibits the reaction [Metribolone results in increased expression of FKBP5 mRNA]

NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,458,940...6,543,118

G

glucose-6-phosphate dehydrogenase

increases response to substance

ISO

G6PD protein mutant form results in increased susceptibility to Dapsone

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

growth regulating estrogen receptor binding 1

multiple interactions

ISO

Dapsone analog inhibits the reaction [Metribolone results in increased expression of GREB1 mRNA]

NCBI chr 6:45,169,289...45,321,973
Ensembl chr 6:45,169,289...45,291,126

G

glutathione-disulfide reductase

multiple interactions

ISO

Dapsone inhibits the reaction [Paraquat results in decreased expression of GSR protein]; Dapsone inhibits the reaction [Paraquat results in increased expression of GSR mRNA]

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

glutathione S-transferase pi 1

multiple interactions

ISO

Dapsone inhibits the reaction [Paraquat results in decreased expression of GSTP1 protein]

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

interferon gamma

multiple interactions

ISO

[Dapsone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

insulin-like growth factor 1 receptor

multiple interactions

ISO

Dapsone analog inhibits the reaction [Metribolone results in increased expression of IGF1R mRNA]

NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664

G

interleukin 1 beta

decreases expression

ISO

Dapsone results in decreased expression of IL1B mRNA

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 2

multiple interactions

ISO

[Dapsone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

MAF bZIP transcription factor

multiple interactions

ISO

Dapsone analog inhibits the reaction [Metribolone results in increased expression of MAF mRNA]

NCBI chr19:60,259,200...60,622,145
Ensembl chr19:60,269,541...60,621,378

G

male germ cell-associated kinase

multiple interactions

ISO

Dapsone analog inhibits the reaction [Metribolone results in increased expression of MAK mRNA]

NCBI chr17:23,889,417...23,936,857
Ensembl chr17:23,889,516...23,936,855

G

mitogen activated protein kinase 1

multiple interactions

ISO

Dapsone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions

ISO

Dapsone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

matrix metallopeptidase 9

multiple interactions

ISO

Dapsone inhibits the reaction [Paraquat results in increased expression of MMP9 protein]

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

N-acetyltransferase 2

increases acetylation

ISO

NAT2 protein results in increased acetylation of Dapsone

NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304

G

NK3 homeobox 1

multiple interactions

ISO

Dapsone analog inhibits the reaction [Metribolone results in increased expression of NKX3-1 mRNA]

NCBI chr15:50,883,661...50,886,253
Ensembl chr15:50,883,597...50,886,251

G

NADPH oxidase 4

multiple interactions

ISO

Dapsone inhibits the reaction [Paraquat results in increased expression of NOX4 mRNA]

PMID:20164675 PMID:21765237

NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

ISO

Dapsone analog inhibits the reaction [Metribolone results in increased expression of NR4A1 mRNA]

NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041

G

period circadian regulator 1

multiple interactions

ISO

Dapsone analog inhibits the reaction [Metribolone results in increased expression of PER1 mRNA]

NCBI chr10:54,299,002...54,313,804
Ensembl chr10:54,302,641...54,314,211

G

phospholipase C, beta 2

multiple interactions

ISO

Dapsone inhibits the reaction [Paraquat results in increased phosphorylation of PLCB2 protein]

NCBI chr 3:126,134,925...126,158,303
Ensembl chr 3:126,138,736...126,158,221

G

protein kinase D1

multiple interactions

ISO

Dapsone inhibits the reaction [Paraquat results in increased phosphorylation of PRKD1 protein]

NCBI chr 6:73,460,640...73,774,433
Ensembl chr 6:73,460,640...73,836,509

G

protein arginine methyltransferase 1

decreases activity

ISO

Dapsone analog results in decreased activity of PRMT1 protein; Dapsone results in decreased activity of PRMT1 protein

NCBI chr 1:104,595,339...104,605,552
Ensembl chr 1:104,595,335...104,604,827

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

Dapsone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

solute carrier family 4 member 2

decreases expression

EXP

Dapsone metabolite results in decreased expression of SLC4A2 protein

NCBI chr 4:11,628,860...11,646,961
Ensembl chr 4:11,628,862...11,645,402

G

superoxide dismutase 2

multiple interactions

EXP
ISO

[SOD2 co-treated with CYP3A4] affects the susceptibility to Dapsone
Dapsone inhibits the reaction [Paraquat results in decreased expression of SOD2 protein]

PMID:19501153 PMID:21765237

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

transforming growth factor, beta 1

multiple interactions

ISO

Dapsone inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

dehydrocostus lactone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

ISO

[dehydrocostus lactone co-treated with berberrubine] results in increased expression of BAX protein

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

ISO

dehydrocostus lactone results in decreased expression of BCL2 protein
[dehydrocostus lactone co-treated with berberrubine] results in decreased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

caspase 3

multiple interactions
increases expression

ISO

[dehydrocostus lactone co-treated with berberrubine] results in increased expression of CASP3 protein
dehydrocostus lactone results in increased expression of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

heme oxygenase 1

increases expression

ISO

dehydrocostus lactone results in increased expression of HMOX1 protein

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

interleukin 6

multiple interactions

ISO

dehydrocostus lactone inhibits the reaction [Hydrogen Peroxide results in increased secretion of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

nitric oxide synthase 2

multiple interactions

ISO

dehydrocostus lactone inhibits the reaction [Ethanol results in increased expression of NOS2 protein]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

dehydrocostus lactone inhibits the reaction [Ethanol results in increased expression of PTGS2 protein]

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

tumor necrosis factor

multiple interactions

ISO

dehydrocostus lactone inhibits the reaction [Ethanol results in increased expression of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF superfamily member 11

multiple interactions

ISO

dehydrocostus lactone inhibits the reaction [Hydrogen Peroxide results in increased secretion of TNFSF11 protein]

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479

ergosterol peroxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases activity

ISO

ergosterol-5,8-peroxide results in increased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

ISO

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily C member 2

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

angiotensin converting enzyme 2

increases expression

ISO

Ethambutol results in increased expression of ACE2 mRNA

NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:110,739,633...110,803,416
Ensembl chr X:110,739,648...110,803,261

G

bone morphogenetic protein 6

decreases expression

ISO

Ethambutol results in decreased expression of BMP6 mRNA

NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261

G

caspase 3

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

catalase

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein; [isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in decreased activity of CAT protein

PMID:34118364 PMID:36878459

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-C motif chemokine ligand 2

affects expression

EXP

Ethambutol affects the expression of CCL2 mRNA

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 5

affects expression

EXP

Ethambutol affects the expression of CCL5 protein

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

cathepsin D

multiple interactions

EXP

Ethambutol results in increased expression of and affects the localization of CTSD protein; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Ethambutol results in increased expression of and affects the localization of CTSD protein]

NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity

ISO

Ethambutol results in decreased activity of CYP1A2 protein

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 2, subfamily c, polypeptide 23

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2C23 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2C23 mRNA]

NCBI chr 1:252,838,427...252,863,081
Ensembl chr 1:252,838,433...252,863,067

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases activity

ISO

Ethambutol results in decreased activity of CYP2C19 protein

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

cytochrome P450, family 2, subfamily d, polypeptide 4

decreases activity

ISO

Ethambutol results in decreased activity of CYP2D6 protein

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity
increases expression
multiple interactions

ISO
EXP

Ethambutol results in decreased activity of CYP2E1 protein
Ethambutol results in increased expression of CYP2E1 mRNA
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Ethambutol results in increased expression of and results in increased activity of CYP2E1 protein; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]

PMID:24910189 PMID:27334974 PMID:27919644

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

ISO
EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

glutamic--pyruvic transaminase

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

PMID:35835356 PMID:36878459

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione peroxidase 4

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629

G

granzyme B

increases secretion

ISO

Ethambutol results in increased secretion of GZMB protein

NCBI chr15:34,459,007...34,462,469
Ensembl chr15:34,459,007...34,462,469

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

interferon gamma

increases secretion

ISO

Ethambutol results in increased secretion of IFNG protein

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interleukin 10

decreases expression

EXP

Ethambutol results in decreased expression of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 13

increases secretion

ISO

Ethambutol results in increased secretion of IL13 protein

NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483

G

interleukin 1 alpha

increases expression

ISO

Ethambutol results in increased expression of IL1A mRNA

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

decreases expression

EXP

Ethambutol results in decreased expression of IL1B mRNA

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

decreases expression

EXP

Ethambutol results in decreased expression of IL6 protein

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

lysosomal-associated membrane protein 2

increases expression
multiple interactions

EXP

Ethambutol results in increased expression of LAMP2 protein
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Ethambutol results in increased expression of LAMP2 protein]

NCBI chr X:122,038,734...122,087,745
Ensembl chr X:121,922,187...122,087,675

G

leptin

decreases expression

EXP

Ethambutol results in decreased expression of LEP protein

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

ISO

Ethambutol results in increased expression of MET mRNA

NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821

G

myeloperoxidase

multiple interactions

EXP

[efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

EXP
ISO

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389

G

phosphotyrosine interaction domain containing 1

increases expression

ISO

Ethambutol results in increased expression of PID1 mRNA

NCBI chr 9:92,732,471...92,951,168
Ensembl chr 9:92,734,214...92,750,070

G

solute carrier family 10 member 1

multiple interactions

ISO

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944

G

solute carrier family 7 member 11

increases expression
multiple interactions

ISO
EXP

Ethambutol results in increased expression of SLC7A11 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]

PMID:32816093 PMID:36878459

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

secretory leukocyte peptidase inhibitor

increases expression

ISO

Ethambutol results in increased expression of SLPI mRNA

NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin converting enzyme 2

decreases expression

ISO

Ethionamide results in decreased expression of ACE2 mRNA

NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596

G

C-C motif chemokine ligand 2

increases expression

EXP

Ethionamide results in increased expression of CCL2 mRNA; Ethionamide results in increased expression of CCL2 protein

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 5

affects expression

EXP

Ethionamide affects the expression of CCL5 protein

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

C-X-C motif chemokine ligand 10

decreases expression

EXP

Ethionamide results in decreased expression of CXCL10 protein

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

flavin containing dimethylaniline monoxygenase 2

increases oxidation

ISO

FMO2 protein results in increased oxidation of Ethionamide

NCBI chr13:77,755,131...77,777,597
Ensembl chr13:77,757,629...77,777,534

G

glutamate cysteine ligase, modifier subunit

multiple interactions

ISO

Ethionamide inhibits the reaction [arsenic trioxide results in increased expression of GCLM mRNA]

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

heme oxygenase 1

multiple interactions

ISO

Ethionamide inhibits the reaction [arsenic trioxide results in increased expression of HMOX1 mRNA]

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

interleukin 10

decreases expression

EXP

Ethionamide results in decreased expression of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 12B

increases expression

EXP

Ethionamide results in increased expression of IL12B protein

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194

G

interleukin 1 alpha

increases expression

EXP

Ethionamide results in increased expression of IL1A protein

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

increases expression
affects expression

EXP

Ethionamide results in increased expression of IL1B mRNA
Ethionamide affects the expression of IL1B protein

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

decreases expression

EXP

Ethionamide results in decreased expression of IL6 protein

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

Kelch-like ECH-associated protein 1

multiple interactions

ISO

KEAP1 mRNA inhibits the reaction [Ethionamide results in increased susceptibility to arsenic trioxide]

NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042

G

leptin

decreases expression

EXP

Ethionamide results in decreased expression of LEP protein

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661

G

NFE2 like bZIP transcription factor 2

multiple interactions

ISO

NFE2L2 mRNA promotes the reaction [Ethionamide results in increased susceptibility to arsenic trioxide]

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

sulfiredoxin 1

multiple interactions

ISO

Ethionamide inhibits the reaction [arsenic trioxide results in increased expression of SRXN1 mRNA]

NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765

G

tumor necrosis factor

increases expression

EXP

Ethionamide results in increased expression of TNF protein

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

vascular endothelial growth factor A

increases expression

EXP

Ethionamide results in increased expression of VEGFA protein

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

increases expression

EXP

Isoniazid results in increased expression of A2M mRNA

NCBI chr 4:156,570,163...156,619,870
Ensembl chr 4:156,569,860...156,619,868

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases expression

EXP
ISO

[Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCB11 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCB11 mRNA]
Isoniazid results in decreased expression of ABCB11 protein
[Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein

PMID:25331106 PMID:25886055 PMID:32673658 PMID:35835356

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily C member 1

increases expression

EXP

Isoniazid results in increased expression of ABCC1 mRNA

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily C member 2

multiple interactions
decreases expression

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCC2 mRNA
Isoniazid results in decreased expression of ABCC2 mRNA

PMID:25331106 PMID:32673658 PMID:35835356

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 3

multiple interactions
decreases expression

EXP

[Lipopolysaccharides co-treated with Isoniazid] results in increased expression of ABCC3 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCC3 mRNA]

PMID:25331106 PMID:32673658

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily C member 4

decreases expression

EXP

Isoniazid results in decreased expression of ABCC4 mRNA

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

G

ATP binding cassette subfamily C member 6

decreases expression

EXP

Isoniazid results in decreased expression of ABCC6 mRNA

NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:105,583,682...105,637,895

G

acetyl-CoA acyltransferase 1A

decreases expression

ISO

Isoniazid results in decreased expression of ACAA1 protein

NCBI chr 8:127,956,126...127,966,348
Ensembl chr 8:127,956,129...127,966,241

G

acetyl-CoA acyltransferase 2

increases expression

ISO

Isoniazid results in increased expression of ACAA2 protein

NCBI chr18:70,620,310...70,648,417
Ensembl chr18:70,620,110...70,648,420

G

acetyl-CoA carboxylase alpha

decreases expression

ISO

Isoniazid results in decreased expression of ACACA protein

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

acyl-CoA dehydrogenase medium chain

decreases expression

ISO

Isoniazid results in decreased expression of ACADM protein

NCBI chr 2:245,518,693...245,542,864
Ensembl chr 2:245,518,693...245,542,864

G

acyl-CoA dehydrogenase short chain

increases expression
decreases expression

ISO

Isoniazid results in increased expression of ACADS protein
Isoniazid results in decreased expression of ACADS mRNA

NCBI chr12:47,154,259...47,163,580
Ensembl chr12:47,154,276...47,164,103

G

acyl-CoA dehydrogenase, short/branched chain

decreases expression

ISO

Isoniazid results in decreased expression of ACADSB protein

NCBI chr 1:195,619,088...195,660,564
Ensembl chr 1:195,619,038...195,660,561

G

acyl-CoA dehydrogenase, very long chain

increases expression
decreases expression

ISO

Isoniazid results in increased expression of ACADVL protein
Isoniazid results in decreased expression of ACADVL mRNA

NCBI chr10:55,231,558...55,236,786
Ensembl chr10:55,231,440...55,236,750

G

acetyl-CoA acetyltransferase 2

decreases expression

ISO

Isoniazid results in decreased expression of ACAT2 protein

NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:50,100,817...50,135,095

G

angiotensin converting enzyme 2

decreases expression

ISO

Isoniazid results in decreased expression of ACE2 mRNA

NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596

G

ATP citrate lyase

decreases expression

ISO

Isoniazid results in decreased expression of ACLY protein

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631

G

aconitase 1

increases expression
decreases expression

ISO

Isoniazid results in increased expression of ACO1 protein
Isoniazid results in decreased expression of ACO1 mRNA

NCBI chr 5:60,055,895...60,111,920
Ensembl chr 5:60,055,866...60,112,600

G

acyl-CoA oxidase 1

decreases expression

ISO

Isoniazid results in decreased expression of ACOX1 protein

NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,905,083...101,930,136

G

acid phosphatase 1

increases expression

ISO

Isoniazid results in increased expression of ACP1 protein

NCBI chr 6:53,233,937...53,249,576
Ensembl chr 6:53,233,948...53,251,959

G

acyl-CoA synthetase family member 3

increases expression

ISO

Isoniazid results in increased expression of ACSF3 protein

NCBI chr19:67,743,660...67,784,109
Ensembl chr19:67,743,490...67,784,084

G

acyl-CoA synthetase long-chain family member 1

decreases expression
increases expression

ISO

Isoniazid results in decreased expression of ACSL1 mRNA
Isoniazid results in increased expression of ACSL1 protein

NCBI chr16:52,487,870...52,554,110
Ensembl chr16:52,487,870...52,554,023

G

acyl-CoA synthetase long-chain family member 3

increases expression

ISO

Isoniazid results in increased expression of ACSL3 protein

NCBI chr 9:87,563,601...87,613,078
Ensembl chr 9:87,563,601...87,613,097

G

acyl-CoA synthetase long-chain family member 4

multiple interactions
decreases expression

EXP
ISO

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein
Isoniazid results in decreased expression of ACSL4 protein

PMID:36878459 PMID:40015660

NCBI chr X:110,739,633...110,803,416
Ensembl chr X:110,739,648...110,803,261

G

acyl-CoA synthetase long-chain family member 5

increases expression

ISO

Isoniazid results in increased expression of ACSL5 protein

NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:264,294,864...264,341,943

G

acyl-CoA synthetase short-chain family member 1

increases expression

ISO

Isoniazid results in increased expression of ACSS1 protein

NCBI chr 3:159,910,809...159,960,748
Ensembl chr 3:159,910,809...159,960,748

G

alcohol dehydrogenase 4 (class II), pi polypeptide

decreases expression

ISO

Isoniazid results in decreased expression of ADH4 protein

NCBI chr 2:229,622,092...229,640,120
Ensembl chr 2:229,622,095...229,641,879

G

alcohol dehydrogenase 5 (class III), chi polypeptide

decreases expression

ISO

Isoniazid results in decreased expression of ADH5 protein

NCBI chr 2:229,648,557...229,660,964
Ensembl chr 2:229,648,501...229,665,232

G

alcohol dehydrogenase 6 (class V)

decreases expression

ISO

Isoniazid results in decreased expression of ADH6 protein

NCBI chr 2:229,576,612...229,608,359
Ensembl chr 2:229,576,636...229,607,914

G

acireductone dioxygenase 1

decreases expression

ISO

Isoniazid results in decreased expression of ADI1 protein

NCBI chr 6:51,035,267...51,042,229
Ensembl chr 6:51,034,931...51,042,855

G

alpha-fetoprotein

decreases expression

ISO

Isoniazid results in decreased expression of AFP mRNA

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649

G

1-acylglycerol-3-phosphate O-acyltransferase 3

increases expression
multiple interactions

EXP

Isoniazid results in increased expression of AGPAT3 mRNA
[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA]

NCBI chr20:10,330,650...10,415,026
Ensembl chr20:10,394,465...10,410,632

G

adenosylhomocysteinase

decreases expression

ISO

Isoniazid results in decreased expression of AHCY protein

NCBI chr 3:164,029,338...164,044,562
Ensembl chr 3:164,029,338...164,044,587

G

aldo-keto reductase family 1 member A1

increases expression

ISO

Isoniazid results in increased expression of AKR1A1 protein

NCBI chr 5:135,329,605...135,367,037
Ensembl chr 5:135,329,606...135,367,035

G

aldo-keto reductase family 1 member B10

increases expression

ISO

Isoniazid results in increased expression of AKR1B10 mRNA

NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847

G

aldo-keto reductase family 1, member C2

decreases expression
increases expression

ISO

Isoniazid results in decreased expression of AKR1C2 mRNA
Isoniazid results in increased expression of AKR1C2 protein

NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686

G

aldo-keto reductase family 1, member C3

increases expression

ISO

Isoniazid results in increased expression of AKR1C3 protein

NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438

G

5'-aminolevulinate synthase 1

increases expression

ISO

Isoniazid results in increased expression of ALAS1 protein

PMID:27438535 PMID:30517741

NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:115,755,238...115,768,642

G

albumin

affects binding

ISO

Isoniazid binds to ALB protein

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865

G

aldehyde dehydrogenase 1 family, member B1

increases expression

ISO

Isoniazid results in increased expression of ALDH1B1 protein

NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365

G

aldehyde dehydrogenase 2 family member

decreases expression

ISO

Isoniazid results in decreased expression of ALDH2 protein

NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219

G

aldehyde dehydrogenase 7 family, member A1

increases expression

ISO

Isoniazid results in increased expression of ALDH7A1 protein

NCBI chr18:52,208,035...52,240,293
Ensembl chr18:52,204,161...52,240,467

G

aldehyde dehydrogenase 9 family, member A1

increases expression

ISO

Isoniazid results in increased expression of ALDH9A1 protein

NCBI chr13:82,038,679...82,055,478
Ensembl chr13:82,038,533...82,055,481

G

alkaline phosphatase, biomineralization associated

increases activity
multiple interactions

ISO

Isoniazid results in increased activity of ALPL protein
[Rifampin co-treated with Isoniazid] results in increased activity of ALPL protein

NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167

G

alanyl aminopeptidase, membrane

decreases expression

ISO

Isoniazid results in decreased expression of ANPEP protein

NCBI chr 1:143,176,645...143,219,447
Ensembl chr 1:143,176,645...143,195,101

G

apolipoprotein A4

affects response to substance

ISO

APOA4 affects the susceptibility to Isoniazid

NCBI chr 8:55,435,779...55,438,160
Ensembl chr 8:55,434,168...55,438,164

G

apolipoprotein A5

multiple interactions
decreases expression

EXP

[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA]
Isoniazid results in decreased expression of APOA5 mRNA

NCBI chr 8:55,446,329...55,460,509
Ensembl chr 8:55,456,899...55,460,507

G

apolipoprotein B

decreases expression

ISO

Isoniazid results in decreased expression of APOB protein

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:36,563,704...36,611,814

G

amyloid beta precursor protein

increases expression

ISO

Isoniazid results in increased expression of APP mRNA

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

ARL6 interacting reticulophagy regulator 1

decreases expression

ISO

Isoniazid results in decreased expression of ARL6IP1 protein

NCBI chr 1:181,864,717...181,874,232
Ensembl chr 1:181,864,746...181,874,232

G

argininosuccinate lyase

increases activity
multiple interactions

EXP

Isoniazid results in increased activity of ASL protein
[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein; Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein]

NCBI chr12:32,295,779...32,313,257
Ensembl chr12:32,295,633...32,317,261

G

activating transcription factor 4

decreases expression

ISO

Isoniazid results in decreased expression of ATF4 mRNA

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

ATPase Na+/K+ transporting subunit beta 1

increases expression

ISO

Isoniazid results in increased expression of ATP1B1 mRNA

NCBI chr13:79,319,708...79,340,226
Ensembl chr13:79,319,706...79,340,549

G

ATP synthase F1 subunit alpha

increases expression
decreases expression

ISO

Isoniazid results in increased expression of ATP5F1A protein
Isoniazid results in decreased expression of ATP5F1A mRNA

NCBI chr18:73,567,537...73,575,473
Ensembl chr18:73,567,526...73,575,922

G

ATP synthase F1 subunit beta

affects expression
increases expression

ISO

Isoniazid affects the expression of ATP5F1B mRNA
Isoniazid results in increased expression of ATP5F1B protein

PMID:24848797 PMID:40015660

NCBI chr 7:1,100,058...1,106,461
Ensembl chr 7:1,099,860...1,106,462

G

ATP synthase F1 subunit gamma

increases expression

ISO

Isoniazid results in increased expression of ATP5F1C protein

NCBI chr17:73,333,584...73,355,872
Ensembl chr17:73,333,588...73,383,073

G

ATP synthase membrane subunit c locus 1

affects expression

ISO

Isoniazid affects the expression of ATP5MC1 mRNA

NCBI chr10:81,520,762...81,523,735
Ensembl chr10:81,520,765...81,523,363

G

ATP synthase membrane subunit c locus 3

affects expression

ISO

Isoniazid affects the expression of ATP5MC3 mRNA

NCBI chr 3:79,218,014...79,220,664
Ensembl chr 3:79,218,014...79,220,664

G

ATP synthase membrane subunit f

increases expression

ISO

Isoniazid results in increased expression of ATP5MF protein

NCBI chr12:14,535,435...14,542,007
Ensembl chr12:14,522,832...14,542,709

G

ATP synthase membrane subunit G

increases expression

ISO

Isoniazid results in increased expression of ATP5MG mRNA; Isoniazid results in increased expression of ATP5MG protein

NCBI chr 8:54,122,457...54,130,407
Ensembl chr 8:54,122,457...54,132,831

G

ATP synthase peripheral stalk-membrane subunit b

affects expression
increases expression

ISO

Isoniazid affects the expression of ATP5PB mRNA
Isoniazid results in increased expression of ATP5PB protein

PMID:24848797 PMID:40015660

NCBI chr 2:196,112,459...196,123,737
Ensembl chr 2:196,112,108...196,124,387

G

ATP synthase peripheral stalk subunit d

increases expression

ISO

Isoniazid results in increased expression of ATP5PD protein

NCBI chr10:101,156,673...101,161,926
Ensembl chr10:101,156,673...101,162,954

G

ATP synthase peripheral stalk subunit F6

affects expression
increases expression

ISO

Isoniazid affects the expression of ATP5PF mRNA
Isoniazid results in increased expression of ATP5PF protein

PMID:24848797 PMID:40015660

NCBI chr11:37,368,045...37,375,721
Ensembl chr11:37,368,042...37,375,466

G

ATP synthase peripheral stalk subunit OSCP

increases expression

ISO

Isoniazid results in increased expression of ATP5PO protein

NCBI chr11:44,651,171...44,657,483
Ensembl chr11:44,651,173...44,657,520

G

ATPase H+ transporting accessory protein 1

increases expression

ISO

Isoniazid results in increased expression of ATP6AP1 protein

NCBI chr X:157,231,243...157,238,323
Ensembl chr X:157,225,327...157,238,323

G

ATPase H+ transporting V0 subunit a1

increases expression

ISO

Isoniazid results in increased expression of ATP6V0A1 mRNA; Isoniazid results in increased expression of ATP6V0A1 protein

NCBI chr10:86,436,089...86,490,185
Ensembl chr10:86,436,141...86,490,181

G

ATPase H+ transporting V0 subunit D1

increases expression

ISO

Isoniazid results in increased expression of ATP6V0D1 protein

NCBI chr19:50,313,268...50,357,248
Ensembl chr19:50,313,273...50,357,395

G

ATPase H+ transporting V1 subunit A

increases expression
decreases expression

ISO

Isoniazid results in increased expression of ATP6V1A protein
Isoniazid results in decreased expression of ATP6V1A mRNA

NCBI chr11:70,066,800...70,120,603
Ensembl chr11:70,035,134...70,120,603

G

ATPase H+ transporting V1 subunit B2

decreases expression
increases expression

ISO

Isoniazid results in decreased expression of ATP6V1B2 mRNA
Isoniazid results in increased expression of ATP6V1B2 protein

NCBI chr16:25,384,254...25,408,388
Ensembl chr16:25,384,257...25,408,839

G

ATPase H+ transporting V1 subunit D

increases expression

ISO

Isoniazid results in increased expression of ATP6V1D protein

NCBI chr 6:103,389,778...103,405,346
Ensembl chr 6:103,389,783...103,405,346

G

ATPase H+ transporting V1 subunit E1

increases expression

ISO

Isoniazid results in increased expression of ATP6V1E1 protein

NCBI chr 4:155,694,534...155,716,660
Ensembl chr 4:155,694,534...155,716,678

G

ATPase H+ transporting V1 subunit F

increases expression

ISO

Isoniazid results in increased expression of ATP6V1F protein

NCBI chr 4:59,033,020...59,035,980

G

ATPase H+ transporting V1 subunit G1

increases expression

ISO

Isoniazid results in increased expression of ATP6V1G1 protein

NCBI chr 5:81,976,959...81,983,139
Ensembl chr 5:81,977,015...81,985,930

G

ATPase H+ transporting V1 subunit H

decreases expression
increases expression

ISO

Isoniazid results in decreased expression of ATP6V1H mRNA
Isoniazid results in increased expression of ATP6V1H protein

NCBI chr 5:19,176,849...19,282,516
Ensembl chr 5:19,176,849...19,282,516

G

BAG cochaperone 2

increases expression

ISO

Isoniazid results in increased expression of BAG2 protein

NCBI chr 9:43,465,993...43,476,637
Ensembl chr 9:43,465,995...43,476,752

G

BCL2 associated X, apoptosis regulator

multiple interactions
decreases expression
affects expression
increases expression

ISO
EXP

[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein]
Isoniazid results in decreased expression of BAX protein
Isoniazid affects the expression of BAX protein
Isoniazid results in increased expression of BAX mRNA
Isoniazid results in increased expression of BAX protein
chrysin inhibits the reaction [Isoniazid results in increased expression of BAX protein]
Quercetin inhibits the reaction [Isoniazid results in increased expression of BAX protein]
Isoniazid results in increased expression of BAX mRNA; Isoniazid results in increased expression of BAX protein

PMID:20433247 PMID:21419764 PMID:31332904 PMID:33121995 PMID:33771660 More...

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

gamma-butyrobetaine hydroxylase 1

increases expression

ISO

Isoniazid results in increased expression of BBOX1 mRNA

NCBI chr 3:117,277,226...117,326,383
Ensembl chr 3:117,277,226...117,326,064

G

B-cell receptor-associated protein 31

increases expression

ISO

Isoniazid results in increased expression of BCAP31 protein

NCBI chr X:156,548,911...156,581,002
Ensembl chr X:156,548,911...156,579,371

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

ISO

[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]
Isoniazid results in decreased expression of BCL2 mRNA
Isoniazid results in decreased expression of BCL2 protein
Quercetin inhibits the reaction [Isoniazid results in decreased expression of BCL2 protein]

PMID:20433247 PMID:21419764 PMID:31332904 PMID:33771660 PMID:40015660

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

betaine-homocysteine S-methyltransferase

increases expression

ISO

Isoniazid results in increased expression of BHMT protein

NCBI chr 2:26,594,852...26,614,429
Ensembl chr 2:26,594,854...26,614,715

G

calreticulin

decreases expression
increases expression

ISO

Isoniazid results in decreased expression of CALR mRNA
Isoniazid results in increased expression of CALR protein

NCBI chr19:40,213,367...40,218,262
Ensembl chr19:40,213,239...40,219,236

G

calnexin

decreases expression
increases expression

ISO

Isoniazid results in decreased expression of CANX mRNA
Isoniazid results in increased expression of CANX protein

NCBI chr10:35,124,941...35,157,954
Ensembl chr10:35,124,941...35,157,857

G

calpain 2

increases expression

ISO

Isoniazid results in increased expression of CAPN2 protein

NCBI chr13:96,681,902...96,732,625
Ensembl chr13:96,681,848...96,732,625

G

caspase 3

multiple interactions
increases activity
increases expression
increases cleavage

ISO
EXP

[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
Isoniazid results in increased activity of CASP3 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3
Isoniazid results in increased expression of CASP3 mRNA
Isoniazid results in increased cleavage of CASP3 protein
acadesine promotes the reaction [Isoniazid results in increased cleavage of CASP3 protein]; Quercetin inhibits the reaction [Isoniazid results in increased cleavage of CASP3 protein]

PMID:20433247 PMID:21419764 PMID:23764483 PMID:28556920 PMID:31332904 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 9

increases cleavage
increases activity
multiple interactions

ISO

Isoniazid results in increased cleavage of CASP9 protein
Isoniazid results in increased activity of CASP9 protein
Quercetin inhibits the reaction [Isoniazid results in increased cleavage of CASP9 protein]

PMID:20433247 PMID:31332904

Ensembl chr 5:159,391,188...159,409,648

G

calcium-sensing receptor

affects expression

EXP

Isoniazid affects the expression of CASR mRNA

NCBI chr11:77,738,398...77,813,639
Ensembl chr11:77,740,614...77,810,167

G

catalase

decreases activity
decreases expression
multiple interactions

EXP
ISO

Isoniazid results in decreased activity of CAT protein
Isoniazid results in decreased expression of CAT protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein; chrysin inhibits the reaction [Isoniazid results in decreased activity of CAT protein]

PMID:20433247 PMID:33121995 PMID:33771660 PMID:36878459 PMID:40015660

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

carbonyl reductase 1

increases expression

ISO

Isoniazid results in increased expression of CBR1 protein

NCBI chr11:46,346,405...46,348,815
Ensembl chr11:46,378,411...46,381,104
Ensembl chr11:46,378,411...46,381,104

G

coiled-coil domain containing 47

decreases expression

ISO

Isoniazid results in decreased expression of CCDC47 protein

NCBI chr10:91,630,101...91,648,626
Ensembl chr10:91,630,106...91,648,626

G

C-C motif chemokine receptor 2

decreases expression

EXP

Isoniazid results in decreased expression of CCR2 mRNA

NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:132,611,410...132,620,059

G

CCAAT/enhancer binding protein alpha

decreases expression

ISO

Isoniazid results in decreased expression of CEBPA mRNA; Isoniazid results in decreased expression of CEBPA protein

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

CCAAT/enhancer binding protein beta

decreases expression

ISO

Isoniazid results in decreased expression of CEBPB protein

NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072

G

CCAAT/enhancer binding protein delta

decreases expression

ISO

Isoniazid results in decreased expression of CEBPD mRNA; Isoniazid results in decreased expression of CEBPD protein

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824

G

choline phosphotransferase 1

affects response to substance

ISO

CHPT1 affects the susceptibility to Isoniazid

NCBI chr 7:24,753,880...24,802,529
Ensembl chr 7:24,750,343...24,802,521

G

cytoskeleton-associated protein 4

increases expression

ISO

Isoniazid results in increased expression of CKAP4 protein

NCBI chr 7:21,118,527...21,126,624
Ensembl chr 7:21,118,085...21,126,624

G

claudin 2

increases expression

ISO

Isoniazid results in increased expression of CLDN2 mRNA

NCBI chr X:108,248,383...108,258,847
Ensembl chr X:108,237,676...108,262,377

G

cytochrome c oxidase copper chaperone COX11

affects expression

ISO

Isoniazid affects the expression of COX11 mRNA

NCBI chr10:75,955,825...75,962,398
Ensembl chr10:75,955,783...75,963,489

G

cytochrome c oxidase copper chaperone COX17

affects expression

ISO

Isoniazid affects the expression of COX17 mRNA

NCBI chr11:75,906,245...75,912,036
Ensembl chr11:75,906,248...75,912,019

G

cytochrome c oxidase subunit 5B

affects expression
decreases expression

ISO

Isoniazid affects the expression of COX5B mRNA
Isoniazid results in decreased expression of COX5B protein

PMID:24848797 PMID:40015660

NCBI chr 9:46,417,735...46,419,664
Ensembl chr 9:46,417,838...46,420,403

G

cytochrome c oxidase subunit 6A1

affects expression

ISO

Isoniazid affects the expression of COX6A1 mRNA

NCBI chr12:46,922,709...46,925,762
Ensembl chr12:46,912,648...46,925,768

G

cytochrome c oxidase subunit 6B1

affects expression
decreases expression

ISO

Isoniazid affects the expression of COX6B1 mRNA
Isoniazid results in decreased expression of COX6B1 protein

PMID:24848797 PMID:40015660

NCBI chr 1:95,002,513...95,011,516
Ensembl chr 1:95,001,707...95,011,431
Ensembl chr 5:95,001,707...95,011,431

G

cytochrome c oxidase subunit 7A2

affects expression
decreases expression

ISO

Isoniazid affects the expression of COX7A2 mRNA
Isoniazid results in decreased expression of COX7A2 protein

PMID:24848797 PMID:40015660

NCBI chr 8:89,597,051...89,611,032
Ensembl chr14:55,514,261...55,514,512
Ensembl chr 8:55,514,261...55,514,512

G

cytochrome c oxidase subunit 7C

decreases expression

ISO

Isoniazid results in decreased expression of COX7C protein

NCBI chr 2:18,577,145...18,579,170
Ensembl chr 2:18,577,149...18,579,170

G

ceruloplasmin

increases expression

ISO

Isoniazid results in increased expression of CP protein

NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:104,368,456...104,427,087

G

carnitine palmitoyltransferase 1A

affects expression
increases expression

ISO

Isoniazid affects the expression of CPT1A mRNA
Isoniazid results in increased expression of CPT1A protein

PMID:24848797 PMID:40015660

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

carnitine palmitoyltransferase 2

increases expression
decreases expression

ISO

Isoniazid results in increased expression of CPT2 protein
Isoniazid results in decreased expression of CPT2 mRNA

NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:127,893,207...127,910,818

G

citrate synthase

increases expression

ISO

Isoniazid results in increased expression of CS protein

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938

G

cystathionine gamma-lyase

decreases expression

ISO

Isoniazid results in decreased expression of CTH protein

NCBI chr 2:249,634,731...249,661,066
Ensembl chr 2:249,634,731...249,661,066

G

C-X-C motif chemokine ligand 10

increases secretion

ISO

Isoniazid results in increased secretion of CXCL10 protein

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

cytochrome b5 type A

multiple interactions
decreases expression

EXP

[Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA]
Isoniazid results in decreased expression of CYB5A mRNA

NCBI chr18:80,487,923...80,520,544
Ensembl chr18:14,453,966...14,455,094
Ensembl chr18:14,453,966...14,455,094

G

cytochrome c, somatic

decreases expression

ISO

Isoniazid results in decreased expression of CYCS protein

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

ISO

[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein]

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 27, subfamily a, polypeptide 1

increases expression

EXP

Isoniazid results in increased expression of CYP27A1 mRNA

NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215

G

cytochrome P450, family 2, subfamily c, polypeptide 23

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2C23 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2C23 mRNA]

NCBI chr 1:252,838,427...252,863,081
Ensembl chr 1:252,838,433...252,863,067

G

cytochrome P450, family 2, subfamily c, polypeptide 79

decreases activity
multiple interactions

ISO

Isoniazid results in decreased activity of CYP2C8 protein
torsemide inhibits the reaction [Isoniazid results in decreased activity of CYP2C8 protein]

G

cytochrome P450, family 2, subfamily e, polypeptide 1

affects response to substance
decreases activity
increases response to substance
multiple interactions
increases activity
increases expression
increases metabolic processing

ISO
EXP

CYP2E1 gene polymorphism affects the susceptibility to Isoniazid; CYP2E1 gene SNP affects the susceptibility to Isoniazid
Isoniazid results in decreased activity of CYP2E1 protein
CYP2E1 protein results in increased susceptibility to Isoniazid
GSTM1 protein inhibits the reaction [CYP2E1 protein results in increased susceptibility to Isoniazid]; NADP promotes the reaction [Isoniazid results in decreased activity of CYP2E1 protein]
Isoniazid results in increased activity of CYP2E1 protein
[Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA]; NADP promotes the reaction [Isoniazid results in decreased activity of CYP2E1 protein]
Isoniazid results in increased expression of CYP2E1; Isoniazid results in increased expression of CYP2E1 mRNA; Isoniazid results in increased expression of CYP2E1 protein
2-(allylthio)pyrazine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Isoniazid results in increased activity of CYP2E1 protein] which results in increased metabolism of 4-dichlorobenzene; [Isoniazid results in increased expression of CYP2E1] which results in increased metabolism of Acetaminophen; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; diphenyleneiodonium inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]; Isoniazid inhibits the reaction [CYP2E1 protein results in increased reduction of Tirapazamine]; Isoniazid results in increased expression of and results in increased activity of CYP2E1 protein; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; NADP promotes the reaction [Isoniazid results in decreased activity of CYP2E1 protein]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]; Thiram inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]; Tiopronin inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]
CYP2E1 protein results in increased metabolism of Isoniazid

PMID:3113478 PMID:7710944 PMID:8074729 PMID:9051121 PMID:9065729 More...

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
decreases activity
increases response to substance

EXP
ISO

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; [SOD2 co-treated with CYP3A4] affects the susceptibility to Isoniazid; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]
Isoniazid results in decreased activity of CYP3A4 protein
CYP3A4 protein results in increased susceptibility to Isoniazid

PMID:15005856 PMID:15304522 PMID:19501153 PMID:21540358 PMID:27919644

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression
increases activity
multiple interactions

EXP

Isoniazid results in increased expression of CYP3A23-3A1 mRNA
Isoniazid results in increased activity of CYP3A23-3A1 protein
diphenyleneiodonium inhibits the reaction [Isoniazid results in increased activity of CYP3A23-3A1 protein]

PMID:12883083 PMID:26880746

NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions
increases expression

EXP
ISO

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein; [Lipopolysaccharides co-treated with Isoniazid] results in increased expression of CYP7A1 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in increased expression of CYP7A1 mRNA]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; [Isoniazid co-treated with Vitamin B 6] results in increased expression of CYP7A1 mRNA

PMID:25331106 PMID:32673658 PMID:35835356

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

DNA-damage inducible transcript 3

increases expression
decreases expression

EXP
ISO

Isoniazid results in increased expression of DDIT3 mRNA
Isoniazid results in decreased expression of DDIT3 mRNA

PMID:12883083 PMID:30008028

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

DEPP autophagy regulator 1

increases expression

ISO

Isoniazid results in increased expression of DEPP1 mRNA

NCBI chr 4:151,583,105...151,585,455
Ensembl chr 4:151,581,502...151,586,233

G

derlin 1

increases expression

ISO

Isoniazid results in increased expression of DERL1 protein

NCBI chr 7:91,293,963...91,316,639
Ensembl chr 7:91,258,382...91,316,678

G

dihydrolipoamide S-acetyltransferase

increases expression

ISO

Isoniazid results in increased expression of DLAT protein

NCBI chr 8:59,875,537...59,900,947
Ensembl chr 8:59,868,214...59,900,818
Ensembl chr 1:59,868,214...59,900,818

G

dihydrolipoamide dehydrogenase

increases expression
decreases expression

ISO

Isoniazid results in increased expression of DLD protein
Isoniazid results in decreased expression of DLD mRNA

NCBI chr 6:53,631,686...53,655,059
Ensembl chr 6:53,619,631...53,652,354

G

dihydrolipoamide S-succinyltransferase

increases expression

ISO

Isoniazid results in increased expression of DLST protein

NCBI chr 6:110,489,576...110,512,841
Ensembl chr 6:110,489,392...110,514,357

G

distal membrane arm assembly component 2 like

increases expression

ISO

Isoniazid results in increased expression of DMAC2L mRNA; Isoniazid results in increased expression of DMAC2L protein

NCBI chr 6:93,941,605...93,959,932
Ensembl chr 6:93,941,690...93,960,662

G

DnaJ heat shock protein family (Hsp40) member A1

decreases expression

ISO

Isoniazid results in decreased expression of DNAJA1 protein

NCBI chr 5:60,638,404...60,649,315
Ensembl chr 5:60,638,410...60,650,160

G

DnaJ heat shock protein family (Hsp40) member B11

increases expression

ISO

Isoniazid results in increased expression of DNAJB11 protein

NCBI chr11:91,656,334...91,672,800
Ensembl chr11:91,656,335...91,672,800

G

DnaJ heat shock protein family (Hsp40) member C10

increases expression

ISO

Isoniazid results in increased expression of DNAJC10 protein

NCBI chr 3:85,636,890...85,679,620
Ensembl chr 3:85,639,589...85,689,368

G

DnaJ heat shock protein family (Hsp40) member C3

increases expression

ISO

Isoniazid results in increased expression of DNAJC3 protein

NCBI chr15:102,432,667...102,475,643
Ensembl chr15:102,432,663...102,475,643

G

DnaJ heat shock protein family (Hsp40) member C9

decreases expression

ISO

Isoniazid results in decreased expression of DNAJC9 protein

NCBI chr15:3,970,843...4,003,009
Ensembl chr15:3,970,114...3,977,304

G

DNA methyltransferase 1

decreases expression

ISO

Isoniazid results in decreased expression of DNMT1 protein

NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119

G

enoyl-CoA hydratase, short chain 1

increases expression

ISO

Isoniazid results in increased expression of ECHS1 protein

NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:204,324,682...204,333,506

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

decreases expression

ISO

Isoniazid results in decreased expression of EHHADH protein

NCBI chr11:92,746,409...92,779,647
Ensembl chr11:92,746,420...92,779,662

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation

ISO

Isoniazid results in increased phosphorylation of EIF2S1 protein

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649

G

ELOVL fatty acid elongase 1

increases expression

ISO

Isoniazid results in increased expression of ELOVL1 protein

NCBI chr 5:137,246,781...137,251,351
Ensembl chr 5:137,246,849...137,251,352

G

ELOVL fatty acid elongase 2

decreases expression

ISO

Isoniazid results in decreased expression of ELOVL2 protein

NCBI chr17:23,750,350...23,790,601
Ensembl chr17:23,750,350...23,790,601

G

enolase-phosphatase 1

increases expression

ISO

Isoniazid results in increased expression of ENOPH1 protein

NCBI chr14:9,835,626...9,862,051
Ensembl chr14:9,835,627...9,873,668

G

epoxide hydrolase 1

increases expression

ISO

Isoniazid results in increased expression of EPHX1 protein

NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981

G

epoxide hydrolase 2

increases expression

ISO

Isoniazid results in increased expression of EPHX2 protein

NCBI chr15:44,465,447...44,503,157
Ensembl chr15:44,465,448...44,503,160

G

eosinophil peroxidase

increases oxidation
multiple interactions

ISO

EPX protein results in increased oxidation of Isoniazid
[EPX protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of isonicotinyl-NAD

NCBI chr10:73,164,096...73,175,180
Ensembl chr10:73,164,096...73,175,180

G

endoplasmic reticulum lectin 1

increases expression

ISO

Isoniazid results in increased expression of ERLEC1 protein

NCBI chr14:108,856,661...108,894,511
Ensembl chr14:108,856,661...108,894,297

G

endoplasmic reticulum oxidoreductase 1 alpha

increases expression

ISO

Isoniazid results in increased expression of ERO1A mRNA; Isoniazid results in increased expression of ERO1A protein

NCBI chr15:20,974,771...21,010,170
Ensembl chr15:20,972,679...21,018,039

G

endoplasmic reticulum protein 29

increases expression

ISO

Isoniazid results in increased expression of ERP29 protein

NCBI chr12:40,750,177...40,756,607
Ensembl chr12:40,750,314...40,757,010

G

fatty acid synthase

decreases expression

ISO

Isoniazid results in decreased expression of FASN protein

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

F-box protein 2

decreases expression

ISO

Isoniazid results in decreased expression of FBXO2 protein

NCBI chr 5:163,876,079...163,881,508
Ensembl chr 5:163,875,757...163,881,508

G

ferrochelatase

decreases expression

ISO

Isoniazid results in decreased expression of FECH protein

PMID:27438535 PMID:30517741

NCBI chr18:60,215,325...60,248,525
Ensembl chr18:60,215,325...60,249,546

G

formimidoyltransferase cyclodeaminase

decreases expression

ISO

Isoniazid results in decreased expression of FTCD protein

NCBI chr20:12,054,710...12,068,219
Ensembl chr20:12,054,711...12,068,237

G

glucose-6-phosphate dehydrogenase

decreases activity
affects expression
increases expression

ISO

Isoniazid results in decreased activity of G6PD protein
Isoniazid affects the expression of G6PD mRNA
Isoniazid results in increased expression of G6PD protein

PMID:20433247 PMID:40015660

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

growth arrest and DNA-damage-inducible, alpha

decreases expression

EXP

Isoniazid results in decreased expression of GADD45A mRNA

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

glucosidase II alpha subunit

increases expression

ISO

Isoniazid results in increased expression of GANAB protein

NCBI chr 1:215,222,918...215,242,808
Ensembl chr 1:215,222,995...215,243,036

G

glyceraldehyde-3-phosphate dehydrogenase

increases expression

EXP

Isoniazid results in increased expression of GAPDH mRNA

NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions
increases expression
decreases expression

ISO
EXP

Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of GCLC mRNA]
Isoniazid results in increased expression of GCLC mRNA; Isoniazid results in increased expression of GCLC protein
chrysin inhibits the reaction [Isoniazid results in increased expression of GCLC mRNA]
Isoniazid results in decreased expression of GCLC mRNA

PMID:24128855 PMID:33121995 PMID:33771660 PMID:40015660

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutamate cysteine ligase, modifier subunit

decreases expression
increases expression
multiple interactions

ISO
EXP

Isoniazid results in decreased expression of GCLM mRNA
Isoniazid results in increased expression of GCLM mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of GCLM mRNA]

PMID:30008028 PMID:33121995 PMID:33771660

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

glial fibrillary acidic protein

multiple interactions
increases expression

EXP

chrysin inhibits the reaction [Isoniazid results in increased expression of GFAP mRNA]; chrysin inhibits the reaction [Isoniazid results in increased expression of GFAP protein]
Isoniazid results in increased expression of GFAP mRNA; Isoniazid results in increased expression of GFAP protein

NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685

G

gamma-glutamyltransferase 1

multiple interactions

EXP

[Lipopolysaccharides co-treated with Isoniazid] results in increased activity of GGT1 protein

NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,141...13,088,050

G

gamma-glutamyltransferase 7

increases expression

ISO

Isoniazid results in increased expression of GGT7 protein

NCBI chr 3:164,438,240...164,464,059
Ensembl chr 3:164,437,812...164,463,068

G

glyoxalase 1

increases expression

ISO

Isoniazid results in increased expression of GLO1 protein

NCBI chr20:8,665,061...8,683,095
Ensembl chr20:8,665,061...8,683,191

G

glutamic-oxaloacetic transaminase 1

multiple interactions
increases expression
increases activity

ISO

[Rifampin co-treated with Isoniazid] results in increased activity of GOT1 protein
Isoniazid results in increased expression of GOT1 protein
Isoniazid results in increased activity of GOT1 protein

PMID:25886055 PMID:40015660

NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871

G

glutamic-oxaloacetic transaminase 2

increases expression

ISO

Isoniazid results in increased expression of GOT2 protein

NCBI chr19:9,180,428...9,206,113
Ensembl chr19:9,180,431...9,206,111

G

glutamic--pyruvic transaminase

increases activity
multiple interactions
increases expression

EXP
ISO

Isoniazid results in increased activity of GPT protein
[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein; [Rifampin co-treated with Isoniazid] results in increased activity of GPT protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein]
Quercetin inhibits the reaction [Isoniazid results in increased expression of GPT protein]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; [Lipopolysaccharides co-treated with Isoniazid] results in increased activity of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]; Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]; Silybin inhibits the reaction [Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]]

PMID:25331106 PMID:25886055 PMID:28619387 PMID:31332904 PMID:32633153 More...

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione peroxidase 1

increases expression
decreases expression

ISO

Isoniazid results in increased expression of GPX1 protein
Isoniazid results in decreased expression of GPX1 mRNA

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

glutathione peroxidase 4

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629

G

growth factor receptor bound protein 2

increases expression

ISO

Isoniazid results in increased expression of GRB2 protein

NCBI chr10:101,380,354...101,448,138
Ensembl chr10:101,380,356...101,448,138

G

glyoxylate and hydroxypyruvate reductase

increases expression

ISO

Isoniazid results in increased expression of GRHPR protein

NCBI chr 5:64,029,856...64,039,287
Ensembl chr 5:64,022,368...64,039,276

G

glutathione-disulfide reductase

increases expression

ISO

Isoniazid results in increased expression of GSR mRNA; Isoniazid results in increased expression of GSR protein

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

glutathione synthetase

decreases expression

ISO

Isoniazid results in decreased expression of GSS protein

NCBI chr 3:164,508,005...164,538,343
Ensembl chr 3:164,508,005...164,538,306

G

glutathione S-transferase alpha 1

decreases expression

ISO

Isoniazid results in decreased expression of GSTA1 protein

NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528

G

glutathione S-transferase alpha 2

increases expression

EXP

Isoniazid results in increased expression of GSTA2 mRNA

NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092

G

glutathione S-transferase kappa 1

decreases expression
increases expression

ISO

Isoniazid results in decreased expression of GSTK1 mRNA
Isoniazid results in increased expression of GSTK1 protein

NCBI chr 4:72,085,532...72,089,934
Ensembl chr 4:72,085,531...72,089,927

G

glutathione S-transferase mu 1

multiple interactions
decreases response to substance

ISO

GSTM1 protein inhibits the reaction [CYP2E1 protein results in increased susceptibility to Isoniazid]
GSTM1 protein results in decreased susceptibility to Isoniazid

NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569

G

glutathione S-transferase, mu 5

increases expression

ISO

Isoniazid results in increased expression of GSTM3 protein

NCBI chr 2:198,219,769...198,222,732
Ensembl chr 2:198,219,647...198,222,731

G

glutathione S-transferase omega 1

increases expression

ISO

Isoniazid results in increased expression of GSTO1 protein

NCBI chr 1:256,662,377...256,672,515
Ensembl chr 1:256,662,531...256,676,167

G

glutathione S-transferase pi 1

decreases expression

EXP

Isoniazid results in decreased expression of GSTP1 mRNA

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

glutathione S-transferase theta 1

multiple interactions

ISO

GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]

PMID:18397238 PMID:20485159

NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,083...12,873,019

G

3-hydroxyacyl-CoA dehydratase 3

increases expression

ISO

Isoniazid results in increased expression of HACD3 protein

NCBI chr 8:74,396,441...74,433,700
Ensembl chr 8:74,396,442...74,433,700

G

hydroxyacyl-CoA dehydrogenase

increases expression

ISO

Isoniazid results in increased expression of HADH protein

NCBI chr 2:222,462,049...222,504,446
Ensembl chr 2:222,462,049...222,504,446

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

decreases expression
increases expression

ISO

Isoniazid results in decreased expression of HADHA mRNA
Isoniazid results in increased expression of HADHA protein

NCBI chr 6:31,907,801...31,947,434
Ensembl chr 6:31,907,291...31,947,698

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta

increases expression
decreases expression

ISO

Isoniazid results in increased expression of HADHB protein
Isoniazid results in decreased expression of HADHB mRNA

NCBI chr 6:31,873,404...31,907,557
Ensembl chr 6:31,873,404...31,907,835

G

hepatitis A virus cellular receptor 1

affects expression

EXP

Isoniazid affects the expression of HAVCR1 mRNA

NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268

G

hepatocyte growth factor

multiple interactions

ISO

HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]

NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

histocompatibility minor 13

decreases expression

ISO

Isoniazid results in decreased expression of HM13 protein

NCBI chr 3:161,606,059...161,641,382
Ensembl chr 3:161,606,052...161,644,805

G

heme oxygenase 1

multiple interactions
increases expression
decreases expression

ISO
EXP

Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]
Isoniazid results in increased expression of HMOX1 mRNA
4-phenylbutyric acid inhibits the reaction [Isoniazid results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Isoniazid results in increased expression of HMOX1 mRNA]; salubrinal inhibits the reaction [Isoniazid results in increased expression of HMOX1 mRNA]; Taurodeoxycholic Acid inhibits the reaction [Isoniazid results in increased expression of HMOX1 mRNA]
Isoniazid results in decreased expression of HMOX1 protein
chrysin inhibits the reaction [Isoniazid results in increased expression of HMOX1 mRNA]
Isoniazid results in decreased expression of HMOX1 mRNA

PMID:24128855 PMID:33121995 PMID:33771660 PMID:40015660

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heme oxygenase 2

increases expression

EXP

Isoniazid results in increased expression of HMOX2 mRNA

NCBI chr10:11,303,512...11,337,640
Ensembl chr10:11,303,512...11,318,800

G

hypoxanthine phosphoribosyltransferase 1

increases expression

EXP

Isoniazid results in increased expression of HPRT1 mRNA

NCBI chr X:137,655,744...137,687,718
Ensembl chr X:137,655,680...137,687,712

G

hydroxysteroid (17-beta) dehydrogenase 12

increases expression

ISO

Isoniazid results in increased expression of HSD17B12 protein

NCBI chr 3:100,445,393...100,568,898
Ensembl chr 3:100,445,400...100,568,938

G

hydroxysteroid (17-beta) dehydrogenase 4

increases expression

ISO

Isoniazid results in increased expression of HSD17B4 protein

NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467

G

heat shock protein 90 alpha family class A member 1

decreases expression

ISO

Isoniazid results in decreased expression of HSP90AA1 protein

NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499

G

heat shock protein 90 alpha family class B member 1

decreases expression

ISO

Isoniazid results in decreased expression of HSP90AB1 protein

NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:22,931,070...22,935,926

G

heat shock protein 90 beta family member 1

increases expression

ISO

Isoniazid results in increased expression of HSP90B1 protein

NCBI chr 7:22,997,962...23,012,293
Ensembl chr 7:22,997,962...23,012,293

G

heat shock protein family A (Hsp70) member 1B

increases expression

ISO

Isoniazid results in increased expression of HSPA1B protein

NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979

G

heat shock protein family A (Hsp70) member 4 like

increases expression

ISO

Isoniazid results in increased expression of HSPA4L protein

NCBI chr 2:125,668,346...125,726,404
Ensembl chr 2:125,668,236...125,720,986

G

heat shock protein family A (Hsp70) member 5

decreases expression

ISO

Isoniazid results in decreased expression of HSPA5 protein

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

heat shock protein family A (Hsp70) member 8

decreases expression

ISO

Isoniazid results in decreased expression of HSPA8 protein

NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372

G

HSPA (Hsp70) binding protein 1

decreases expression

ISO

Isoniazid results in decreased expression of HSPBP1 protein

NCBI chr 1:78,194,067...78,217,836
Ensembl chr 1:78,189,305...78,217,835

G

heat shock protein family H (Hsp110) member 1

increases expression

ISO

Isoniazid results in increased expression of HSPH1 protein

NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891

G

hypoxia up-regulated 1

increases expression

ISO

Isoniazid results in increased expression of HYOU1 mRNA; Isoniazid results in increased expression of HYOU1 protein

NCBI chr 8:53,602,882...53,614,998
Ensembl chr 8:53,602,604...53,614,997

G

isocitrate dehydrogenase (NADP(+)) 2

increases expression

ISO

Isoniazid results in increased expression of IDH2 protein

NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248

G

isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha

increases expression

ISO

Isoniazid results in increased expression of IDH3A mRNA; Isoniazid results in increased expression of IDH3A protein

NCBI chr 8:63,867,882...63,887,223
Ensembl chr 8:63,867,820...63,887,223

G

isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma

decreases expression
increases expression

ISO

Isoniazid results in decreased expression of IDH3G mRNA
Isoniazid results in increased expression of IDH3G protein

NCBI chr X:156,666,573...156,675,482
Ensembl chr X:156,666,577...156,675,799

G

interferon gamma

increases secretion

ISO

Isoniazid results in increased secretion of IFNG protein

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interleukin 10

increases secretion

ISO

Isoniazid results in increased secretion of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 12A

increases secretion

ISO

Isoniazid results in increased secretion of IL12A protein

NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997

G

interleukin 12B

increases secretion

ISO

Isoniazid results in increased secretion of IL12B protein

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194

G

interleukin 17A

increases secretion

ISO

Isoniazid results in increased secretion of IL17A protein

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331

G

interleukin 1 alpha

increases secretion
increases expression

ISO

Isoniazid results in increased secretion of IL1A protein
Isoniazid results in increased expression of IL1A mRNA

PMID:28444390 PMID:32816093

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

increases secretion
multiple interactions
increases expression

ISO
EXP

Isoniazid results in increased secretion of IL1B protein
chrysin inhibits the reaction [Isoniazid results in increased expression of IL1B mRNA]

PMID:28444390 PMID:32816093 PMID:33121995

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 2

multiple interactions

ISO

[Isoniazid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 24

increases expression

ISO

Isoniazid results in increased expression of IL24 mRNA

NCBI chr13:44,905,362...44,910,760
Ensembl chr13:44,905,363...44,910,760

G

interleukin 6

increases expression
multiple interactions
increases secretion

ISO
EXP

Isoniazid results in increased expression of IL6 protein
Isoniazid results in increased expression of IL6 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of IL6 mRNA]
Isoniazid results in increased secretion of IL6 protein

PMID:19575532 PMID:28444390 PMID:33121995

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

inhibin subunit beta E

increases expression

ISO

Isoniazid results in increased expression of INHBE mRNA

NCBI chr 7:65,061,531...65,064,519
Ensembl chr 7:65,061,531...65,064,519

G

inositol 1,4,5-trisphosphate receptor, type 3

increases expression

ISO

Isoniazid results in increased expression of ITPR3 protein

NCBI chr20:5,138,553...5,204,189
Ensembl chr20:5,118,834...5,204,184

G

IZUMO1 receptor, JUNO

decreases expression

ISO

Isoniazid results in decreased expression of IZUMO1R protein

NCBI chr 8:20,025,830...20,030,829
Ensembl chr 8:20,025,831...20,029,578

G

Kelch-like ECH-associated protein 1

decreases expression

ISO

Isoniazid results in decreased expression of KEAP1 mRNA

NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042

G

lysosomal-associated membrane protein 1

affects response to substance

ISO

LAMP1 affects the susceptibility to Isoniazid

NCBI chr16:83,058,131...83,082,843
Ensembl chr16:83,058,385...83,075,159

G

LanC like glutathione S-transferase 1

decreases expression

ISO

Isoniazid results in decreased expression of LANCL1 protein

NCBI chr 9:75,968,284...75,998,397
Ensembl chr 9:75,968,286...76,003,475

G

leucine aminopeptidase 3

increases expression

ISO

Isoniazid results in increased expression of LAP3 protein

NCBI chr14:69,820,907...69,839,891
Ensembl chr14:69,820,908...69,839,891

G

lipocalin 2

increases expression

EXP

Isoniazid results in increased expression of LCN2 mRNA

NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842

G

lactate dehydrogenase A

decreases expression

ISO

Isoniazid results in decreased expression of LDHA protein

NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521

G

lectin, mannose-binding, 1

increases expression

ISO

Isoniazid results in increased expression of LMAN1 protein

NCBI chr18:61,778,971...61,800,960
Ensembl chr18:61,772,917...61,800,820

G

lectin, mannose-binding 2

increases expression

ISO

Isoniazid results in increased expression of LMAN2 protein

NCBI chr17:9,274,362...9,294,950
Ensembl chr17:9,274,136...9,292,370

G

lysophosphatidylcholine acyltransferase 3

increases expression

ISO

Isoniazid results in increased expression of LPCAT3 protein

NCBI chr 4:159,154,690...159,196,176
Ensembl chr 4:159,154,158...159,196,358

G

LDL receptor related protein associated protein 1

increases expression

ISO

Isoniazid results in increased expression of LRPAP1 protein

NCBI chr14:79,876,002...79,888,011
Ensembl chr14:79,875,708...79,890,034

G

mannosidase, alpha, class 1A, member 1

decreases expression

ISO

Isoniazid results in decreased expression of MAN1A1 protein

NCBI chr20:33,745,158...33,928,584
Ensembl chr20:33,745,165...33,928,584

G

microtubule-associated protein 2

affects expression

ISO

Isoniazid affects the expression of MAP2 mRNA

NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:75,288,262...75,428,459

G

mitogen activated protein kinase kinase 2

decreases expression

ISO

Isoniazid results in decreased expression of MAP2K2 protein

NCBI chr 7:9,241,449...9,264,216
Ensembl chr 7:9,241,310...9,260,940

G

mitogen activated protein kinase kinase 7

decreases expression

ISO

Isoniazid results in decreased expression of MAP2K7 protein

NCBI chr12:7,389,032...7,398,377
Ensembl chr12:7,389,155...7,398,377

G

mitogen activated protein kinase 1

decreases phosphorylation
multiple interactions

ISO

Isoniazid results in decreased phosphorylation of MAPK1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK1 protein]]; Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions
decreases expression
decreases phosphorylation

ISO

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK3 protein]]; Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK3 protein]
Isoniazid results in decreased expression of MAPK3 protein

PMID:31332904 PMID:40015660

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 9

increases expression

ISO

Isoniazid results in increased expression of MAPK9 protein

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228

G

methionine adenosyltransferase 1A

decreases expression

ISO

Isoniazid results in decreased expression of MAT1A protein

NCBI chr16:17,017,168...17,035,368
Ensembl chr16:17,016,030...17,035,367

G

methionine adenosyltransferase 2A

decreases expression

ISO

Isoniazid results in decreased expression of MAT2A protein

NCBI chr 4:106,048,043...106,053,612
Ensembl chr 4:106,038,254...106,053,645

G

methionine adenosyltransferase 2 non-catalytic beta subunit

decreases expression

ISO

Isoniazid results in decreased expression of MAT2B protein

NCBI chr10:25,609,202...25,626,694
Ensembl chr10:25,609,204...25,625,176

G

malate dehydrogenase 1

increases expression

ISO

Isoniazid results in increased expression of MDH1 protein

NCBI chr14:99,831,934...99,847,227
Ensembl chr14:99,831,615...99,847,232

G

malate dehydrogenase 2

increases expression

ISO

Isoniazid results in increased expression of MDH2 protein

NCBI chr12:26,530,886...26,543,841
Ensembl chr12:26,530,881...26,543,841

G

mitochondrial trans-2-enoyl-CoA reductase

increases expression

ISO

Isoniazid results in increased expression of MECR protein

NCBI chr 5:149,313,765...149,339,964
Ensembl chr 5:149,313,774...149,342,825

G

microsomal glutathione S-transferase 1

increases expression

ISO

Isoniazid results in increased expression of MGST1 mRNA
Isoniazid results in increased expression of MGST1 protein

PMID:33771660 PMID:40015660

NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:172,760,886...172,776,875

G

microsomal glutathione S-transferase 2

increases expression

ISO

Isoniazid results in increased expression of MGST2 protein

NCBI chr 2:137,821,787...137,866,664
Ensembl chr 2:137,836,140...137,866,661

G

microRNA 106b

decreases expression

EXP

Isoniazide decreased expression of miR106b miRNA in the liver

RGD

NCBI chr12:22,157,053...22,157,134

G

microRNA 186

multiple interactions

ISO

[Isoniazid co-treated with Rifampin] results in increased expression of MIR186 mRNA

NCBI chr 2:249,241,650...249,241,735
Ensembl chr 2:249,241,650...249,241,735

G

mannosyl-oligosaccharide glucosidase

increases expression

ISO

Isoniazid results in increased expression of MOGS protein

NCBI chr 4:117,179,335...117,182,738
Ensembl chr 4:117,179,335...117,182,744

G

myeloperoxidase

multiple interactions
increases oxidation

ISO

[[MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of Free Radicals] which results in increased chemical synthesis of isonicotinyl-NAD; [MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of Free Radicals; [MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of isonicotinyl-NAD

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

methylthioribose-1-phosphate isomerase 1

decreases expression

ISO

Isoniazid results in decreased expression of MRI1 protein

NCBI chr19:40,812,114...40,819,846
Ensembl chr19:40,812,094...40,822,607

G

mitochondrially encoded ATP synthase membrane subunit 6

increases expression

ISO

Isoniazid results in increased expression of ATP6 protein

NCBI chr MT:7,919...8,599
Ensembl chr MT:7,904...8,584

G

mitochondrially encoded cytochrome c oxidase II

increases expression
decreases expression

ISO

Isoniazid results in increased expression of COX2 mRNA
Isoniazid results in decreased expression of COX2 protein

NCBI chr MT:7,006...7,689
Ensembl chr MT:6,991...7,674

G

mitochondrially encoded cytochrome c oxidase III

increases expression

EXP

Isoniazid results in increased expression of COX3 mRNA

NCBI chr MT:8,599...9,382
Ensembl chr MT:8,584...9,367

G

mitochondrially encoded cytochrome b

increases expression

ISO

Isoniazid results in increased expression of CYTB protein

NCBI chr MT:14,136...15,278
Ensembl chr MT:14,124...15,266

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3

decreases expression
increases expression

ISO

Isoniazid results in decreased expression of ND3 protein
Isoniazid results in increased expression of ND3 mRNA

NCBI chr MT:9,451...9,798
Ensembl chr MT:9,436...9,783

G

methylthioadenosine phosphorylase

increases expression

ISO

Isoniazid results in increased expression of MTAP protein

NCBI chr 5:108,990,270...109,036,494
Ensembl chr 5:108,988,830...109,055,214

G

mucin 1, cell surface associated

increases expression

ISO

Isoniazid results in increased expression of MUC1 mRNA

NCBI chr 2:176,933,312...176,938,497
Ensembl chr 2:176,933,047...176,938,491

G

myosin ID

increases expression

ISO

Isoniazid results in increased expression of MYO1D protein

NCBI chr10:65,986,900...66,263,538
Ensembl chr10:65,975,122...66,263,958

G

N-acetyltransferase 2

increases acetylation
affects acetylation
multiple interactions
decreases expression
decreases acetylation
increases metabolic processing
affects metabolic processing
affects response to substance

ISO
EXP

NAT2 protein polymorphism results in increased acetylation of Isoniazid; NAT2 protein results in increased acetylation of Isoniazid
NAT2 protein polymorphism affects the acetylation of Isoniazid
[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA]
Isoniazid results in decreased expression of NAT2 mRNA
[NAT2 gene polymorphism results in decreased acetylation of Isoniazid] which results in decreased abundance of acetylisoniazid; [NAT2 gene polymorphism results in decreased metabolism of Isoniazid] which results in increased abundance of hydrazine
NAT2 protein results in increased metabolism of Isoniazid
NAT2 protein affects the metabolism of Isoniazid; NAT2 protein polymorphism affects the metabolism of Isoniazid
NAT2 gene polymorphism affects the susceptibility to Isoniazid; NAT2 gene SNP affects the susceptibility to Isoniazid

PMID:11379777 PMID:11915035 PMID:15546075 PMID:15565348 PMID:15618686 More...

NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304

G

natural killer cell cytotoxicity receptor 3 ligand 1

increases expression

ISO

Isoniazid results in increased expression of NCR3LG1 mRNA; Isoniazid results in increased expression of NCR3LG1 protein

NCBI chr 1:105,701,953...105,718,251
Ensembl chr 1:105,710,883...105,716,732

G

NADH:ubiquinone oxidoreductase subunit A1

affects expression

ISO

Isoniazid affects the expression of NDUFA1 mRNA

NCBI chr X:121,289,904...121,293,555
Ensembl chr X:121,289,925...121,293,555

G

NADH:ubiquinone oxidoreductase subunit A10

affects expression

ISO

Isoniazid affects the expression of NDUFA10 mRNA

NCBI chr 9:100,454,498...100,490,023
Ensembl chr 9:100,437,379...100,489,264

G

NADH:ubiquinone oxidoreductase subunit A12

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFA12 mRNA
Isoniazid results in decreased expression of NDUFA12 mRNA; Isoniazid results in decreased expression of NDUFA12 protein

PMID:24848797 PMID:40015660

NCBI chr 7:30,658,316...30,685,302
Ensembl chr 7:30,658,322...30,686,300

G

NADH:ubiquinone oxidoreductase subunit A13

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFA13 mRNA
Isoniazid results in decreased expression of NDUFA13 protein

PMID:24848797 PMID:40015660

NCBI chr16:19,560,526...19,567,500
Ensembl chr 7:32,257,006...32,257,492

G

NADH:ubiquinone oxidoreductase subunit A2

decreases expression

ISO

Isoniazid results in decreased expression of NDUFA2 mRNA; Isoniazid results in decreased expression of NDUFA2 protein

NCBI chr18:28,629,795...28,631,884
Ensembl chr18:28,629,795...28,631,884

G

Ndufa4, mitochondrial complex associated

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFA4 mRNA
Isoniazid results in decreased expression of COXFA4 mRNA; Isoniazid results in decreased expression of COXFA4 protein

PMID:24848797 PMID:40015660

NCBI chr 4:40,968,391...40,975,559
Ensembl chr 4:40,968,391...40,975,559

G

NADH:ubiquinone oxidoreductase subunit A5

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFA5 mRNA
Isoniazid results in decreased expression of NDUFA5 protein

PMID:24848797 PMID:40015660

NCBI chr 4:53,962,877...53,971,235
Ensembl chr 4:53,962,877...53,971,235

G

NADH:ubiquinone oxidoreductase subunit A8

affects expression

ISO

Isoniazid affects the expression of NDUFA8 mRNA

NCBI chr 3:39,783,479...39,799,507
Ensembl chr 3:39,783,479...39,799,507

G

NADH:ubiquinone oxidoreductase subunit A9

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFA9 mRNA
Isoniazid results in decreased expression of NDUFA9 protein

PMID:24848797 PMID:40015660

NCBI chr 4:161,345,398...161,374,188
Ensembl chr 4:161,345,400...161,375,025

G

NADH:ubiquinone oxidoreductase subunit AB1

affects expression
increases expression

ISO

Isoniazid affects the expression of NDUFAB1 mRNA
Isoniazid results in increased expression of NDUFAB1 protein

PMID:24848797 PMID:40015660

NCBI chr 1:186,075,933...186,091,843
Ensembl chr 1:186,057,113...186,089,373

G

NADH:ubiquinone oxidoreductase subunit B1

decreases expression

ISO

Isoniazid results in decreased expression of NDUFB1 protein

NCBI chr 6:126,880,537...126,888,935
Ensembl chr 6:126,880,537...126,888,864

G

NADH:ubiquinone oxidoreductase subunit B10

affects expression

ISO

Isoniazid affects the expression of NDUFB10 mRNA

NCBI chr10:14,253,805...14,255,966
Ensembl chr10:14,253,805...14,255,966

G

NADH:ubiquinone oxidoreductase subunit B2

affects expression

ISO

Isoniazid affects the expression of NDUFB2 mRNA

NCBI chr 4:69,334,307...69,341,394
Ensembl chr 4:69,334,307...69,340,136
Ensembl chr15:69,334,307...69,340,136

G

NADH:ubiquinone oxidoreductase subunit B3

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFB3 mRNA
Isoniazid results in decreased expression of NDUFB3 protein

PMID:24848797 PMID:40015660

NCBI chr 9:67,623,417...67,633,629
Ensembl chr 9:67,623,614...67,633,613

G

NADH:ubiquinone oxidoreductase subunit B5

affects expression

ISO

Isoniazid affects the expression of NDUFB5 mRNA

NCBI chr 2:117,447,605...117,461,943
Ensembl chr 2:117,447,035...117,461,590

G

NADH:ubiquinone oxidoreductase subunit B6

affects expression

ISO

Isoniazid affects the expression of NDUFB6 mRNA

NCBI chr 5:60,196,585...60,206,152
Ensembl chr 5:60,196,585...60,206,055

G

NADH:ubiquinone oxidoreductase subunit B7

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFB7 mRNA
Isoniazid results in decreased expression of NDUFB7 mRNA; Isoniazid results in decreased expression of NDUFB7 protein

PMID:24848797 PMID:40015660

NCBI chr19:41,472,953...41,477,291
Ensembl chr19:41,472,953...41,477,291

G

NADH:ubiquinone oxidoreductase subunit B9

decreases expression

ISO

Isoniazid results in decreased expression of NDUFB9 protein

NCBI chr 7:92,370,423...92,376,841
Ensembl chr 7:92,370,467...92,379,955

G

NADH:ubiquinone oxidoreductase core subunit S1

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFS1 mRNA
Isoniazid results in decreased expression of NDUFS1 mRNA; Isoniazid results in decreased expression of NDUFS1 protein

PMID:24848797 PMID:40015660

NCBI chr 9:72,040,286...72,073,605
Ensembl chr 9:72,040,090...72,073,605

G

NADH:ubiquinone oxidoreductase core subunit S2

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFS2 mRNA
Isoniazid results in decreased expression of NDUFS2 protein

PMID:24848797 PMID:40015660

NCBI chr13:86,186,867...86,203,914
Ensembl chr13:86,186,870...86,203,608

G

NADH:ubiquinone oxidoreductase core subunit S3

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFS3 mRNA
Isoniazid results in decreased expression of NDUFS3 protein

PMID:24848797 PMID:40015660

NCBI chr 3:97,332,477...97,339,654
Ensembl chr 3:97,332,477...97,345,323

G

NADH:ubiquinone oxidoreductase subunit S4

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFS4 mRNA
Isoniazid results in decreased expression of NDUFS4 mRNA; Isoniazid results in decreased expression of NDUFS4 protein

PMID:24848797 PMID:40015660

NCBI chr 2:47,684,420...47,794,914
Ensembl chr 2:47,684,406...47,794,931

G

NADH:ubiquinone oxidoreductase subunit S5

decreases expression

ISO

Isoniazid results in decreased expression of NDUFS5 mRNA; Isoniazid results in decreased expression of NDUFS5 protein

NCBI chr 5:141,258,828...141,264,552
Ensembl chr 2:184,849,197...185,028,909
Ensembl chr 5:184,849,197...185,028,909
Ensembl chr14:184,849,197...185,028,909

G

NADH:ubiquinone oxidoreductase subunit S6

decreases expression

ISO

Isoniazid results in decreased expression of NDUFS6 protein

NCBI chr 1:31,797,400...31,805,965
Ensembl chr 1:31,797,394...31,805,965

G

NADH:ubiquinone oxidoreductase core subunit S7

decreases expression

ISO

Isoniazid results in decreased expression of NDUFS7 mRNA; Isoniazid results in decreased expression of NDUFS7 protein

NCBI chr 7:10,103,226...10,110,862
Ensembl chr 7:10,103,227...10,110,691

G

NADH:ubiquinone oxidoreductase core subunit S8

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFS8 mRNA
Isoniazid results in decreased expression of NDUFS8 mRNA; Isoniazid results in decreased expression of NDUFS8 protein

PMID:24848797 PMID:40015660

NCBI chr 1:210,569,823...210,573,707
Ensembl chr 1:210,569,824...210,572,971

G

NADH:ubiquinone oxidoreductase core subunit V1

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFV1 mRNA
Isoniazid results in decreased expression of NDUFV1 mRNA; Isoniazid results in decreased expression of NDUFV1 protein

PMID:24848797 PMID:40015660

NCBI chr 1:210,729,856...210,735,103
Ensembl chr 1:210,729,858...210,734,949

G

NADH:ubiquinone oxidoreductase core subunit V2

affects expression
decreases expression

ISO

Isoniazid affects the expression of NDUFV2 mRNA
Isoniazid results in decreased expression of NDUFV2 protein

PMID:24848797 PMID:40015660

NCBI chr 9:113,137,305...113,157,571
Ensembl chr 9:113,137,306...113,157,520

G

NFE2 like bZIP transcription factor 2

increases activity
affects localization
increases expression
affects response to substance
multiple interactions

ISO
EXP

Isoniazid results in increased activity of NFE2L2 protein
Isoniazid affects the localization of NFE2L2 protein
Isoniazid results in increased expression of NFE2L2 mRNA
NFE2L2 protein affects the susceptibility to Isoniazid
NFE2L2 protein affects the reaction [Isoniazid results in increased expression of HMOX1 mRNA]
chrysin inhibits the reaction [Isoniazid results in increased expression of NFE2L2 mRNA]

PMID:30203046 PMID:33121995 PMID:33771660 PMID:40015660

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor kappa B subunit 1

increases expression
multiple interactions

EXP

Isoniazid results in increased expression of NFKB1 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of NFKB1 mRNA]

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

NPL4 homolog, ubiquitin recognition factor

decreases expression

ISO

Isoniazid results in decreased expression of NPLOC4 protein

NCBI chr10:106,152,756...106,208,306
Ensembl chr10:106,153,173...106,208,264

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression
decreases expression

ISO
EXP

Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]
Isoniazid results in increased expression of NQO1 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of NQO1 mRNA]
Isoniazid results in increased expression of NQO1 mRNA; Isoniazid results in increased expression of NQO1 protein
Isoniazid results in decreased expression of NQO1 mRNA

PMID:24128855 PMID:28444390 PMID:33121995 PMID:33771660 PMID:40015660

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 0, group B, member 2

decreases expression
multiple interactions

EXP
ISO

Isoniazid results in decreased expression of NR0B2 mRNA
[Isoniazid co-treated with Vitamin B 6] results in decreased expression of NR0B2 mRNA
obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR0B2 mRNA]

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions
decreases expression

EXP
ISO

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of NR1H4 mRNA; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of NR1H4 protein; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR1H4 mRNA]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; [Isoniazid co-treated with Vitamin B 6] results in decreased expression of NR1H4 mRNA
isoniazide decreases expression of nr1h4 protein in rat liver

CTD
RGD

PMID:25331106 PMID:32673658 PMID:35835356 PMID:30068870

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389

G

nuclear receptor subfamily 1, group I, member 3

increases activity

ISO

Isoniazid results in increased activity of NR1I3 protein

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370

G

NRAS proto-oncogene, GTPase

increases expression

ISO

Isoniazid results in increased expression of NRAS protein

NCBI chr 2:193,271,399...193,282,023
Ensembl chr 2:193,271,430...193,278,543

G

nuclear respiratory factor 1

multiple interactions
decreases expression

ISO

acadesine inhibits the reaction [Isoniazid results in decreased expression of NRF1 protein]

NCBI chr 4:59,632,366...59,738,166
Ensembl chr 4:59,632,372...59,738,353

G

nuclear protein 1, transcriptional regulator

increases expression

ISO

Isoniazid results in increased expression of NUPR1 mRNA

NCBI chr 1:190,643,866...190,645,901
Ensembl chr 1:190,643,867...190,645,901

G

oxoglutarate dehydrogenase

affects expression
increases expression

ISO

Isoniazid affects the expression of OGDH mRNA
Isoniazid results in increased expression of OGDH mRNA; Isoniazid results in increased expression of OGDH protein

PMID:24848797 PMID:40015660

NCBI chr14:85,363,949...85,431,405
Ensembl chr14:85,364,014...85,432,271

G

5-oxoprolinase (ATP-hydrolysing)

decreases expression

ISO

Isoniazid results in decreased expression of OPLAH protein

NCBI chr 7:109,892,136...109,932,403
Ensembl chr 7:109,891,405...109,915,979

G

prolyl 4-hydroxylase subunit beta

increases expression

ISO

Isoniazid results in increased expression of P4HB protein

NCBI chr10:106,335,300...106,346,911
Ensembl chr10:106,335,300...106,346,911

G

Parkinsonism associated deglycase

affects expression

ISO

Isoniazid affects the expression of PARK7 mRNA

NCBI chr 5:166,636,551...166,659,825
Ensembl chr 5:166,636,552...166,659,825

G

pyruvate carboxylase

increases expression

ISO

Isoniazid results in increased expression of PC protein

NCBI chr 1:211,228,708...211,327,792
Ensembl chr 1:211,228,731...211,329,940

G

poly(rC) binding protein 1

decreases expression

ISO

Isoniazid results in decreased expression of PCBP1 protein

NCBI chr 4:120,530,100...120,532,107
Ensembl chr 4:120,529,172...120,539,111

G

poly(rC) binding protein 2

decreases expression

ISO

Isoniazid results in decreased expression of PCBP2 protein

NCBI chr 7:135,483,702...135,508,254
Ensembl chr 7:135,483,856...135,509,412

G

phosphoenolpyruvate carboxykinase 2 (mitochondrial)

decreases expression

ISO

Isoniazid results in decreased expression of PCK2 protein

NCBI chr15:32,997,853...33,006,691
Ensembl chr15:32,997,834...33,016,864

G

pyruvate dehydrogenase E1 subunit alpha 1

increases expression

ISO

Isoniazid results in increased expression of PDHA1 protein

NCBI chr X:38,509,158...38,522,986
Ensembl chr X:38,509,084...38,522,536

G

pyruvate dehydrogenase E1 subunit beta

increases expression

ISO

Isoniazid results in increased expression of PDHB protein

NCBI chr15:19,182,789...19,188,731
Ensembl chr15:19,181,208...19,188,976

G

protein disulfide isomerase family A, member 3

increases expression

ISO

Isoniazid results in increased expression of PDIA3 mRNA; Isoniazid results in increased expression of PDIA3 protein

NCBI chr 3:128,841,781...128,865,733
Ensembl chr 3:128,841,917...128,867,327

G

protein disulfide isomerase family A, member 4

decreases expression
increases expression

ISO

Isoniazid results in decreased expression of PDIA4 mRNA
Isoniazid results in increased expression of PDIA4 protein

NCBI chr 4:78,134,144...78,153,191
Ensembl chr 4:78,134,144...78,153,191

G

protein disulfide isomerase family A, member 6

increases expression

ISO

Isoniazid results in increased expression of PDIA6 protein

NCBI chr 6:45,791,704...45,808,947
Ensembl chr 6:45,791,678...45,810,091

G

progesterone receptor membrane component 1

increases expression

ISO

Isoniazid results in increased expression of PGRMC1 protein

NCBI chr X:120,698,610...120,706,805
Ensembl chr X:120,698,610...120,706,805

G

phosphoglycerate dehydrogenase

decreases expression

ISO

Isoniazid results in decreased expression of PHGDH protein

NCBI chr 2:188,595,700...188,624,789
Ensembl chr 2:188,595,700...188,624,789

G

phosphotyrosine interaction domain containing 1

increases expression

ISO

Isoniazid results in increased expression of PID1 mRNA

NCBI chr 9:92,732,471...92,951,168
Ensembl chr 9:92,734,214...92,750,070

G

pyruvate kinase L/R

decreases expression

ISO

Isoniazid results in decreased expression of PKLR protein

NCBI chr 2:176,840,779...176,849,637
Ensembl chr 2:176,840,764...176,849,644

G

pyruvate kinase M1/2

increases expression

ISO

Isoniazid results in increased expression of PKM protein

NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396

G

phospholipase D1

increases expression

ISO

Isoniazid results in increased expression of PLD1 protein

NCBI chr 2:112,777,820...112,975,857
Ensembl chr 2:112,777,951...112,976,245

G

procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1

decreases expression

ISO

Isoniazid results in decreased expression of PLOD1 protein

NCBI chr 5:163,623,847...163,650,737
Ensembl chr 5:163,623,848...163,651,110

G

procollagen lysine, 2-oxoglutarate 5-dioxygenase 2

increases expression
affects expression

ISO

Isoniazid results in increased expression of PLOD2 mRNA
Isoniazid affects the expression of PLOD2 protein

PMID:15997088 PMID:40015660

NCBI chr 8:101,964,318...102,047,022
Ensembl chr 8:101,964,318...102,047,022

G

procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3

increases expression

ISO

Isoniazid results in increased expression of PLOD3 protein

NCBI chr12:25,313,070...25,323,631
Ensembl chr12:25,313,072...25,323,631

G

cytochrome p450 oxidoreductase

multiple interactions
decreases expression

EXP

[Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA]
Isoniazid results in decreased expression of POR mRNA

NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809

G

inorganic pyrophosphatase 1

decreases expression

ISO

Isoniazid results in decreased expression of PPA1 protein

NCBI chr20:30,132,088...30,160,492
Ensembl chr20:30,133,504...30,160,489

G

peroxisome proliferator activated receptor alpha

increases activity
multiple interactions

ISO

Isoniazid results in increased activity of PPARA protein
[Isoniazid co-treated with Rifampin] results in decreased expression of PPARA protein

PMID:30203046 PMID:36347327

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

peroxisome proliferator-activated receptor gamma

decreases expression
multiple interactions

ISO

Isoniazid results in decreased expression of PPARG mRNA
[Isoniazid co-treated with Rifampin] results in decreased expression of PPARG protein
Isoniazid results in decreased expression of PPARG mRNA; Isoniazid results in decreased expression of PPARG protein

PMID:24128855 PMID:36347327

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

PPARG coactivator 1 alpha

decreases expression
multiple interactions

ISO

Isoniazid results in decreased expression of PPARGC1A protein
acadesine inhibits the reaction [Isoniazid results in decreased expression of PPARGC1A protein]

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

peptidylprolyl isomerase B

increases expression

ISO

Isoniazid results in increased expression of PPIB protein

NCBI chr 8:75,498,966...75,504,823
Ensembl chr 8:75,498,797...75,504,847

G

protein phosphatase 5, catalytic subunit

increases expression

ISO

Isoniazid results in increased expression of PPP5C protein

NCBI chr 1:86,818,297...86,842,505
Ensembl chr 1:86,818,297...86,842,950

G

palmitoyl-protein thioesterase 1

increases expression

ISO

Isoniazid results in increased expression of PPT1 protein

NCBI chr 5:140,406,318...140,427,201
Ensembl chr 5:140,406,214...140,427,200

G

peroxiredoxin 6

decreases expression

ISO

Isoniazid results in decreased expression of PRDX6 protein

NCBI chr13:76,062,082...76,072,631
Ensembl chr13:76,061,554...76,072,657

G

PRKCSH beta subunit of glucosidase II

increases expression

ISO

Isoniazid results in increased expression of PRKCSH protein

NCBI chr 8:28,810,836...28,822,503
Ensembl chr 8:28,810,889...28,822,503

G

phosphoserine aminotransferase 1

decreases expression

ISO

Isoniazid results in decreased expression of PSAT1 protein

NCBI chr 1:222,623,553...222,646,187
Ensembl chr 1:222,623,556...222,655,693

G

presenilin 1

affects expression

ISO

Isoniazid affects the expression of PSEN1 mRNA

NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189

G

proteasome assembly chaperone 1

decreases expression

ISO

Isoniazid results in decreased expression of PSMG1 protein

NCBI chr11:48,745,581...48,755,040
Ensembl chr11:48,745,581...48,755,040

G

proteasome assembly chaperone 2

increases expression

ISO

Isoniazid results in increased expression of PSMG2 protein

NCBI chr18:63,478,620...63,493,193

G

prostaglandin E synthase 3

decreases expression

ISO

Isoniazid results in decreased expression of PTGES3 protein

NCBI chr 7:1,075,230...1,092,363
Ensembl chr 7:1,075,227...1,092,695

G

prostaglandin-endoperoxide synthase 2

increases expression

ISO

Isoniazid results in increased expression of PTGS2 mRNA

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

protein tyrosine phosphatase, non-receptor type 1

increases expression

ISO

Isoniazid results in increased expression of PTPN1 protein

NCBI chr 3:177,056,588...177,106,424
Ensembl chr 3:177,057,659...177,106,416

G

protein tyrosine phosphatase, non-receptor type 11

increases expression

ISO

Isoniazid results in increased expression of PTPN11 protein

NCBI chr12:41,026,079...41,085,577
Ensembl chr12:41,043,785...41,085,577

G

RAB14, member RAS oncogene family

increases expression

ISO

Isoniazid results in increased expression of RAB14 protein

NCBI chr 3:38,899,430...38,920,572
Ensembl chr 3:38,901,400...38,912,273

G

RAD23 homolog B, nucleotide excision repair protein

decreases expression

ISO

Isoniazid results in decreased expression of RAD23B protein

NCBI chr 5:74,885,518...74,923,621
Ensembl chr 5:74,885,516...74,962,426

G

ribosomal protein L10

decreases expression

ISO

Isoniazid results in decreased expression of RPL10 protein

NCBI chr X:157,205,850...157,208,057
Ensembl chr X:157,205,836...157,208,049

G

ribosomal protein L18

decreases expression

ISO

Isoniazid results in decreased expression of RPL18 protein

NCBI chr 1:105,325,269...105,327,911
Ensembl chr 1:105,325,250...105,327,910

G

ribosomal protein L27

decreases expression

ISO

Isoniazid results in decreased expression of RPL27 protein

NCBI chr10:86,875,758...86,879,457
Ensembl chr10:86,876,024...86,879,441

G

ribosomal protein L4

decreases expression

ISO

Isoniazid results in decreased expression of RPL4 protein

NCBI chr 8:73,566,477...73,571,600
Ensembl chr 8:73,566,466...73,571,788

G

ribosomal protein L6

decreases expression

ISO

Isoniazid results in decreased expression of RPL6 protein

NCBI chr12:41,008,142...41,012,756
Ensembl chr12:41,008,142...41,025,733

G

ribophorin I

increases expression

ISO

Isoniazid results in increased expression of RPN1 protein

NCBI chr 4:122,100,976...122,122,382
Ensembl chr 4:122,100,813...122,122,382

G

ribosomal protein S21, pseudogene 1

decreases expression

ISO

Isoniazid results in decreased expression of RPS21 protein

NCBI chr 5:158,670,141...158,670,484
Ensembl chr 5:158,670,116...158,670,490

G

ribosomal protein S23

decreases expression

ISO

Isoniazid results in decreased expression of RPS23 protein

NCBI chr 2:23,814,517...23,816,087
Ensembl chr 2:23,814,497...23,816,088

G

ribosomal protein S26

decreases expression

ISO

Isoniazid results in decreased expression of RPS26 protein

NCBI chr 7:1,641,846...1,643,404
Ensembl chr 7:1,641,421...1,643,399

G

ribosomal protein S28

decreases expression

ISO

Isoniazid results in decreased expression of RPS28 protein

NCBI chr 7:15,309,964...15,311,333
Ensembl chr16:72,591,164...72,591,373
Ensembl chr 7:72,591,164...72,591,373
Ensembl chr16:72,591,164...72,591,373

G

ribosomal protein S29

decreases expression

ISO

Isoniazid results in decreased expression of RPS29 protein

NCBI chr 6:93,371,293...93,372,731
Ensembl chr13:87,816,954...87,817,267
Ensembl chr 6:87,816,954...87,817,267

G

ribosome binding protein 1

decreases expression

ISO

Isoniazid results in decreased expression of RRBP1 protein

NCBI chr 3:151,768,386...151,830,255
Ensembl chr 3:151,768,386...151,830,255

G

ribonucleotide reductase catalytic subunit M1

decreases expression

ISO

Isoniazid results in decreased expression of RRM1 protein

NCBI chr 1:166,235,904...166,260,206
Ensembl chr 1:166,235,900...166,260,944

G

ribonucleotide reductase regulatory subunit M2

decreases expression

ISO

Isoniazid results in decreased expression of RRM2 protein

NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370

G

ribonucleotide reductase regulatory TP53 inducible subunit M2B

increases expression

ISO

Isoniazid results in increased expression of RRM2B protein

NCBI chr 7:70,962,008...70,993,726
Ensembl chr 7:70,965,590...70,993,670

G

RuvB-like AAA ATPase 1

increases expression

ISO

Isoniazid results in increased expression of RUVBL1 protein

NCBI chr 4:122,489,754...122,524,666
Ensembl chr 4:122,489,680...122,524,665

G

secretion associated, Ras related GTPase 1A

increases expression

ISO

Isoniazid results in increased expression of SAR1A protein

NCBI chr20:30,166,310...30,178,718
Ensembl chr20:30,166,334...30,178,710

G

stearoyl-CoA desaturase

decreases expression

ISO

Isoniazid results in decreased expression of SCD protein

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785

G

sterol carrier protein 2

increases expression

ISO

Isoniazid results in increased expression of SCP2 protein

NCBI chr 5:128,035,714...128,110,015
Ensembl chr 5:128,008,125...128,110,043

G

stromal cell derived factor 2

increases expression

ISO

Isoniazid results in increased expression of SDF2 protein

NCBI chr10:63,638,634...63,649,109
Ensembl chr10:63,638,634...63,649,108

G

succinate dehydrogenase complex flavoprotein subunit A

affects expression
increases expression
decreases expression

ISO

Isoniazid affects the expression of SDHA mRNA
Isoniazid results in increased expression of SDHA mRNA
Isoniazid results in decreased expression of SDHA protein

PMID:24848797 PMID:40015660

NCBI chr 1:30,764,553...30,789,523
Ensembl chr 1:30,764,590...30,790,121

G

succinate dehydrogenase complex iron sulfur subunit B

affects expression
decreases expression

ISO

Isoniazid affects the expression of SDHB mRNA
Isoniazid results in decreased expression of SDHB mRNA; Isoniazid results in decreased expression of SDHB protein

PMID:24848797 PMID:40015660

NCBI chr 5:158,547,775...158,568,589
Ensembl chr 5:158,547,689...158,569,667

G

succinate dehydrogenase complex subunit C

decreases expression
increases expression

ISO

Isoniazid results in decreased expression of SDHC protein
Isoniazid results in increased expression of SDHC mRNA

NCBI chr13:86,077,133...86,098,025
Ensembl chr13:86,077,134...86,098,044

G

succinate dehydrogenase complex subunit D

affects expression

ISO

Isoniazid affects the expression of SDHD mRNA

NCBI chr 8:59,841,090...59,850,641
Ensembl chr 8:59,841,090...59,850,641

G

SEC24 homolog B, COPII coat complex component

decreases expression

ISO

Isoniazid results in decreased expression of SEC24B protein

NCBI chr 2:221,236,897...221,306,986
Ensembl chr 2:221,236,898...221,306,919

G

SEC31 homolog A, COPII coat complex component

decreases expression

ISO

Isoniazid results in decreased expression of SEC31A protein

NCBI chr14:9,518,655...9,573,579
Ensembl chr14:9,518,648...9,573,585

G

Sec61 translocon subunit gamma

decreases expression

ISO

Isoniazid results in decreased expression of SEC61G protein

NCBI chr14:95,113,083...95,119,458
Ensembl chr 9:48,798,504...48,798,710
Ensembl chr14:48,798,504...48,798,710

G

SEC63 homolog, protein translocation regulator

decreases expression

ISO

Isoniazid results in decreased expression of SEC63 protein

NCBI chr20:47,827,291...47,896,248
Ensembl chr20:47,827,291...47,896,248

G

SEL1L adaptor subunit of SYVN1 ubiquitin ligase

increases expression

ISO

Isoniazid results in increased expression of SEL1L protein

NCBI chr 6:116,466,163...116,510,436
Ensembl chr 6:116,466,163...116,510,578

G

stratifin

decreases expression

ISO

Isoniazid results in decreased expression of SFN mRNA

NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:151,110,530...151,111,995

G

SIL1 nucleotide exchange factor

decreases expression

ISO

Isoniazid results in decreased expression of SIL1 protein

NCBI chr18:27,146,526...27,378,459
Ensembl chr18:27,146,527...27,307,693

G

sirtuin 1

multiple interactions
decreases expression

ISO

acadesine inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein]; Quercetin inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein]

PMID:28556920 PMID:31332904

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

S-phase kinase-associated protein 1

decreases expression

ISO

Isoniazid results in decreased expression of SKP1 protein

NCBI chr10:36,898,670...36,917,828
Ensembl chr10:36,903,078...36,918,308

G

solute carrier family 10 member 1

decreases expression
multiple interactions

EXP
ISO

Isoniazid results in decreased expression of SLC10A1 mRNA
Isoniazid results in decreased expression of SLC10A1 protein
[Rifampin co-treated with Isoniazid] results in decreased expression of SLC10A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1
obeticholic acid promotes the reaction [Isoniazid results in decreased expression of SLC10A1 mRNA]

PMID:25886055 PMID:32673658 PMID:35835356

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944

G

solute carrier family 11 member 1

affects expression

EXP

Isoniazid affects the expression of SLC11A1 mRNA

NCBI chr 9:83,406,327...83,417,252
Ensembl chr 9:83,406,427...83,417,238

G

solute carrier family 11 member 2

increases expression

ISO

Isoniazid results in increased expression of SLC11A2 protein

NCBI chr 7:133,381,878...133,429,921
Ensembl chr 7:133,381,878...133,418,941

G

solute carrier family 25 member 1

affects expression

ISO

Isoniazid affects the expression of SLC25A1 mRNA

NCBI chr11:96,560,054...96,563,071
Ensembl chr11:96,560,041...96,565,052

G

solute carrier family 25 member 13

decreases expression

ISO

Isoniazid results in decreased expression of SLC25A13 mRNA

NCBI chr 4:35,145,721...35,328,403
Ensembl chr 4:35,145,721...35,328,360

G

solute carrier family 25 member 24

increases expression

ISO

Isoniazid results in increased expression of SLC25A24 mRNA

NCBI chr 2:199,449,425...199,487,287
Ensembl chr 2:199,449,345...199,487,290

G

solute carrier family 25 member 4

increases expression

ISO

Isoniazid results in increased expression of SLC25A4 protein

NCBI chr16:52,805,521...52,809,316
Ensembl chr16:52,805,523...52,811,700

G

solute carrier family 25 member 5

increases expression

ISO

Isoniazid results in increased expression of SLC25A5 protein

NCBI chr X:120,897,616...120,900,683
Ensembl chr X:120,897,563...120,900,688

G

solute carrier family 25 member 5, pseudogene 11

decreases expression

ISO

Isoniazid results in decreased expression of SLC25A6 protein

NCBI chr18:70,846,358...70,847,597
Ensembl chr18:70,846,358...70,847,597

G

solute carrier family 39 member 14

decreases expression

ISO

Isoniazid results in decreased expression of SLC39A14 protein

NCBI chr15:51,786,517...51,833,260
Ensembl chr15:51,786,623...51,833,229

G

solute carrier family 3 member 2

decreases expression

ISO

Isoniazid results in decreased expression of SLC3A2 protein

NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:215,033,601...215,048,064

G

solute carrier family 7 member 11

multiple interactions
increases expression

EXP
ISO

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]
Isoniazid results in increased expression of SLC7A11 mRNA

PMID:36878459 PMID:40015660

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

solute carrier family 7 member 5

decreases expression

ISO

Isoniazid results in decreased expression of SLC7A5 mRNA

NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412

G

solute carrier organic anion transporter family, member 1c1

decreases expression

EXP

Isoniazid results in decreased expression of SLCO1B1 mRNA

NCBI chr 4:176,197,736...176,244,401
Ensembl chr 4:176,197,741...176,244,395

G

secretory leukocyte peptidase inhibitor

increases expression

ISO

Isoniazid results in increased expression of SLPI mRNA

NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822

G

spermine synthase

increases expression

ISO

Isoniazid results in increased expression of SMS protein

NCBI chr X:41,331,693...41,387,713
Ensembl chr X:41,331,799...41,387,712

G

superoxide dismutase 1

increases expression

ISO

Isoniazid results in increased expression of SOD1 mRNA

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

superoxide dismutase 2

multiple interactions
increases expression
affects expression

EXP
ISO

[SOD2 co-treated with CYP3A4] affects the susceptibility to Isoniazid
Isoniazid results in increased expression of SOD2 protein
Isoniazid affects the expression of SOD2 mRNA

PMID:19501153 PMID:24848797 PMID:40015660

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

secreted phosphoprotein 1

affects expression
decreases expression

EXP
ISO

Isoniazid affects the expression of SPP1 mRNA
Isoniazid results in decreased expression of SPP1 mRNA

PMID:20623750 PMID:30008028

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820

G

SRC proto-oncogene, non-receptor tyrosine kinase

increases expression

ISO

Isoniazid results in increased expression of SRC protein

NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462

G

spermidine synthase

decreases expression

ISO

Isoniazid results in decreased expression of SRM protein

NCBI chr 5:164,309,002...164,312,203
Ensembl chr 5:164,308,991...164,332,705

G

SRP receptor subunit alpha

decreases expression

ISO

Isoniazid results in decreased expression of SRPRA protein

NCBI chr 8:41,818,199...41,824,292
Ensembl chr 8:41,818,229...41,824,280

G

sulfiredoxin 1

increases expression

ISO

Isoniazid results in increased expression of SRXN1 mRNA

NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765

G

signal sequence receptor subunit 4

increases expression

ISO

Isoniazid results in increased expression of SSR4 protein

NCBI chr X:156,675,658...156,679,545
Ensembl chr X:156,675,566...156,679,543

G

staufen double-stranded RNA binding protein 1

decreases expression

ISO

Isoniazid results in decreased expression of STAU1 protein

NCBI chr 3:176,099,053...176,144,947
Ensembl chr 3:176,099,053...176,144,947

G

STEAP3 metalloreductase

decreases expression

ISO

Isoniazid results in decreased expression of STEAP3 protein

NCBI chr13:33,904,710...33,950,100
Ensembl chr13:33,904,710...33,950,080

G

stress-induced phosphoprotein 1

increases expression

ISO

Isoniazid results in increased expression of STIP1 protein

NCBI chr 1:213,638,641...213,657,654
Ensembl chr 1:213,638,641...213,657,654

G

STT3 oligosaccharyltransferase complex catalytic subunit A

increases expression

ISO

Isoniazid results in increased expression of STT3A protein

NCBI chr 8:44,632,473...44,671,960
Ensembl chr 8:44,632,473...44,672,226

G

STT3 oligosaccharyltransferase complex catalytic subunit B

increases expression

ISO

Isoniazid results in increased expression of STT3B protein

NCBI chr 8:123,806,836...123,872,179
Ensembl chr 8:123,795,983...123,872,180

G

succinate-CoA ligase ADP-forming subunit beta

increases expression

ISO

Isoniazid results in increased expression of SUCLA2 protein

NCBI chr15:55,161,894...55,215,031
Ensembl chr15:55,161,868...55,215,029

G

succinate-CoA ligase GDP/ADP-forming subunit alpha

increases expression

ISO

Isoniazid results in increased expression of SUCLG1 protein

NCBI chr 4:106,866,329...106,895,686
Ensembl chr 4:106,866,114...106,895,689

G

succinate-CoA ligase GDP-forming subunit beta

increases expression

ISO

Isoniazid results in increased expression of SUCLG2 protein

NCBI chr 4:129,623,833...129,893,937
Ensembl chr 4:129,623,834...129,937,296

G

SURF1, cytochrome c oxidase assembly factor

affects expression

ISO

Isoniazid affects the expression of SURF1 mRNA

NCBI chr 3:30,639,868...30,642,759

G

synoviolin 1

increases expression

ISO

Isoniazid results in increased expression of SYVN1 protein

NCBI chr 1:212,766,736...212,775,426
Ensembl chr 1:212,768,907...212,776,457

G

transferrin

increases expression
decreases expression

EXP
ISO

Isoniazid results in increased expression of TF mRNA
Isoniazid results in decreased expression of TF protein

PMID:12883083 PMID:40015660

NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:112,647,642...112,695,400

G

transferrin receptor

increases expression

ISO

Isoniazid results in increased expression of TFRC protein

NCBI chr11:81,668,478...81,690,318
Ensembl chr11:81,668,478...81,690,318

G

transmembrane protein 258

increases expression

ISO

Isoniazid results in increased expression of TMEM258 protein

NCBI chr 1:216,274,607...216,278,505

G

tumor necrosis factor

increases expression
multiple interactions
increases secretion

EXP
ISO

Isoniazid results in increased expression of TNF protein
[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein; chrysin inhibits the reaction [Isoniazid results in increased expression of TNF protein]; Isoniazid promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein]
Isoniazid results in increased secretion of TNF protein

PMID:25331106 PMID:28444390 PMID:28619387 PMID:33121995

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

thyroid peroxidase

decreases activity

EXP

Isoniazid results in decreased activity of TPO protein

NCBI chr 6:52,425,998...52,495,793
Ensembl chr 6:52,426,010...52,495,793

G

trafficking kinesin protein 1

affects expression

ISO

Isoniazid affects the expression of TRAK1 mRNA

NCBI chr 8:129,861,967...130,016,870
Ensembl chr 8:129,861,977...130,016,870

G

translocation associated membrane protein 1

decreases expression

ISO

Isoniazid results in decreased expression of TRAM1 protein

NCBI chr 5:10,425,710...10,450,669
Ensembl chr 5:10,425,633...10,470,056

G

tribbles pseudokinase 3

increases expression

ISO

Isoniazid results in increased expression of TRIB3 mRNA

NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:161,269,955...161,274,802

G

thiosulfate sulfurtransferase

increases expression

ISO

Isoniazid results in increased expression of TST protein

NCBI chr 7:111,828,557...111,836,980
Ensembl chr 7:111,828,558...111,837,116

G

thioredoxin 2

affects expression

ISO

Isoniazid affects the expression of TXN2 mRNA

NCBI chr 7:111,377,338...111,390,940
Ensembl chr 7:111,386,805...111,390,022

G

thioredoxin domain containing 12

increases expression

ISO

Isoniazid results in increased expression of TXNDC12 protein

NCBI chr 5:128,815,471...128,841,574
Ensembl chr 5:128,815,374...128,841,571

G

thioredoxin domain containing 5

increases expression

ISO

Isoniazid results in increased expression of TXNDC5 protein

NCBI chr17:26,495,467...26,523,608
Ensembl chr17:26,490,047...26,523,597

G

thioredoxin reductase 1

increases expression

ISO

Isoniazid results in increased expression of TXNRD1 mRNA

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817

G

thioredoxin reductase 2

affects expression

ISO

Isoniazid affects the expression of TXNRD2 mRNA

NCBI chr11:96,024,321...96,072,475
Ensembl chr11:96,024,324...96,072,475

G

ubiquitin-like modifier activating enzyme 1

increases expression

ISO

Isoniazid results in increased expression of UBA1 protein

NCBI chr X:4,062,216...4,084,192
Ensembl chr X:4,062,182...4,084,246

G

ubiquilin 1

increases expression

ISO

Isoniazid results in increased expression of UBQLN1 protein

NCBI chr17:6,438,456...6,482,498
Ensembl chr17:6,444,124...6,482,499

G

UBX domain protein 1

decreases expression

ISO

Isoniazid results in decreased expression of UBXN1 protein

NCBI chr 1:215,194,418...215,198,343
Ensembl chr 1:215,174,216...215,198,343

G

UDP-glucose glycoprotein glucosyltransferase 1

increases expression

ISO

Isoniazid results in increased expression of UGGT1 protein

NCBI chr 9:45,851,127...45,964,454
Ensembl chr 9:45,854,985...45,964,455

G

UDP-glucose glycoprotein glucosyltransferase 2

increases expression

ISO

Isoniazid results in increased expression of UGGT2 protein

NCBI chr15:102,480,239...102,646,291
Ensembl chr15:102,480,781...102,646,410

G

UDP glucuronosyltransferase family 1 member A1

increases expression

ISO

Isoniazid results in increased expression of UGT1A1 protein

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

ubiquinol-cytochrome c reductase binding protein

affects expression

ISO

Isoniazid affects the expression of UQCRB mRNA

NCBI chr 7:65,700,016...65,705,382
Ensembl chr 7:65,700,029...65,705,558

G

ubiquinol cytochrome c reductase core protein 2

affects expression

ISO

Isoniazid affects the expression of UQCRC2 mRNA

NCBI chr 1:184,599,240...184,629,804
Ensembl chr 1:184,599,212...184,630,946

G

ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1

decreases expression

ISO

Isoniazid results in decreased expression of UQCRFS1 protein

NCBI chr17:34,173,787...34,190,952
Ensembl chr17:34,173,833...34,190,950

G

ubiquinol-cytochrome c reductase hinge protein

increases expression

ISO

Isoniazid results in increased expression of UQCRH protein

NCBI chr 5:134,782,687...134,790,882
Ensembl chr 5:134,782,255...134,790,926

G

valosin-containing protein

increases expression

ISO

Isoniazid results in increased expression of VCP protein

NCBI chr 5:62,005,984...62,025,387
Ensembl chr 5:62,005,985...62,025,387

G

voltage-dependent anion channel 1

increases expression

ISO

Isoniazid results in increased expression of VDAC1 protein

NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541

G

voltage-dependent anion channel 2

increases expression

ISO

Isoniazid results in increased expression of VDAC2 protein

NCBI chr15:2,512,214...2,526,105
Ensembl chr15:2,512,216...2,532,229

G

voltage-dependent anion channel 3

increases expression

ISO

Isoniazid results in increased expression of VDAC3 protein

NCBI chr16:76,137,489...76,153,933
Ensembl chr16:76,137,504...76,155,304

G

vitronectin

increases expression

ISO

Isoniazid results in increased expression of VTN protein

NCBI chr10:63,892,782...63,895,862
Ensembl chr10:63,892,766...63,895,860

G

wolframin ER transmembrane glycoprotein

increases expression

ISO

Isoniazid results in increased expression of WFS1 protein

NCBI chr14:78,035,205...78,059,718
Ensembl chr14:78,034,864...78,060,459

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

affects binding

ISO

lomefloxacin binds to KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

matrix metallopeptidase 2

increases expression
increases activity

EXP

lomefloxacin results in increased expression of MMP2 mRNA
lomefloxacin results in increased activity of MMP2 protein

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

increases expression
increases activity

EXP

lomefloxacin results in increased expression of MMP9 mRNA
lomefloxacin results in increased activity of MMP9 protein

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

pyrazine-2-carboxylic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminocarboxymuconate semialdehyde decarboxylase

decreases activity

EXP

pyrazinoic acid metabolite results in decreased activity of ACMSD protein

NCBI chr13:41,752,894...41,798,427
Ensembl chr13:41,752,875...41,798,427

G

catalase

decreases expression

EXP

pyrazinoic acid results in decreased expression of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

glutamic--pyruvic transaminase

increases activity

EXP

pyrazinoic acid results in increased activity of GPT protein

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

solute carrier family 22 member 12

multiple interactions

EXP
ISO

pyrazinoic acid promotes the reaction [SLC22A12 protein affects the transport of Uric Acid]

PMID:14747372 PMID:21074513

NCBI chr 1:213,274,266...213,282,793
Ensembl chr 1:213,274,275...213,281,380

G

solute carrier family 22 member 6

multiple interactions

ISO

pyrazinoic acid inhibits the reaction [SLC22A6 protein affects the transport of Uric Acid]

NCBI chr 1:214,951,493...214,960,317
Ensembl chr 1:214,951,867...214,960,311

pyrazinecarboxamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression

EXP

Pyrazinamide results in increased expression of ABCA1 mRNA

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

ATP binding cassette subfamily A member 3

decreases expression

EXP

Pyrazinamide results in decreased expression of ABCA3 mRNA

NCBI chr10:13,886,948...13,944,286
Ensembl chr10:13,887,083...13,944,285

G

ATP binding cassette subfamily B member 11

decreases expression
multiple interactions

EXP
ISO

Pyrazinamide results in decreased expression of ABCB11 mRNA; Pyrazinamide results in decreased expression of ABCB11 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein
obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB11 mRNA]

PMID:27255380 PMID:35835356

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily B member 4

multiple interactions
decreases expression

EXP

obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB4 mRNA]
Pyrazinamide results in decreased expression of ABCB4 mRNA; Pyrazinamide results in decreased expression of ABCB4 protein

NCBI chr 4:26,106,895...26,164,440

G

ATP binding cassette subfamily B member 6

increases expression

EXP

Pyrazinamide results in increased expression of ABCB6 mRNA

NCBI chr 9:84,117,222...84,125,939
Ensembl chr 9:84,117,220...84,125,526

G

ATP binding cassette subfamily C member 2

multiple interactions
decreases expression

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCC2 mRNA]
Pyrazinamide results in decreased expression of ABCC2 mRNA; Pyrazinamide results in decreased expression of ABCC2 protein

PMID:27255380 PMID:35835356

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 3

increases expression

EXP

Pyrazinamide results in increased expression of ABCC3 mRNA; Pyrazinamide results in increased expression of ABCC3 protein

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP-binding cassette, subfamily G (WHITE), member 3-like 1

decreases expression

EXP

Pyrazinamide results in decreased expression of ABCG3L1 mRNA

NCBI chr14:5,429,242...5,481,948
Ensembl chr14:5,429,243...5,481,876

G

acetyl-CoA acyltransferase 1A

increases expression
multiple interactions

EXP

Pyrazinamide results in increased expression of ACAA1 mRNA
Fenofibrate promotes the reaction [Pyrazinamide results in increased expression of ACAA1 mRNA]; Pyrazinamide promotes the reaction [Fenofibrate results in increased expression of ACAA1 mRNA]

PMID:22431067 PMID:27071702

NCBI chr 8:127,956,126...127,966,348
Ensembl chr 8:127,956,129...127,966,241

G

acetyl-Coenzyme A acyltransferase 1B

increases expression

EXP

Pyrazinamide results in increased expression of ACAA1B mRNA

NCBI chr 8:127,750,771...127,759,589
Ensembl chr 8:127,750,743...127,759,569

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:110,739,633...110,803,416
Ensembl chr X:110,739,648...110,803,261

G

acyl-CoA synthetase medium-chain family member 2

increases expression

EXP

Pyrazinamide results in increased expression of ACSM2 mRNA

NCBI chr 1:183,347,705...183,386,453
Ensembl chr 1:183,347,705...183,386,453

G

aldo-keto reductase family 7 member A3

increases expression

EXP

Pyrazinamide results in increased expression of AKR7A3 mRNA

NCBI chr 5:156,876,721...156,884,599
Ensembl chr 5:156,874,086...156,885,153

G

aldehyde dehydrogenase 1 family, member A1

increases expression

EXP

Pyrazinamide results in increased expression of ALDH1A1 mRNA

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

aldehyde dehydrogenase 1 family, member L1

increases expression

EXP

Pyrazinamide results in increased expression of ALDH1L1 mRNA

NCBI chr 4:124,617,182...124,663,674
Ensembl chr 4:124,617,217...124,664,704

G

alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase

decreases expression

EXP

Pyrazinamide results in decreased expression of ALKBH2 mRNA

NCBI chr12:48,156,825...48,161,489
Ensembl chr12:48,156,827...48,161,483

G

apolipoprotein A1

multiple interactions
increases expression

EXP

[Fenofibrate co-treated with Pyrazinamide] results in increased expression of APOA1 mRNA
Pyrazinamide results in increased expression of APOA1 mRNA

PMID:22431067 PMID:27071702

NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:55,423,825...55,425,729

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression

EXP

Pyrazinamide results in increased expression of ASNS mRNA

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

activating transcription factor 3

increases expression

EXP

Pyrazinamide results in increased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

activating transcription factor 4

multiple interactions
increases expression

ISO
EXP

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of ATF4 protein]
Pyrazinamide results in increased expression of ATF4 mRNA; Pyrazinamide results in increased expression of ATF4 protein

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

activating transcription factor 6

increases expression

ISO

Pyrazinamide results in increased expression of ATF6 mRNA

NCBI chr13:85,460,312...85,639,959
Ensembl chr13:85,462,840...85,640,033

G

Bcl2-like 10

decreases expression

EXP

Pyrazinamide results in decreased expression of BCL2L10 mRNA

NCBI chr 8:84,987,833...84,993,878
Ensembl chr 8:84,987,833...84,993,872

G

Bcl2-like 2

decreases expression

EXP

Pyrazinamide results in decreased expression of BCL2L2 mRNA

NCBI chr15:32,326,686...32,337,834
Ensembl chr15:32,326,020...32,335,379

G

BAF chromatin remodeling complex subunit BCL7C

increases expression

EXP

Pyrazinamide results in increased expression of BCL7C mRNA

NCBI chr 1:191,703,432...191,754,751
Ensembl chr 1:191,691,089...191,754,641

G

Bcl2 modifying factor

decreases expression

EXP

Pyrazinamide results in decreased expression of BMF mRNA

NCBI chr 3:125,953,466...125,974,087
Ensembl chr 3:125,953,466...125,974,258

G

caspase 3

increases cleavage
multiple interactions

ISO
EXP

Pyrazinamide results in increased cleavage of CASP3 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3

PMID:28063906 PMID:35835356

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

catalase

decreases expression
multiple interactions

EXP

Pyrazinamide results in decreased expression of CAT protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein

PMID:28425350 PMID:36878459

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

cell division cycle and apoptosis regulator 1

decreases expression

EXP

Pyrazinamide results in decreased expression of CCAR1 mRNA

NCBI chr20:31,228,624...31,271,233
Ensembl chr20:31,228,624...31,271,227

G

cyclin E2

decreases expression

EXP

Pyrazinamide results in decreased expression of CCNE2 mRNA

NCBI chr 5:29,082,169...29,094,879
Ensembl chr 5:29,082,703...29,094,882

G

cyclin-dependent kinase 20

decreases expression

EXP

Pyrazinamide results in decreased expression of CDK20 mRNA

NCBI chr17:706,863...717,828
Ensembl chr17:706,865...713,567

G

cyclin-dependent kinase 4

increases expression

EXP

Pyrazinamide results in increased expression of CDK4 mRNA

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163

G

cyclin dependent kinase inhibitor 2D

increases expression

EXP

Pyrazinamide results in increased expression of CDKN2D mRNA

NCBI chr 8:28,108,036...28,110,809
Ensembl chr 8:28,108,044...28,110,809

G

CCAAT/enhancer binding protein beta

increases expression

EXP

Pyrazinamide results in increased expression of CEBPB mRNA

NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072

G

CCAAT/enhancer binding protein delta

increases expression

EXP

Pyrazinamide results in increased expression of CEBPD mRNA

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824

G

carboxylesterase 1C

increases expression

EXP

Pyrazinamide results in increased expression of CES1C mRNA

NCBI chr19:30,099,383...30,128,531
Ensembl chr19:30,099,323...30,128,528

G

collagen type I alpha 1 chain

increases expression

EXP

Pyrazinamide results in increased expression of COL1A1 mRNA

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

carnitine palmitoyltransferase 1B

decreases expression
multiple interactions

EXP

Pyrazinamide results in decreased expression of CPT1B mRNA
Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of CPT1B mRNA]

PMID:22431067 PMID:27071702

NCBI chr 7:122,370,974...122,380,473
Ensembl chr 7:122,370,444...122,380,036

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

EXP

Pyrazinamide results in increased expression of CYP1A2 mRNA

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 2, subfamily b, polypeptide 1

increases expression

EXP

Pyrazinamide results in increased expression of CYP2B1 mRNA

NCBI chr 1:90,646,098...90,669,762

G

cytochrome P450, family 2, subfamily b, polypeptide 2

increases expression

EXP

Pyrazinamide results in increased expression of CYP2B2 mRNA

NCBI chr 1:90,722,243...90,736,272

G

cytochrome P450, family 2, subfamily b, polypeptide 21

increases expression

EXP

Pyrazinamide results in increased expression of CYP2B21 mRNA

NCBI chr 1:91,013,781...91,042,752
Ensembl chr 1:91,013,782...91,042,752

G

cytochrome P450, family 2, subfamily c, polypeptide 23

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2C23 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2C23 mRNA]

NCBI chr 1:252,838,427...252,863,081
Ensembl chr 1:252,838,433...252,863,067

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases expression

EXP

Pyrazinamide results in increased expression of CYP2D4 mRNA

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily d, polypeptide 5

increases expression

EXP

Pyrazinamide results in increased expression of CYP2D5 mRNA

NCBI chr 7:115,779,981...115,784,554

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 2, subfamily j, polypeptide 3

decreases expression

EXP

Pyrazinamide results in decreased expression of CYP2J3 mRNA

NCBI chr 5:116,335,755...116,360,677
Ensembl chr 5:116,335,755...116,360,499

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression

EXP

Pyrazinamide results in increased expression of CYP3A23-3A1 mRNA

NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813

G

cytochrome P450, family 3, subfamily a, polypeptide 9

decreases expression

EXP

Pyrazinamide results in decreased expression of CYP3A9 mRNA

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytochrome P450, family 51

increases expression

EXP

Pyrazinamide results in increased expression of CYP51 mRNA

NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450

G

cytochrome P450 family 7 subfamily A member 1

increases expression
multiple interactions

EXP
ISO

Pyrazinamide results in increased expression of CYP7A1 mRNA; Pyrazinamide results in increased expression of CYP7A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein

PMID:27255380 PMID:35835356

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

cytochrome P450 family 8 subfamily B member 1

decreases expression
increases expression

EXP

Pyrazinamide results in decreased expression of CYP8B1 mRNA; Pyrazinamide results in decreased expression of CYP8B1 protein
Pyrazinamide results in increased expression of CYP8B1 mRNA

PMID:22431067 PMID:27255380

NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

EXP
ISO

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of DDIT3 protein]
Pyrazinamide results in increased expression of DDIT3 mRNA; Pyrazinamide results in increased expression of DDIT3 protein

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

dual specificity tyrosine phosphorylation regulated kinase 2

decreases expression

EXP

Pyrazinamide results in decreased expression of DYRK2 mRNA

NCBI chr 7:56,235,276...56,265,741
Ensembl chr 7:56,235,276...56,265,942

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions
increases phosphorylation

ISO
EXP

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased phosphorylation of EIF2AK3 protein]

NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation
multiple interactions

ISO
EXP

Pyrazinamide results in increased phosphorylation of EIF2S1 protein
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649

G

E1A binding protein p300

decreases expression

EXP

Pyrazinamide results in decreased expression of EP300 mRNA

NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574

G

epoxide hydrolase 1

increases expression

EXP

Pyrazinamide results in increased expression of EPHX1 mRNA

NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981

G

ERCC excision repair 1, endonuclease non-catalytic subunit

increases expression

EXP

Pyrazinamide results in increased expression of ERCC1 mRNA

NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:88,118,891...88,139,120

G

endoplasmic reticulum to nucleus signaling 1

increases expression

ISO

Pyrazinamide results in increased expression of ERN1 mRNA

NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791

G

fatty acid binding protein 1

multiple interactions
decreases expression

EXP

Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of FABP1 mRNA]

NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:104,744,309...104,753,113

G

fatty acid binding protein 7

decreases expression

EXP

Pyrazinamide results in decreased expression of FABP7 mRNA

NCBI chr20:37,667,125...37,673,299
Ensembl chr20:37,669,601...37,675,907

G

F-box and WD repeat domain containing 11

decreases expression

EXP

Pyrazinamide results in decreased expression of FBXW11 mRNA

NCBI chr10:17,737,181...17,834,834
Ensembl chr10:17,720,444...17,834,834

G

flavin containing dimethylaniline monoxygenase 1

increases expression

EXP

Pyrazinamide results in increased expression of FMO1 mRNA

NCBI chr13:77,715,405...77,747,666
Ensembl chr13:77,715,402...77,747,874

G

growth arrest and DNA-damage-inducible, alpha

increases expression

EXP

Pyrazinamide results in increased expression of GADD45A mRNA

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

growth arrest-specific 2

increases expression

EXP

Pyrazinamide results in increased expression of GAS2 mRNA

NCBI chr 1:110,587,952...110,721,572
Ensembl chr 1:110,717,312...110,718,541

G

glutamic--pyruvic transaminase

increases expression
increases activity
multiple interactions

EXP

Pyrazinamide results in increased expression of GPT protein
Pyrazinamide results in increased activity of GPT protein
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of GPT protein]; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; Fenofibrate inhibits the reaction [Pyrazinamide results in increased expression of GPT protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

PMID:27071702 PMID:28063906 PMID:28425350 PMID:35835356 PMID:36878459

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione peroxidase 4

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629

G

glutathione S-transferase alpha 4

increases expression

EXP

Pyrazinamide results in increased expression of GSTA4 mRNA

NCBI chr 8:87,947,247...87,964,490
Ensembl chr 8:87,930,566...87,964,488

G

glutathione S-transferase alpha 5

increases expression

EXP

Pyrazinamide results in increased expression of GSTA5 mRNA

NCBI chr 8:87,985,768...87,997,766
Ensembl chr 8:87,985,258...87,997,765

G

glutathione S-transferase mu 1

increases expression

EXP

Pyrazinamide results in increased expression of GSTM1 mRNA

NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569

G

glutathione S-transferase mu 2

increases expression

EXP

Pyrazinamide results in increased expression of GSTM2 mRNA

NCBI chr 2:198,312,179...198,316,962

G

glutathione S-transferase pi 1

increases expression

EXP

Pyrazinamide results in increased expression of GSTP1 mRNA

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

glutathione S-transferase theta 1

multiple interactions

ISO

GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]

NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,083...12,873,019

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

increases expression

EXP

Pyrazinamide results in increased expression of HMGCS1 mRNA

NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

increases expression

EXP

Pyrazinamide results in increased expression of HMGCS2 mRNA

NCBI chr 2:188,564,348...188,590,872
Ensembl chr 2:188,547,767...188,592,242

G

heme oxygenase 1

increases expression

EXP

Pyrazinamide results in increased expression of HMOX1 mRNA

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

hydroxysteroid 11-beta dehydrogenase 1

increases expression

EXP

Pyrazinamide results in increased expression of HSD11B1 mRNA

NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases expression

EXP
ISO

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of HSPA5 protein]
Pyrazinamide results in increased expression of HSPA5 mRNA; Pyrazinamide results in increased expression of HSPA5 protein

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

inositol 1,4,5-trisphosphate receptor, type 1

decreases expression

EXP

Pyrazinamide results in decreased expression of ITPR1 mRNA

NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:142,743,334...143,066,504

G

lipoprotein lipase

decreases expression
multiple interactions

EXP

Pyrazinamide results in decreased expression of LPL mRNA
Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of LPL mRNA]

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107

G

malic enzyme 1

increases expression

EXP

Pyrazinamide results in increased expression of ME1 mRNA

PMID:22431067 PMID:27071702

NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275

G

microsomal glutathione S-transferase 3

increases expression

EXP

Pyrazinamide results in increased expression of MGST3 mRNA

NCBI chr13:82,059,480...82,080,418
Ensembl chr13:82,059,480...82,080,575

G

Mix paired-like homeobox 1

decreases expression

EXP

Pyrazinamide results in decreased expression of MIXL1 mRNA

NCBI chr13:94,953,907...94,957,938
Ensembl chr13:94,953,907...94,957,938

G

mitochondrial ribosomal protein S14

decreases expression

EXP

Pyrazinamide results in decreased expression of MRPS14 mRNA

NCBI chr13:74,962,597...74,968,344
Ensembl chr13:74,962,515...74,970,975

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions
decreases expression

EXP

obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of NR0B2 mRNA]

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions
decreases expression

EXP
ISO

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of NR1H4 mRNA]
Pyrazinamide results in decreased expression of NR1H4 mRNA; Pyrazinamide results in decreased expression of NR1H4 protein

PMID:27255380 PMID:35835356

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389

G

NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL

increases expression

EXP

Pyrazinamide results in increased expression of NSDHL mRNA

NCBI chr X:155,817,301...155,848,224
Ensembl chr X:155,817,340...155,848,220

G

neurotrophic receptor tyrosine kinase 1

decreases expression

EXP

Pyrazinamide results in decreased expression of NTRK1 mRNA

NCBI chr 2:175,534,844...175,551,664
Ensembl chr 2:175,534,844...175,551,787

G

p53 apoptosis effector related to PMP22

increases expression

EXP

Pyrazinamide results in increased expression of PERP mRNA

NCBI chr 1:15,361,784...15,374,230
Ensembl chr 1:15,361,778...15,374,687

G

phosphoglycerate dehydrogenase

increases expression

EXP

Pyrazinamide results in increased expression of PHGDH mRNA

NCBI chr 2:188,595,700...188,624,789
Ensembl chr 2:188,595,700...188,624,789

G

peroxisome proliferator activated receptor alpha

multiple interactions
decreases expression

ISO
EXP

[Pyrazinamide co-treated with Glucose] binds to PPARA protein; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]
Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of PPARA mRNA]
Pyrazinamide results in decreased expression of PPARA mRNA; Pyrazinamide results in decreased expression of PPARA protein

PMID:18812576 PMID:27071702

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

protein phosphatase 2 scaffold subunit A alpha

increases expression

EXP

Pyrazinamide results in increased expression of PPP2R1A mRNA

NCBI chr 1:69,213,198...69,232,441
Ensembl chr 1:69,213,038...69,238,242

G

prominin 1

decreases expression

EXP

Pyrazinamide results in decreased expression of PROM1 mRNA

NCBI chr14:71,202,303...71,307,008
Ensembl chr14:71,202,336...71,307,002

G

solute carrier family 10 member 1

increases expression
multiple interactions

EXP
ISO

Pyrazinamide results in increased expression of SLC10A1 mRNA; Pyrazinamide results in increased expression of SLC10A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1

PMID:27255380 PMID:35835356

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944

G

solute carrier family 16, member 11

decreases expression

EXP

Pyrazinamide results in decreased expression of SLC16A11 mRNA

NCBI chr10:55,427,773...55,431,678
Ensembl chr10:55,427,903...55,431,678

G

solute carrier family 17 member 1

increases expression

EXP

Pyrazinamide results in increased expression of SLC17A1 mRNA

NCBI chr17:41,647,332...41,683,078
Ensembl chr17:41,649,919...41,681,174

G

solute carrier family 22 member 12

affects activity

ISO

Pyrazinamide affects the activity of SLC22A12 protein

NCBI chr 1:213,274,266...213,282,793
Ensembl chr 1:213,274,275...213,281,380

G

solute carrier family 22 member 13

decreases expression

EXP

Pyrazinamide results in decreased expression of SLC22A13 mRNA

NCBI chr 8:127,800,097...127,811,750
Ensembl chr 8:127,800,097...127,811,724

G

solute carrier family 25, member 39

increases expression

EXP

Pyrazinamide results in increased expression of SLC25A39 mRNA

NCBI chr10:87,862,630...87,867,626
Ensembl chr10:87,862,631...87,866,973

G

solute carrier family 25 member 4

decreases expression

EXP

Pyrazinamide results in decreased expression of SLC25A4 mRNA

NCBI chr16:52,805,521...52,809,316
Ensembl chr16:52,805,523...52,811,700

G

solute carrier family 25, member 42

decreases expression

EXP

Pyrazinamide results in decreased expression of SLC25A42 mRNA

NCBI chr16:19,247,874...19,286,598
Ensembl chr16:19,247,725...19,270,976

G

solute carrier family 29 member 1

decreases expression

EXP

Pyrazinamide results in decreased expression of SLC29A1 mRNA

NCBI chr 9:22,897,099...22,911,640
Ensembl chr 9:22,902,471...22,914,620

G

solute carrier family 51 member A

decreases expression

EXP

Pyrazinamide results in decreased expression of SLC51A mRNA; Pyrazinamide results in decreased expression of SLC51A protein

NCBI chr11:81,804,141...81,818,539
Ensembl chr11:81,803,972...81,818,539

G

SLC51 subunit beta

multiple interactions
decreases expression

EXP

obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLC51B mRNA]
Pyrazinamide results in decreased expression of SLC51B mRNA; Pyrazinamide results in decreased expression of SLC51B protein

NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109

G

solute carrier family 6 member 9

decreases expression

EXP

Pyrazinamide results in decreased expression of SLC6A9 mRNA

NCBI chr 5:136,660,022...136,694,173
Ensembl chr 5:136,659,948...136,694,172

G

solute carrier family 7 member 10

decreases expression

EXP

Pyrazinamide results in decreased expression of SLC7A10 mRNA

NCBI chr 1:96,966,030...96,982,020
Ensembl chr 1:96,966,076...96,982,018

G

solute carrier family 7 member 11

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

solute carrier organic anion transporter family, member 1a1

decreases expression
multiple interactions

EXP

Pyrazinamide results in decreased expression of SLCO1A1 mRNA; Pyrazinamide results in decreased expression of SLCO1A1 protein
obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLCO1A1 mRNA]

NCBI chr 4:176,606,924...176,682,027
Ensembl chr 4:176,607,687...176,681,992

G

solute carrier organic anion transporter family, member 1a4

increases expression

EXP

Pyrazinamide results in increased expression of SLCO1A4 mRNA; Pyrazinamide results in increased expression of SLCO1A4 protein

NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816

G

solute carrier organic anion transporter family member 1B2

decreases expression
multiple interactions

EXP

Pyrazinamide results in decreased expression of SLCO1B2 mRNA; Pyrazinamide results in decreased expression of SLCO1B2 protein
obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLCO1B2 mRNA]

NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083

G

solute carrier organic anion transporter family, member 4a1

decreases expression

EXP

Pyrazinamide results in decreased expression of SLCO4A1 mRNA

NCBI chr 3:187,936,735...187,955,873
Ensembl chr 3:187,936,820...187,955,871

G

spermidine synthase

increases expression

EXP

Pyrazinamide results in increased expression of SRM mRNA

NCBI chr 5:164,309,002...164,312,203
Ensembl chr 5:164,308,991...164,332,705

G

sulfotransferase family 1C member 2A

decreases expression

EXP

Pyrazinamide results in decreased expression of SULT1C2A mRNA

NCBI chr 9:7,075,873...7,103,316
Ensembl chr 9:7,066,905...7,244,132

G

sulfotransferase family 2A member 1

decreases expression

EXP

Pyrazinamide results in decreased expression of SULT2A1 mRNA

NCBI chr 1:84,582,011...84,639,001

G

TOPBP1-interacting checkpoint and replication regulator

decreases expression

EXP

Pyrazinamide results in decreased expression of TICRR mRNA

NCBI chr 1:143,006,989...143,048,836
Ensembl chr 1:143,006,924...143,049,133

G

transmembrane protein 176A

increases expression

EXP

Pyrazinamide results in increased expression of TMEM176A mRNA

NCBI chr 4:79,101,946...79,109,499
Ensembl chr 4:79,101,857...79,111,175

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases expression

EXP

Pyrazinamide results in increased expression of UGT1A2 mRNA

NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

voltage-dependent anion channel 1

increases expression

EXP

Pyrazinamide results in increased expression of VDAC1 mRNA

NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541

G

X-box binding protein 1

increases expression

ISO

Pyrazinamide results in increased expression of XBP1 mRNA alternative form

NCBI chr14:84,604,623...84,609,707
Ensembl chr14:84,604,107...84,609,706

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta

increases expression

EXP

Pyrazinamide results in increased expression of YWHAH mRNA

NCBI chr14:81,920,819...81,930,202
Ensembl chr14:81,920,590...81,947,930

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arylacetamide deacetylase

multiple interactions
decreases acetylation

ISO

AADAC mRNA affects the reaction [Rifabutin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]

NCBI chr 2:146,293,449...146,351,061
Ensembl chr 2:146,313,279...146,324,525

G

ATP binding cassette subfamily B member 11

decreases activity

ISO

Rifabutin results in decreased activity of ABCB11 protein

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily B member 1A

increases expression

ISO

Rifabutin results in increased expression of ABCB1 mRNA

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression
affects activity
multiple interactions

ISO

Rifabutin results in increased expression of CYP3A4 mRNA
Rifabutin affects the activity of CYP3A4 protein
AADAC mRNA affects the reaction [Rifabutin results in increased expression of CYP3A4 mRNA]

PMID:16837568 PMID:21856291 PMID:37285043 PMID:38713375

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

nuclear receptor subfamily 1, group I, member 2

increases activity

ISO

Rifabutin results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arylacetamide deacetylase

multiple interactions
increases hydrolysis
decreases acetylation

ISO

AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]
AADAC protein results in increased hydrolysis of Rifampin

PMID:21856291 PMID:22207054

NCBI chr 2:146,293,449...146,351,061
Ensembl chr 2:146,313,279...146,324,525

G

ATP binding cassette subfamily A member 1

decreases expression
increases expression

ISO

Rifampin results in decreased expression of ABCA1 mRNA; Rifampin results in decreased expression of ABCA1 protein
Rifampin results in increased expression of ABCA1 mRNA; Rifampin results in increased expression of ABCA1 protein

PMID:15883047 PMID:17088262

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

ATP binding cassette subfamily A member 2

increases expression

ISO

Rifampin results in increased expression of ABCA2 mRNA

NCBI chr 3:28,642,660...28,662,689
Ensembl chr 3:28,642,758...28,662,681

G

ATP binding cassette subfamily A member 8

decreases expression

ISO

Rifampin results in decreased expression of ABCA8 mRNA

NCBI chr10:95,416,984...95,490,647
Ensembl chr10:95,416,205...95,490,452

G

ATP binding cassette subfamily B member 11

decreases expression
multiple interactions
decreases activity

ISO
EXP

Rifampin results in decreased expression of ABCB11 mRNA
[Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein
Rifampin results in decreased expression of ABCB11 protein
tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 protein]
Rifampin results in decreased activity of ABCB11 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Rifampin results in decreased expression of ABCB11 mRNA; Rifampin results in decreased expression of ABCB11 protein

PMID:12135489 PMID:16837569 PMID:20829430 PMID:24014644 PMID:25886055 More...

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression
decreases activity
affects activity

ISO
EXP

[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter]
Rifampin results in increased expression of ABCB1 mRNA; Rifampin results in increased expression of ABCB1 protein
[Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate
Rifampin affects the activity of ABCB1 protein

PMID:8632764 PMID:11744607 PMID:14722322 PMID:15276086 PMID:15290871 More...

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily B member 4

increases expression

ISO

Rifampin results in increased expression of ABCB4 mRNA

NCBI chr 4:26,106,895...26,164,440

G

ATP binding cassette subfamily B member 6

increases expression

ISO

Rifampin results in increased expression of ABCB6 mRNA

NCBI chr 9:84,117,222...84,125,939
Ensembl chr 9:84,117,220...84,125,526

G

ATP binding cassette subfamily C member 1

increases expression

ISO

Rifampin results in increased expression of ABCC1 mRNA

PMID:17191263 PMID:35972551

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily C member 10

increases expression

ISO

Rifampin results in increased expression of ABCC10 mRNA

NCBI chr 9:22,154,811...22,174,743
Ensembl chr 9:22,154,804...22,174,743

G

ATP binding cassette subfamily C member 2

affects export
multiple interactions
increases expression

ISO
EXP

ABCC2 protein affects the export of Rifampin
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein
Rifampin results in increased expression of ABCC2; Rifampin results in increased expression of ABCC2 mRNA; Rifampin results in increased expression of ABCC2 protein
[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein

PMID:11836020 PMID:12206135 PMID:15652233 PMID:16837569 PMID:16952291 More...

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 3

multiple interactions
increases expression
increases activity

ISO

[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; Rifampin inhibits the reaction [Decitabine results in increased expression of ABCC3 mRNA]
Rifampin results in increased expression of ABCC3 mRNA
Rifampin results in increased activity of ABCC3 protein

PMID:14570758 PMID:16837569 PMID:16952291 PMID:19041851 PMID:20832446 More...

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily C member 5

increases expression

ISO

Rifampin results in increased expression of ABCC5 mRNA

NCBI chr11:93,975,579...94,071,659
Ensembl chr11:93,978,274...94,071,655

G

ATP binding cassette subfamily C member 6

increases expression

ISO

Rifampin results in increased expression of ABCC6 mRNA

NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:105,583,682...105,637,895

G

ATP binding cassette subfamily F member 1

increases expression

ISO

Rifampin results in increased expression of ABCF1 mRNA

NCBI chr20:2,807,315...2,820,240
Ensembl chr20:2,807,106...2,820,240

G

ATP binding cassette subfamily G member 1

increases expression

ISO

Rifampin results in increased expression of ABCG1 mRNA; Rifampin results in increased expression of ABCG1 protein

PMID:12040753 PMID:17088262

NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,127,803...9,186,563

G

ATP binding cassette subfamily G member 2

increases expression
multiple interactions

ISO

Rifampin results in increased expression of ABCG2 mRNA; Rifampin results in increased expression of ABCG2 protein
Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]; Rifampin promotes the reaction [Lipopolysaccharides results in decreased expression of ABCG2 mRNA]

PMID:16837569 PMID:27199754 PMID:35972551 PMID:38423481

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

ATP binding cassette subfamily G member 8

increases expression

ISO

Rifampin results in increased expression of ABCG8 mRNA

NCBI chr 6:15,698,448...15,717,730
Ensembl chr 6:15,698,448...15,717,730

G

ABI family, member 3

decreases expression

ISO

Rifampin results in decreased expression of ABI3 mRNA

NCBI chr10:81,266,571...81,277,561
Ensembl chr10:81,266,571...81,277,561

G

acetyl-CoA carboxylase alpha

increases expression

ISO

Rifampin results in increased expression of ACACA mRNA

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

angiotensin converting enzyme 2

decreases expression

ISO

Rifampin results in decreased expression of ACE2 mRNA

NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:110,739,633...110,803,416
Ensembl chr X:110,739,648...110,803,261

G

actin related protein 10

increases expression

ISO

Rifampin results in increased expression of ACTR10 mRNA

NCBI chr 6:95,182,082...95,208,325
Ensembl chr 6:95,182,111...95,209,021

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

increases expression

ISO

Rifampin results in increased expression of ADH1C mRNA

NCBI chr 2:229,470,703...229,482,291
Ensembl chr 2:229,470,703...229,482,291

G

adiponectin, C1Q and collagen domain containing

multiple interactions

ISO

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of ADIPOQ mRNA

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

adenosine A2a receptor

decreases expression

ISO

Rifampin results in decreased expression of ADORA2A mRNA

NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,270...13,332,802

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 2

decreases expression

ISO

Rifampin results in decreased expression of AGAP2 mRNA

NCBI chr 7:64,782,618...64,799,624
Ensembl chr 7:64,782,612...64,799,640

G

aryl hydrocarbon receptor

multiple interactions
increases expression

ISO

[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in decreased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of AHR protein; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA]
Rifampin results in increased expression of AHR mRNA; Rifampin results in increased expression of AHR protein

PMID:22733800 PMID:28428138

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

aldo-keto reductase family 1 member B10

increases expression
multiple interactions

ISO

Rifampin results in increased expression of AKR1B10 mRNA
pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]

NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847

G

5'-aminolevulinate synthase 1

increases expression

ISO

Rifampin results in increased expression of ALAS1 mRNA

PMID:24259679 PMID:24552687

NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:115,755,238...115,768,642

G

alkaline phosphatase, biomineralization associated

increases activity
multiple interactions

ISO

Rifampin results in increased activity of ALPL protein
[Rifampin co-treated with Isoniazid] results in increased activity of ALPL protein

NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167

G

angiopoietin-like 3

decreases expression

ISO

Rifampin results in decreased expression of ANGPTL3 mRNA

NCBI chr 5:118,818,494...118,825,531
Ensembl chr 5:118,818,499...118,826,444

G

angiopoietin-like 4

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA

NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681

G

ankyrin repeat domain 65

decreases expression

ISO

Rifampin results in decreased expression of ANKRD65 mRNA

NCBI chr 5:171,680,597...171,682,854
Ensembl chr 5:171,680,597...171,683,431

G

ankyrin repeat and sterile alpha motif domain containing 1B

decreases expression

ISO

Rifampin results in decreased expression of ANKS1B mRNA

NCBI chr 7:26,200,649...27,366,552
Ensembl chr 7:26,201,240...27,364,943

G

annexin A5

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA

NCBI chr 2:121,242,133...121,272,935
Ensembl chr 2:121,242,136...121,281,400

G

apolipoprotein B

decreases expression
multiple interactions
affects secretion

ISO

Rifampin results in decreased expression of APOB mRNA
ursodoxicoltaurine inhibits the reaction [Rifampin results in decreased expression of APOB mRNA]
Rifampin affects the secretion of APOB protein

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:36,563,704...36,611,814

G

apolipoprotein C3

decreases expression
decreases secretion

ISO

Rifampin results in decreased expression of APOC3 mRNA
Rifampin results in decreased secretion of APOC3 protein

NCBI chr 8:55,428,172...55,430,352
Ensembl chr 8:55,428,024...55,458,679

G

aquaporin 3 (Gill blood group)

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA

NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:61,035,166...61,040,685

G

aquaporin 4

decreases expression

ISO

Rifampin results in decreased expression of AQP4 mRNA

NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098

G

arylsulfatase family, member J

decreases expression

ISO

Rifampin results in decreased expression of ARSJ mRNA

NCBI chr 2:217,449,147...217,529,142
Ensembl chr 2:217,449,147...217,529,142

G

activating transcription factor 3

multiple interactions

ISO

[Rifampin co-treated with Cobicistat] results in increased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

activating transcription factor 4

multiple interactions
increases expression

EXP
ISO

ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein]
Rifampin results in increased expression of ATF4 mRNA; Rifampin results in increased expression of ATF4 protein
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 protein]

PMID:24638036 PMID:27470132

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

activating transcription factor 6

increases expression

ISO

Rifampin results in increased expression of ATF6 mRNA

NCBI chr13:85,460,312...85,639,959
Ensembl chr13:85,462,840...85,640,033

G

ATM serine/threonine kinase

multiple interactions
decreases expression

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein
Rifampin results in decreased expression of ATM mRNA

PMID:21224054 PMID:24552687

NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:62,727,291...62,828,629

G

ATPase H+ transporting V0 subunit a1

increases expression
multiple interactions

ISO

Rifampin results in increased expression of ATP6V0A1 protein
[Rotenone co-treated with Rifampin] results in increased expression of ATP6V0A1 protein; Rifampin inhibits the reaction [Rotenone results in decreased expression of ATP6V0A1 mRNA]; Rotenone inhibits the reaction [Rifampin results in increased expression of ATP6V0A1 protein]

NCBI chr10:86,436,089...86,490,185
Ensembl chr10:86,436,141...86,490,181

G

ATPase H+ transporting V0 subunit D1

multiple interactions

ISO

ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]

NCBI chr19:50,313,268...50,357,248
Ensembl chr19:50,313,273...50,357,395

G

ATRX, chromatin remodeler

increases expression

ISO

Rifampin results in increased expression of ATRX mRNA

NCBI chr X:74,916,548...75,062,880
Ensembl chr X:74,916,548...75,062,880

G

BCL2 associated X, apoptosis regulator

multiple interactions
decreases expression

ISO

[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of BAX mRNA; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein]
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein
Rifampin results in decreased expression of BAX protein

PMID:11958592 PMID:12645856 PMID:21224054 PMID:21419764 PMID:31629065 More...

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

increases expression
multiple interactions

ISO

Rifampin results in increased expression of BCL2 protein
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein
[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]

PMID:11958592 PMID:21419764 PMID:31629065

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

increases expression
multiple interactions

ISO

Rifampin results in increased expression of BCL2L1 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA

PMID:11958592 PMID:12645856 PMID:21224054

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

basic helix-loop-helix family, member e40

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA

NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783

G

bone morphogenetic protein 4

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA

NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172

G

similar to human chromosome 9 open reading frame 153

decreases expression

ISO

Rifampin results in decreased expression of C9ORF153 mRNA

NCBI chr17:4,978,994...4,987,920
Ensembl chr17:4,981,452...4,987,918

G

similar to human chromosome 4 open reading frame 51

decreases expression

ISO

Rifampin results in decreased expression of C4ORF51 mRNA

NCBI chr19:45,573,267...45,608,796
Ensembl chr19:45,573,330...45,608,796

G

carbonic anhydrase 1

decreases expression

ISO

Rifampin results in decreased expression of CA1 mRNA

NCBI chr 2:88,550,681...88,593,454
Ensembl chr 2:88,495,475...88,593,454

G

caspase 1

multiple interactions

ISO

Rifampin inhibits the reaction [Rotenone results in increased cleavage of CASP1 protein]

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 3

multiple interactions

ISO
EXP

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3
[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]

PMID:11958592 PMID:12645856 PMID:17936189 PMID:21419764 PMID:23764483 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

multiple interactions

ISO

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]

PMID:11958592 PMID:12645856

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

catalase

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

carbonyl reductase 3

multiple interactions

ISO

[Rifampin co-treated with Cobicistat] results in increased expression of CBR3 mRNA

NCBI chr11:46,478,295...46,486,555
Ensembl chr11:46,478,274...46,486,558

G

C-C motif chemokine ligand 2

decreases expression

EXP

Rifampin results in decreased expression of CCL2 mRNA

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 5

decreases expression

EXP

Rifampin results in decreased expression of CCL5 protein

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

cellular communication network factor 1

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA

NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883

G

cyclin D1

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin G1

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA

NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,677,885...25,683,766

G

C-C motif chemokine receptor 6

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA

NCBI chr 1:55,022,037...55,055,857
Ensembl chr 1:55,021,833...55,046,059

G

C-C motif chemokine receptor 7

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA

NCBI chr10:84,594,399...84,604,514
Ensembl chr10:84,593,594...84,604,501

G

CD36 molecule

increases expression

ISO

Rifampin results in increased expression of CD36 mRNA

NCBI chr 4:18,209,088...18,302,142

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 2B

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA

NCBI chr 5:109,123,308...109,134,906
Ensembl chr 5:109,114,322...109,134,855

G

CCAAT/enhancer binding protein alpha

multiple interactions

ISO

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPA mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

CCAAT/enhancer binding protein beta

multiple interactions

ISO

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPB mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]

NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072

G

CCAAT/enhancer binding protein delta

multiple interactions

ISO

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPD mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824

G

carboxylesterase 1D

increases expression

ISO

Rifampin results in increased expression of CES1 protein

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449

G

carboxylesterase 2H

increases expression
multiple interactions

ISO

Rifampin results in increased expression of CES2 mRNA; Rifampin results in increased expression of CES2 protein
Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]

PMID:10640517 PMID:17003103

NCBI chr19:49,884,164...49,898,764
Ensembl chr19:49,884,164...49,898,752

G

CASP8 and FADD-like apoptosis regulator

multiple interactions
increases expression

ISO

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]
Rifampin results in increased expression of CFLAR protein

PMID:11958592 PMID:12645856

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434

G

checkpoint kinase 2

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA

NCBI chr12:51,448,838...51,481,159
Ensembl chr12:51,449,140...51,480,667

G

CDKN1A interacting zinc finger protein 1

decreases expression

ISO

Rifampin results in decreased expression of CIZ1 mRNA

NCBI chr 3:36,055,753...36,071,510
Ensembl chr 3:36,056,370...36,075,192

G

CDC-like kinase 2

decreases expression

ISO

Rifampin results in decreased expression of CLK2 mRNA

NCBI chr 2:176,868,423...176,880,412
Ensembl chr 2:176,869,490...176,880,411

G

centlein

increases expression

ISO

Rifampin results in increased expression of CNTLN mRNA

NCBI chr 5:104,340,801...104,622,491
Ensembl chr 5:104,342,173...104,630,976

G

carnitine palmitoyltransferase 1A

increases expression

ISO

Rifampin results in increased expression of CPT1A mRNA

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

corticotropin releasing hormone receptor 1

decreases expression

ISO

Rifampin results in decreased expression of CRHR1 mRNA

NCBI chr10:89,540,192...89,583,466
Ensembl chr10:89,540,192...89,583,466

G

C-reactive protein

multiple interactions

ISO

[Floxacillin co-treated with Gentamicins co-treated with Rifampin] results in increased expression of CRP protein

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514

G

casein kinase 1, gamma 1

decreases expression

ISO

Rifampin results in decreased expression of CSNK1G1 mRNA

NCBI chr 8:75,334,751...75,472,339
Ensembl chr 8:75,334,895...75,467,515

G

C-X-C motif chemokine ligand 1

increases expression

EXP

Rifampin results in increased expression of CXCL1 protein

NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811

G

C-X-C motif chemokine ligand 10

multiple interactions
affects expression

ISO
EXP

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA
Rifampin affects the expression of CXCL10 protein

PMID:21224054 PMID:25051504

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

cytochrome b5 reductase-like

increases expression

ISO

Rifampin results in increased expression of CYB5RL mRNA

NCBI chr 5:127,075,034...127,097,551
Ensembl chr 5:127,074,535...127,097,518

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases activity
increases expression

EXP
ISO

Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
Rifampin results in increased activity of CYP1A1 protein
Rifampin results in increased expression of CYP1A1 mRNA; Rifampin results in increased expression of CYP1A1 protein
[Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP1A1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 protein; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A1 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

PMID:12040753 PMID:18493746 PMID:19118567 PMID:19409404 PMID:22733800 More...

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression

ISO
EXP

[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A2 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]
Rifampin results in increased expression of CYP1A2 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein]
Rifampin results in increased expression of CYP1A2 mRNA; Rifampin results in increased expression of CYP1A2 protein

PMID:15977188 PMID:17590308 PMID:18493746 PMID:25835148 PMID:29162470 More...

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1B1 mRNA

PMID:21224054 PMID:29162470

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 24, subfamily a, polypeptide 1

multiple interactions
increases expression
increases activity

ISO

NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter]
Rifampin results in increased activity of CYP24A1 protein

PMID:15630458 PMID:21127053

NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083

G

cytochrome P450, family 26, subfamily a, polypeptide 1

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA

NCBI chr 1:244,883,822...244,887,657
Ensembl chr 1:244,883,752...244,887,657

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions
increases expression

ISO

Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]
Rifampin results in increased expression of CYP27A1 mRNA

NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215

G

cytochrome P450, family 2, subfamily a, polypeptide 1

increases expression
decreases expression

EXP
ISO

Rifampin results in increased expression of CYP2A1 mRNA
Rifampin results in increased expression of CYP2A13 mRNA
Rifampin results in decreased expression of CYP2A13 mRNA

PMID:19118567 PMID:22258563

NCBI chr 1:91,359,278...91,372,554
Ensembl chr 1:91,359,272...91,389,730

G

cytochrome P450, family 2, subfamily a, polypeptide 3

increases expression

ISO

Rifampin results in increased expression of CYP2A4 mRNA

NCBI chr 1:91,299,584...91,307,650
Ensembl chr 1:91,299,561...91,307,649

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases activity
multiple interactions
increases expression

ISO

Rifampin results in increased activity of CYP2B6 protein
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA
Rifampin results in increased expression of CYP2B10 mRNA
Rifampin results in increased expression of CYP2B6 mRNA; Rifampin results in increased expression of CYP2B6 protein
[Rifampin co-treated with Monocrotophos] results in increased activity of CYP2B6 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP2B6 protein

PMID:12040753 PMID:12571232 PMID:12695351 PMID:14709624 PMID:14977870 More...

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, subfamily 2, polypeptide 11

decreases expression

ISO

Rifampin results in decreased expression of CYP2C18 mRNA; Rifampin results in decreased expression of CYP2C18 protein

PMID:22258563 PMID:31629065

NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:246,174,711...246,211,853

G

cytochrome P450, family 2, subfamily c, polypeptide 23

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2C23 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2C23 mRNA]

NCBI chr 1:252,838,427...252,863,081
Ensembl chr 1:252,838,433...252,863,067

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases activity
increases expression
multiple interactions

ISO

Rifampin results in increased activity of CYP2C19 protein
Rifampin results in increased expression of CYP2C29 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein
Rifampin results in increased expression of CYP2C19 mRNA; Rifampin results in increased expression of CYP2C19 protein
Rifampin results in increased expression of and results in increased activity of CYP2C19 protein

PMID:12584154 PMID:14709624 PMID:15629111 PMID:17954527 PMID:19118567 More...

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

cytochrome P450, family 2, subfamily c, polypeptide 79

affects binding
multiple interactions
increases expression
increases activity

ISO

[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]
Rifampin results in increased expression of CYP2C8 mRNA; Rifampin results in increased expression of CYP2C8 protein
Rifampin results in increased activity of CYP2C8 protein

PMID:12040753 PMID:15771232 PMID:15933212 PMID:17954527 PMID:19118567 More...

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases expression
increases activity
decreases expression

ISO

Rifampin results in increased expression of CYP2D6 mRNA
Rifampin results in increased activity of CYP2D6 protein
Rifampin results in decreased expression of CYP2D22 mRNA

PMID:19041851 PMID:30503582 PMID:33844597

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases activity
decreases expression
multiple interactions
increases expression

ISO
EXP

Rifampin results in increased activity of CYP2E1 protein
Rifampin results in decreased expression of CYP2E1 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA
Rifampin results in increased expression of CYP2E1 mRNA; Rifampin results in increased expression of CYP2E1 protein
[Rifampin co-treated with Monocrotophos] results in increased activity of CYP2E1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 protein
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]

PMID:15132840 PMID:18071298 PMID:22258563 PMID:22733800 PMID:25835148 More...

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 2, subfamily f, polypeptide 4

decreases expression

ISO

Rifampin results in decreased expression of CYP2F1 mRNA

NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:91,543,768...91,557,553

G

cytochrome P450, family 2, subfamily j, polypeptide 4

decreases expression

ISO

Rifampin results in decreased expression of CYP2J2 mRNA

NCBI chr 5:116,295,691...116,323,219
Ensembl chr 5:116,295,694...116,323,042

G

cytochrome P450, family 2, subfamily s, polypeptide 1

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA

NCBI chr 1:90,437,741...90,453,073
Ensembl chr 1:90,438,224...90,453,073

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
affects activity
increases expression
decreases response to substance
increases activity

EXP
ISO

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A2 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A2 protein
Rifampin affects the activity of CYP3A4 protein
Rifampin results in increased expression of CYP3A4; Rifampin results in increased expression of CYP3A4 mRNA; Rifampin results in increased expression of CYP3A4 mRNA alternative form; Rifampin results in increased expression of CYP3A4 protein
[[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA; [HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP3A4 mRNA; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP3A4 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Ethinyl Estradiol; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [Rifampin results in increased expression of CYP3A4 protein] which results in increased hydroxylation of Testosterone; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Arsenic Trioxide inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 4-hydroxymidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased hydroxylation of Midazolam]; Dexamethasone promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Econazole promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; lorlatinib inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin binds to and results in increased activity of CYP3A4 protein; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [Calcitriol results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased metabolism of Lidocaine]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A4 protein; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; sulforaphane inhibits the reaction [Rifampin results in increased expression of CYP3A4]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; trichostatin A affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; trichostatin A promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]
CYP3A4 protein results in decreased susceptibility to Rifampin
[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of CYP3A4 protein
Rifampin results in increased expression of CYP3A2 mRNA; Rifampin results in increased expression of CYP3A4 mRNA

PMID:8632764 PMID:9298257 PMID:9512926 PMID:10219967 PMID:10640517 More...

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions
increases expression

EXP

[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A23-3A1 mRNA]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA]

PMID:12370413 PMID:19041297 PMID:22159698 PMID:22310326 PMID:39909212

NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

ISO

Rifampin results in increased expression of CYP3A5 mRNA

PMID:12040753 PMID:12673034 PMID:15629111 PMID:15681896 PMID:19118567 More...

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions
decreases expression

ISO
EXP

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein
Rifampin results in decreased expression of CYP7A1 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]

PMID:15629111 PMID:21127053 PMID:21224054 PMID:22258563 PMID:24259679 More...

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689

G

DDB1 and CUL4 associated factor 5

decreases expression

ISO

Rifampin results in decreased expression of DCAF5 mRNA

NCBI chr 6:104,904,423...104,993,150
Ensembl chr 6:104,904,423...104,993,103

G

DNA cross-link repair 1B

decreases expression

ISO

Rifampin results in decreased expression of DCLRE1B mRNA

NCBI chr 2:193,998,350...194,006,873
Ensembl chr 2:193,998,354...194,006,864

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of DDIT3 mRNA]
Rifampin results in increased expression of DDIT3 mRNA; Rifampin results in increased expression of DDIT3 protein

PMID:21224054 PMID:27470132 PMID:32535746 PMID:33629115

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

24-dehydrocholesterol reductase

multiple interactions

ISO

[Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA

NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:126,573,338...126,599,936

G

iodothyronine deiodinase 1

increases expression

ISO

Rifampin results in increased expression of DIO1 mRNA

NCBI chr 5:127,303,089...127,319,784
Ensembl chr 5:127,303,083...127,319,771

G

distal-less homeobox 4

decreases expression

ISO

Rifampin results in decreased expression of DLX4 mRNA

NCBI chr10:80,581,878...80,587,272
Ensembl chr10:80,582,303...80,587,294

G

DnaJ heat shock protein family (Hsp40) member A1

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA

NCBI chr 5:60,638,404...60,649,315
Ensembl chr 5:60,638,410...60,650,160

G

E2F transcription factor 1

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA

NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563

G

endothelin 1

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

early growth response 1

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA

PMID:21127053 PMID:21224054

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

early growth response 2

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA

NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748

G

early growth response 4

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA

NCBI chr 4:119,605,358...119,607,817
Ensembl chr 4:119,605,357...119,608,368

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases phosphorylation
increases expression
multiple interactions

EXP
ISO

Rifampin results in increased phosphorylation of EIF2AK3 protein
Rifampin results in increased expression of EIF2AK3 mRNA; Rifampin results in increased expression of EIF2AK3 protein
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 protein]

PMID:24638036 PMID:27470132

NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation

EXP

Rifampin results in increased phosphorylation of EIF2S1 protein

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649

G

ETS transcription factor ELK1

decreases expression

ISO

Rifampin results in decreased expression of ELK1 mRNA

NCBI chr X:3,692,367...3,709,252
Ensembl chr X:3,693,293...3,709,249

G

endothelial PAS domain protein 1

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA

NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:13,544,389...13,624,729

G

epoxide hydrolase 1

increases expression
multiple interactions

ISO

Rifampin results in increased expression of EPHX1 mRNA
pimecrolimus inhibits the reaction [Rifampin results in increased expression of EPHX1 mRNA]

PMID:22258563 PMID:25313206 PMID:29356861

NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions
increases expression

ISO

Rifampin results in increased expression of and results in increased phosphorylation of ERN1 protein
Rifampin results in increased expression of ERN1 mRNA

NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791

G

ethanolamine-phosphate phospho-lyase

increases expression

ISO

Rifampin results in increased expression of ETNPPL mRNA

NCBI chr 2:221,847,210...221,868,827
Ensembl chr 2:221,847,250...221,866,357

G

coagulation factor XIII B chain

increases expression

ISO

Rifampin results in increased expression of F13B mRNA

NCBI chr13:53,681,639...53,707,114
Ensembl chr13:53,681,622...53,707,300

G

Fas cell surface death receptor

multiple interactions

ISO

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]

PMID:11958592 PMID:12645856

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fas ligand

multiple interactions
decreases expression

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA
Rifampin results in decreased expression of FASLG mRNA; Rifampin results in decreased expression of FASLG protein
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]

PMID:11958592 PMID:12645856 PMID:21224054 PMID:24552687

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

fatty acid synthase

increases expression
affects expression
multiple interactions

ISO

Rifampin results in increased expression of FASN mRNA
Rifampin affects the expression of FASN mRNA
pimecrolimus inhibits the reaction [Rifampin results in increased expression of FASN mRNA]

PMID:27806127 PMID:29356861 PMID:34689256

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

fibroblast growth factor 19

multiple interactions
increases expression

ISO

[Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA
Rifampin results in increased expression of FGF19 mRNA

NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:209,485,813...209,490,267

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA

NCBI chr13:77,715,405...77,747,666
Ensembl chr13:77,715,402...77,747,874

G

flavin containing dimethylaniline monoxygenase 4

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA

NCBI chr13:77,687,909...77,706,100
Ensembl chr13:77,687,909...77,706,100

G

forkhead box A1

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA

NCBI chr 6:80,838,380...80,871,195
Ensembl chr 6:80,800,960...80,871,191

G

forkhead box P1

increases expression

ISO

Rifampin results in increased expression of FOXP1 mRNA

NCBI chr 4:133,117,346...133,808,647
Ensembl chr 4:133,122,055...133,500,272

G

fucosyltransferase 1

decreases expression

ISO

Rifampin results in decreased expression of FUT1 mRNA

NCBI chr 1:105,223,399...105,226,817
Ensembl chr 1:105,223,390...105,227,513

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions
decreases expression
affects expression

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]
Rifampin results in decreased expression of G6PC1 mRNA

PMID:24204015 PMID:34689256

NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033

G

growth arrest and DNA-damage-inducible, alpha

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

ISO

NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA]

NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718

G

GATA binding protein 5

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA

NCBI chr 3:187,796,140...187,804,327
Ensembl chr 3:187,796,142...187,804,327

G

glucokinase

decreases expression
multiple interactions

ISO

Rifampin results in decreased expression of GCK protein
NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein]

NCBI chr14:84,999,019...85,041,098
Ensembl chr14:84,999,020...85,040,949

G

GLIS family zinc finger 2

increases expression

ISO

Rifampin results in increased expression of GLIS2 mRNA

NCBI chr10:11,457,594...11,484,948
Ensembl chr10:11,457,792...11,477,995

G

G protein subunit alpha L

decreases expression

ISO

Rifampin results in decreased expression of GNAL mRNA

NCBI chr18:62,892,257...63,032,510
Ensembl chr18:62,892,226...63,043,129

G

glutamic-oxaloacetic transaminase 1

multiple interactions
increases activity

ISO

[Rifampin co-treated with Isoniazid] results in increased activity of GOT1 protein
Rifampin results in increased activity of GOT1 protein

NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871

G

glutamic--pyruvic transaminase

multiple interactions
increases activity
increases expression

ISO
EXP

4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of GPT protein]; [Rifampin co-treated with Acetaminophen] results in decreased activity of GPT protein
Rifampin results in increased activity of GPT protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]
[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein; [Rifampin co-treated with Isoniazid] results in increased activity of GPT protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein]; Rifampin inhibits the reaction [Acetaminophen results in increased expression of GPT protein]

PMID:24685772 PMID:25886055 PMID:27470132 PMID:31678598 PMID:32633153 More...

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione peroxidase 2

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of GPX2 mRNA

PMID:21224054 PMID:33629115

NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862

G

glutathione peroxidase 4

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629

G

glutamate ionotropic receptor AMPA type subunit 1

decreases expression

ISO

Rifampin results in decreased expression of GRIA1 mRNA

NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309

G

glutathione-disulfide reductase

increases activity

ISO

Rifampin results in increased activity of GSR protein

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

glutathione S-transferase alpha 1

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of GSTA1 mRNA; Ketoconazole inhibits the reaction [Rifampin results in increased expression of GSTA1 mRNA]

PMID:16608920 PMID:19118567 PMID:29162470

NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528

G

glutathione S-transferase mu 1

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein

NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569

G

glutathione S-transferase, mu 5

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA

NCBI chr 2:198,219,769...198,222,732
Ensembl chr 2:198,219,647...198,222,731

G

glutathione S-transferase pi 1

multiple interactions
increases expression

ISO

[Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 protein
Rifampin results in increased expression of GSTP1 mRNA; Rifampin results in increased expression of GSTP1 protein

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

glutathione S-transferase theta 1

multiple interactions

ISO

GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]

PMID:18397238 PMID:20485159

NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,083...12,873,019

G

GTF2I repeat domain containing 2

increases expression

ISO

Rifampin results in increased expression of GTF2IRD2 mRNA

NCBI chr12:28,134,199...28,179,089
Ensembl chr12:28,133,792...28,172,876

G

granzyme B

increases secretion

ISO

Rifampin results in increased secretion of GZMB protein

NCBI chr15:34,459,007...34,462,469
Ensembl chr15:34,459,007...34,462,469

G

heparin-binding EGF-like growth factor

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA

NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220

G

histone deacetylase 3

multiple interactions

ISO

Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]

NCBI chr18:30,021,847...30,041,061
Ensembl chr18:30,021,941...30,041,025

G

histone deacetylase 5

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA

NCBI chr10:87,653,139...87,688,078
Ensembl chr10:87,652,656...87,694,244

G

hes-related family bHLH transcription factor with YRPW motif 1

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA

NCBI chr 2:95,003,935...95,006,457
Ensembl chr 2:95,002,943...95,007,624

G

hepatocyte growth factor

multiple interactions

ISO

HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]

NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

ISO
EXP

[Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

PMID:21127053 PMID:36878459

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

high mobility group nucleosome binding domain 5

increases expression

ISO

Rifampin results in increased expression of HMGN5 mRNA

NCBI chr X:78,161,439...78,170,613
Ensembl chr X:78,161,442...78,169,924

G

heme oxygenase 1

multiple interactions
increases expression

ISO
EXP

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA
dorsomorphin inhibits the reaction [Rifampin results in increased expression of HMOX1 protein]
Rifampin results in increased expression of HMOX1 mRNA; Rifampin results in increased expression of HMOX1 protein
[arsenite co-treated with Rifampin] results in increased expression of HMOX1 mRNA

PMID:21224054 PMID:22159698 PMID:22258563 PMID:31678598

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

hepatocyte nuclear factor 4, alpha

multiple interactions

ISO

[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein]

PMID:21127053 PMID:21292004 PMID:21764778 PMID:25069801

NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:172,606,220...172,667,758

G

histamine receptor H 1

increases expression

ISO

Rifampin results in increased expression of HRH1 mRNA

NCBI chr 4:149,120,511...149,204,267
Ensembl chr 4:149,120,039...149,208,248

G

heat shock protein family A (Hsp70) member 1 like

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA

NCBI chr20:3,853,496...3,860,223
Ensembl chr20:3,853,331...3,876,877

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases expression

EXP
ISO

ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein]
[Rifampin co-treated with Cobicistat] results in increased expression of HSPA5 mRNA
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 protein]
Rifampin results in increased expression of HSPA5 mRNA; Rifampin results in increased expression of HSPA5 protein

PMID:24638036 PMID:27470132 PMID:32535746 PMID:33629115

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

heat shock protein family A (Hsp70) member 8

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA

NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372

G

heat shock protein family B (small) member 1

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA

NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301

G

heat shock protein family D (Hsp60) member 1

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA

NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:64,073,611...64,084,037

G

heat shock protein family E (Hsp10) member 1

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA

NCBI chr 9:64,084,327...64,087,415
Ensembl chr 9:64,085,068...64,087,502

G

interferon gamma

increases secretion

ISO

Rifampin results in increased secretion of IFNG protein

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

insulin-like growth factor binding protein 1

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA

NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344

G

insulin-like growth factor binding protein 3

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA

NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944

G

insulin-like growth factor binding protein 4

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA

NCBI chr10:84,491,471...84,503,487
Ensembl chr10:84,485,775...84,503,473

G

interleukin 10

affects expression

EXP

Rifampin affects the expression of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 12 receptor subunit beta 2

decreases expression

ISO

Rifampin results in decreased expression of IL12RB2 mRNA

NCBI chr 4:97,756,089...97,844,937
Ensembl chr 4:97,756,089...97,844,937

G

interleukin 13

increases secretion

ISO

Rifampin results in increased secretion of IL13 protein

NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483

G

interleukin 18

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 beta

multiple interactions
decreases expression

ISO
EXP

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; Rifampin inhibits the reaction [Rotenone results in increased expression of and results in increased secretion of IL1B protein]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]
Rifampin results in decreased expression of IL1B mRNA; Rifampin results in decreased expression of IL1B protein

PMID:21224054 PMID:25051504 PMID:26086368 PMID:31648047

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

decreases expression
multiple interactions
increases expression

ISO
EXP

Rifampin results in decreased expression of IL6 protein
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]
Rifampin results in increased expression of IL6 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA

PMID:21224054 PMID:21357946 PMID:25051504 PMID:31648047

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

INO80 complex subunit D

decreases expression

ISO

Rifampin results in decreased expression of INO80D mRNA

NCBI chr 9:71,940,941...72,007,879
Ensembl chr 9:71,951,031...72,040,232

G

insulin 2

multiple interactions

ISO

INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]
Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]

PMID:24204015 PMID:33412187

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805

G

integrator complex subunit 6

decreases expression

ISO

Rifampin results in decreased expression of INTS6 mRNA

NCBI chr15:41,080,584...41,224,350
Ensembl chr15:41,109,125...41,197,519

G

IQ motif containing with AAA domain 1

decreases expression

ISO

Rifampin results in decreased expression of DRC11 mRNA

NCBI chr 9:98,074,389...98,190,233
Ensembl chr 9:98,073,887...98,190,066

G

integrin subunit beta like 1

decreases expression

ISO

Rifampin results in decreased expression of ITGBL1 mRNA

NCBI chr15:107,186,792...107,448,335
Ensembl chr15:107,186,689...107,451,098

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

kirre like nephrin family adhesion molecule 3

decreases expression

ISO

Rifampin results in decreased expression of KIRREL3 mRNA

NCBI chr 8:41,123,692...41,663,528
Ensembl chr 8:41,123,878...41,664,147

G

KLF transcription factor 2

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA

NCBI chr16:17,555,136...17,557,768
Ensembl chr16:17,555,136...17,557,768

G

KLF transcription factor 5

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA

NCBI chr15:82,472,081...82,487,267
Ensembl chr15:82,472,065...82,487,262

G

KLF transcription factor 6

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA

NCBI chr17:69,449,483...69,458,478
Ensembl chr17:69,441,493...69,498,601

G

low density lipoprotein receptor

increases expression

ISO

Rifampin results in increased expression of LDLR mRNA

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675

G

left right determination factor 1

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA

NCBI chr13:95,188,091...95,191,488
Ensembl chr13:95,188,091...95,191,488

G

leptin

increases expression

EXP

Rifampin results in increased expression of LEP protein

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661

G

leukocyte receptor tyrosine kinase

increases expression

ISO

Rifampin results in increased expression of LTK mRNA

NCBI chr 3:127,188,479...127,195,356
Ensembl chr 3:127,188,480...127,197,402

G

MAF bZIP transcription factor F

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA

NCBI chr 7:112,792,787...112,804,139
Ensembl chr 7:112,791,416...112,804,147

G

microtubule-associated protein 1 light chain 3 beta

decreases metabolic processing
multiple interactions
increases lipidation

ISO

Rifampin results in decreased metabolism of MAP1LC3B protein
ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [Rifampin results in increased lipidation of MAP1LC3B protein]; Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]

PMID:29908302 PMID:31648047

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen-activated protein kinase 8

multiple interactions

ISO

Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]]; Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

MAPK activated protein kinase 2

increases phosphorylation

ISO

Rifampin results in increased phosphorylation of MAPKAPK2 protein

NCBI chr13:45,066,027...45,112,326
Ensembl chr13:45,066,031...45,112,326

G

microtubule-associated protein, RP/EB family, member 3

increases expression

ISO

Rifampin results in increased expression of MAPRE3 mRNA

NCBI chr 6:31,233,736...31,278,626
Ensembl chr 6:31,233,736...31,278,775

G

matrilin 2

increases expression

ISO

Rifampin results in increased expression of MATN2 mRNA

NCBI chr 7:67,380,140...67,529,767
Ensembl chr 7:67,380,168...67,530,153

G

myelin basic protein

affects expression

EXP

Rifampin affects the expression of MBP mRNA

NCBI chr18:78,130,652...78,241,174
Ensembl chr18:78,130,325...78,241,174

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions

ISO

[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

MDM2 proto-oncogene

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA

NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791

G

mediator complex subunit 1

multiple interactions
decreases expression

ISO

Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]
Rifampin results in decreased expression of MED1 mRNA

PMID:21292004 PMID:22214767 PMID:24552687

NCBI chr10:83,641,851...83,685,560
Ensembl chr10:83,641,862...83,685,545

G

multiple inositol-polyphosphate phosphatase 1

increases expression

ISO

Rifampin results in increased expression of MINPP1 mRNA

NCBI chr 1:239,766,809...239,793,023
Ensembl chr 1:239,767,286...239,793,015

G

microRNA 143

increases expression

ISO

Rifampin results in increased expression of MIR143 mRNA

NCBI chr18:57,371,349...57,371,453

G

microRNA 145

increases expression

ISO

Rifampin results in increased expression of MIR145 mRNA

NCBI chr18:57,369,983...57,370,070

G

microRNA 148b

decreases expression

ISO

Rifampin results in decreased expression of MIR148B mRNA

NCBI chr 7:136,299,870...136,299,966
Ensembl chr 7:136,299,870...136,299,966

G

microRNA 15b

increases expression

ISO

Rifampin results in increased expression of MIR15B mRNA

NCBI chr 2:155,555,178...155,555,275
Ensembl chr 2:155,555,178...155,555,275

G

microRNA 186

multiple interactions

ISO

[Isoniazid co-treated with Rifampin] results in increased expression of MIR186 mRNA

NCBI chr 2:249,241,650...249,241,735
Ensembl chr 2:249,241,650...249,241,735

G

microRNA 192

decreases expression

ISO

Rifampin results in decreased expression of MIR192 mRNA

NCBI chr 1:212,994,209...212,994,318
Ensembl chr 1:212,994,209...212,994,318

G

microRNA 200a

increases expression

ISO

Rifampin results in increased expression of MIR200A mRNA

NCBI chr 5:171,930,717...171,930,805

G

microRNA 202

increases expression

ISO

Rifampin results in increased expression of MIR202 mRNA

NCBI chr 1:204,184,345...204,184,416

G

microRNA 204

increases expression

ISO

Rifampin results in increased expression of MIR204 mRNA

NCBI chr 1:229,743,461...229,743,570
Ensembl chr 1:229,743,461...229,743,570

G

microRNA 20b

increases expression

ISO

Rifampin results in increased expression of MIR20B mRNA

NCBI chr X:137,343,197...137,343,268

G

microRNA 21

increases expression

ISO

Rifampin results in increased expression of MIR21 mRNA

NCBI chr10:71,902,600...71,902,691

G

microRNA 212

decreases expression

ISO

Rifampin results in decreased expression of MIR212 mRNA

NCBI chr10:60,521,740...60,521,850
Ensembl chr10:60,521,740...60,521,850

G

microRNA 22

increases expression

ISO

Rifampin results in increased expression of MIR22 mRNA

NCBI chr10:60,805,331...60,805,425
Ensembl chr10:60,805,331...60,805,425

G

microRNA 26b

increases expression

ISO

Rifampin results in increased expression of MIR26B mRNA

NCBI chr 9:83,425,709...83,425,793
Ensembl chr 9:83,425,709...83,425,793

G

microRNA 296

decreases expression

ISO

Rifampin results in decreased expression of MIR296 mRNA

NCBI chr 3:183,470,069...183,470,146

G

microRNA 29a

decreases expression

ISO

Rifampin results in decreased expression of MIR29A mRNA

NCBI chr 4:60,617,955...60,618,042

G

microRNA 31

increases expression

ISO

Rifampin results in increased expression of MIR31 mRNA

NCBI chr 5:108,714,849...108,714,954

G

microRNA 328

increases expression

ISO

Rifampin results in increased expression of MIR328 mRNA

NCBI chr19:50,094,691...50,094,774

G

microRNA 340

increases expression

ISO

Rifampin results in increased expression of MIR340 mRNA

NCBI chr10:34,894,650...34,894,747
Ensembl chr10:34,894,650...34,894,747

G

microRNA 34a

decreases expression

ISO

Rifampin results in decreased expression of MIR34A mRNA

NCBI chr 5:165,815,952...165,816,053
Ensembl chr 5:165,815,952...165,816,053

G

microRNA 374b

increases expression

ISO

Rifampin results in increased expression of MIR374B mRNA

NCBI chr X:72,657,495...72,657,562

G

microRNA 532

decreases expression

ISO

Rifampin results in decreased expression of MIR532 mRNA

NCBI chr X:17,919,185...17,919,263
Ensembl chr X:17,919,185...17,919,263

G

microRNA 628

decreases expression

ISO

Rifampin results in decreased expression of MIR628 mRNA

NCBI chr 8:82,620,496...82,620,579
Ensembl chr 8:82,620,496...82,620,579

G

microRNA 652

decreases expression

ISO

Rifampin results in decreased expression of MIR652 mRNA

NCBI chr X:111,140,079...111,140,159
Ensembl chr X:111,140,079...111,140,159

G

microRNA 874

decreases expression

ISO

Rifampin results in decreased expression of MIR874 mRNA

NCBI chr17:6,626,032...6,626,107
Ensembl chr17:6,626,032...6,626,107

G

marker of proliferation Ki-67

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

matrix metallopeptidase 3

decreases secretion

ISO

Rifampin results in decreased secretion of MMP3 protein

NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826

G

myeloperoxidase

multiple interactions

EXP

Rifampin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

major histocompatibility complex, class I-related

affects expression

ISO

Rifampin affects the expression of MR1 mRNA

NCBI chr13:69,850,420...69,868,302
Ensembl chr13:69,850,420...69,868,502

G

microsomal triglyceride transfer protein

decreases expression

ISO

Rifampin results in decreased expression of MTTP mRNA

NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:229,286,501...229,327,650

G

myosin heavy chain 6

increases expression

ISO

Rifampin results in increased expression of MYH6 mRNA

NCBI chr15:32,388,102...32,413,663
Ensembl chr15:32,387,487...32,411,333

G

nuclear assembly factor 1 ribonucleoprotein

decreases expression

ISO

Rifampin results in decreased expression of NAF1 mRNA

NCBI chr16:27,604,228...27,634,963
Ensembl chr16:27,603,918...27,634,963

G

nucleosome assembly protein 1-like 5

increases expression

ISO

Rifampin results in increased expression of NAP1L5 mRNA

NCBI chr 4:89,352,834...89,354,704
Ensembl chr 4:89,351,926...89,361,736

G

nuclear receptor coactivator 1

multiple interactions

ISO

Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Miconazole promotes the reaction [Rifampin results in increased expression of NCOA1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]

PMID:11581012 PMID:12072427 PMID:16819505 PMID:17088262 PMID:17438109 More...

NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:32,952,090...33,195,924

G

nuclear receptor coactivator 2

multiple interactions

ISO

Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]

NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:10,618,722...10,852,776

G

nuclear receptor coactivator 6

multiple interactions

ISO

NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]

NCBI chr 3:164,351,062...164,422,079
Ensembl chr 3:164,351,062...164,421,991

G

nuclear receptor co-repressor 1

multiple interactions

ISO

Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein]

NCBI chr10:47,498,852...47,641,612
Ensembl chr10:47,498,852...47,640,350

G

nuclear receptor co-repressor 2

multiple interactions

ISO

[NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]

PMID:12072427 PMID:22214767 PMID:25313206 PMID:26883953 PMID:28289823 More...

NCBI chr12:37,127,736...37,289,612
Ensembl chr12:37,127,686...37,289,612

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions
decreases expression
decreases activity

ISO
EXP

Rifampin results in increased expression of NFE2L2 protein
[tanshinone co-treated with Rifampin] results in increased expression of NFE2L2 mRNA; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 protein]
Rifampin results in decreased expression of NFE2L2 mRNA; Rifampin results in decreased expression of NFE2L2 protein
Rifampin inhibits the reaction [arsenite results in increased activity of NFE2L2 protein]
Rifampin results in decreased activity of NFE2L2 protein

PMID:31678598 PMID:33307820 PMID:33412187

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear transcription factor Y subunit alpha

decreases expression

ISO

Rifampin results in decreased expression of NFYA mRNA

NCBI chr 9:20,085,067...20,111,521
Ensembl chr 9:20,085,073...20,111,504

G

nerve growth factor receptor

multiple interactions

ISO

[Rifampin co-treated with Cobicistat] results in increased expression of TNFRSF10B mRNA

NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305

G

NLR family, pyrin domain containing 3

multiple interactions

ISO

Rifampin inhibits the reaction [Rotenone results in increased expression of NLRP3 protein]

NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394

G

nitric oxide synthase 2

multiple interactions
increases expression

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA
Rifampin results in increased expression of NOS2 mRNA

PMID:21224054 PMID:24552687

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

neuronal PAS domain protein 1

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA

NCBI chr 1:86,295,509...86,316,018
Ensembl chr 1:86,295,515...86,314,893

G

natriuretic peptide B

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA

NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310

G

nuclear receptor subfamily 0, group B, member 2

increases expression
decreases expression

ISO

Rifampin results in increased expression of NR0B2 mRNA
Rifampin results in decreased expression of NR0B2 mRNA

PMID:15670600 PMID:34689256

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

ISO

NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]

NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

EXP
ISO

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389

G

nuclear receptor subfamily 1, group I, member 2

affects response to substance
affects localization
decreases acetylation
increases response to substance
increases activity
decreases response to substance
multiple interactions
increases expression
increases localization
affects binding

ISO
EXP

NR1I2 protein affects the susceptibility to Rifampin
Rifampin affects the localization of NR1I2 protein
Rifampin results in decreased acetylation of NR1I2 protein
NR1I2 protein results in increased susceptibility to Rifampin
[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of NR1I2 protein
NR1I2 protein mutant form results in decreased susceptibility to Rifampin
1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [fexofenadine co-treated with Rifampin] results in increased activity of NR1I2 protein; [Ketoconazole co-treated with Rifampin] results in increased activity of NR1I2 protein; [Loperamide co-treated with Rifampin] results in increased activity of NR1I2 protein; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I2 protein; [Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Camptothecin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; caraway oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Clove Oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; coriander oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Doxorubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Epirubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Fluconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; hydroxyitraconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Itraconazole promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; jasmine oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin binds to and results in increased activity of NR1I2 protein]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; lemongrass oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Miconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of amprenavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Midazolam]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Nelfinavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Saquinavir]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased abundance of Lipids]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Oils, Volatile inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Oils, Volatile promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; oxiconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pazopanib inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin binds to and results in increased activity of NR1I2 protein; Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin inhibits the reaction [oxiconazole results in increased expression of NR1I2 mRNA]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin inhibits the reaction [trichostatin A results in increased acetylation of NR1I2 protein]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; sulforaphane inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; trichostatin A affects the reaction [Rifampin affects the localization of NR1I2 protein]; triptolide inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]
Rifampin results in increased expression of NR1I2 mRNA; Rifampin results in increased expression of NR1I2 protein
Rifampin results in increased localization of NR1I2 protein
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased localization of NR1I2 protein]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA]
Rifampin binds to NR1I2 gene mutant form
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CES2A mRNA; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CYP3A11 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; NR1I2 affects the reaction [Rifampin results in increased activity of CYP3A4 protein]; Rifampin affects the localization of and results in increased activity of NR1I2 protein; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]
[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter; Rifampin binds to NR1I2 protein

PMID:11581012 PMID:12065438 PMID:12072427 PMID:12370413 PMID:12417264 More...

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 1, group I, member 3

increases expression
multiple interactions

EXP
ISO

Rifampin results in increased expression of NR1I3 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein
Rifampin results in increased expression of NR1I3 mRNA; Rifampin results in increased expression of NR1I3 protein
[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 protein

PMID:19118567 PMID:22733800 PMID:25835148

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
increases expression

ISO

Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]
Rifampin results in increased expression of NR3C1 mRNA

PMID:10219967 PMID:12673034 PMID:12695351

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

neural retina leucine zipper

increases expression

ISO

Rifampin results in increased expression of NRL mRNA

NCBI chr15:32,977,023...32,981,442
Ensembl chr15:32,977,035...32,981,442

G

obscurin like cytoskeletal adaptor 1

decreases expression

ISO

Rifampin results in decreased expression of OBSL1 mRNA

NCBI chr 9:84,416,447...84,442,415
Ensembl chr 9:84,416,240...84,442,415

G

occludin

affects localization

ISO

Rifampin affects the localization of OCLN protein

NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411

G

olfactory receptor family 4 subfamily A member 47

decreases expression

ISO

Rifampin results in decreased expression of OR4A47 mRNA

NCBI chr 3:96,330,089...96,331,018
Ensembl chr 3:96,330,089...96,331,018

G

prolyl 4-hydroxylase subunit beta

decreases expression

ISO

Rifampin results in decreased expression of P4HB mRNA

NCBI chr10:106,335,300...106,346,911
Ensembl chr10:106,335,300...106,346,911

G

poly (ADP-ribose) polymerase 1

multiple interactions

ISO

Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein]

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

paired box 7

decreases expression

ISO

Rifampin results in decreased expression of PAX7 mRNA

NCBI chr 5:157,279,623...157,381,188
Ensembl chr 5:157,279,623...157,381,121

G

phosphoenolpyruvate carboxykinase 1

multiple interactions
increases expression

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA]
Rifampin results in increased expression of PCK1 mRNA

PMID:24204015 PMID:34689256

NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561

G

PCNA clamp associated factor

increases expression

ISO

Rifampin results in increased expression of PCLAF mRNA

NCBI chr 8:75,311,028...75,328,108
Ensembl chr 8:75,315,707...75,328,106

G

PDGFA associated protein 1

decreases expression

ISO

Rifampin results in decreased expression of PDAP1 mRNA

NCBI chr12:14,584,414...14,594,641
Ensembl chr12:14,584,398...14,594,641

G

phosphodiesterase 4D

decreases expression

ISO

Rifampin results in decreased expression of PDE4D mRNA

NCBI chr 2:41,748,337...43,262,567
Ensembl chr 2:42,110,838...43,262,569

G

paternally expressed 3

increases expression

ISO

Rifampin results in increased expression of PEG3 mRNA

NCBI chr 1:76,130,965...76,157,774
Ensembl chr 1:76,130,948...76,157,743

G

protein inhibitor of activated STAT, 1

multiple interactions

ISO

Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]

NCBI chr 8:72,233,566...72,347,085
Ensembl chr 8:72,233,566...72,334,315

G

paired immunoglobin-like type 2 receptor alpha

decreases expression

ISO

Rifampin results in decreased expression of PILRA mRNA

NCBI chr12:23,452,626...23,464,772

G

phosphatidylinositol-5-phosphate 4-kinase type 2 alpha

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA

NCBI chr17:86,405,080...86,576,597
Ensembl chr17:86,405,081...86,576,430

G

polycystin 2 like 1, transient receptor potential cation channel

decreases expression

ISO

Rifampin results in decreased expression of PKD2L1 mRNA

NCBI chr 1:252,982,096...253,019,235
Ensembl chr 1:252,982,096...253,023,359

G

pyruvate kinase L/R

increases expression

ISO

Rifampin results in increased expression of PKLR mRNA

NCBI chr 2:176,840,779...176,849,637
Ensembl chr 2:176,840,764...176,849,644

G

plasminogen activator, tissue type

decreases expression

ISO

Rifampin results in decreased expression of PLAT mRNA

NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696

G

paraoxonase 1

increases expression

ISO

Rifampin results in increased expression of PON1 mRNA

NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:34,261,289...34,287,924

G

cytochrome p450 oxidoreductase

increases activity

ISO

Rifampin results in increased activity of POR protein

NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809

G

POU class 2 homeobox 1

decreases expression

ISO

Rifampin results in decreased expression of POU2F1 mRNA

NCBI chr13:80,653,602...80,796,279
Ensembl chr13:80,663,714...80,796,356

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA
[Isoniazid co-treated with Rifampin] results in decreased expression of PPARA protein

PMID:16292757 PMID:36347327

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

ISO

[Isoniazid co-treated with Rifampin] results in decreased expression of PPARG protein; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA alternative form; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]; Rifampin results in increased expression of and affects the localization of PPARG protein
Rifampin results in increased expression of PPARG mRNA

PMID:27806127 PMID:33412187 PMID:36347327

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

PPARG coactivator 1 alpha

multiple interactions

ISO

[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [PPARGC1A protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein]

PMID:16857725 PMID:21292004 PMID:25069801

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

protein kinase, DNA-activated, catalytic subunit

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2B9 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A14 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A4 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA; PRKDC gene mutant form results in increased susceptibility to [Rifampin co-treated with Phenytoin co-treated with Monocrotaline]

NCBI chr11:98,544,952...98,762,499
Ensembl chr11:98,544,954...98,762,108

G

protein arginine methyltransferase 1

multiple interactions

ISO

PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]

NCBI chr 1:104,595,339...104,605,552
Ensembl chr 1:104,595,335...104,604,827

G

prune exopolyphosphatase 1

decreases expression

ISO

Rifampin results in decreased expression of PRUNE1 mRNA

NCBI chr 2:185,519,569...185,548,402
Ensembl chr 2:185,520,781...185,548,402

G

PC4 and SRSF1 interacting protein 1

increases expression

ISO

Rifampin results in increased expression of PSIP1 mRNA

NCBI chr 5:102,892,929...102,925,191
Ensembl chr 5:102,892,932...102,925,170

G

PSMC3 interacting protein

increases expression

ISO

Rifampin results in increased expression of PSMC3IP mRNA

NCBI chr10:86,524,546...86,527,764
Ensembl chr10:86,524,571...86,527,666

G

RAD50 double strand break repair protein

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA

NCBI chr10:38,310,147...38,362,100
Ensembl chr10:38,310,147...38,362,100

G

RIC8 guanine nucleotide exchange factor B

decreases expression

ISO

Rifampin results in decreased expression of RIC8B mRNA

NCBI chr 7:20,636,337...20,730,066
Ensembl chr 7:20,636,687...20,730,178

G

ring finger protein 6

decreases expression

ISO

Rifampin results in decreased expression of RNF6 mRNA

NCBI chr12:13,929,160...13,940,663
Ensembl chr12:13,931,074...13,940,652

G

Ras-related GTP binding B

decreases expression

ISO

Rifampin results in decreased expression of RRAGB mRNA

NCBI chr X:21,560,313...21,610,550
Ensembl chr X:21,560,361...21,610,346

G

R-spondin 3

decreases expression

ISO

Rifampin results in decreased expression of RSPO3 mRNA

NCBI chr 1:30,112,529...30,197,267
Ensembl chr 1:30,112,114...30,197,938

G

RT1 class II, locus Bb

affects expression

ISO

Rifampin affects the expression of HLA-DQB1 mRNA

NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,598,475...4,604,118

G

RT1 class II, locus DMa

increases expression

ISO

Rifampin results in increased expression of HLA-DMA mRNA

NCBI chr20:4,708,932...4,712,335
Ensembl chr20:4,708,933...4,712,335

G

RT1 class Ib, locus M3, gene 1

affects expression

ISO

Rifampin affects the expression of HLA-G mRNA

NCBI chr20:1,329,227...1,333,394
Ensembl chr20:1,329,225...1,333,366

G

retinoid X receptor alpha

multiple interactions

ISO
EXP

1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]
[Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]
[Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]

PMID:12370413 PMID:16292757 PMID:16632523 PMID:21315811 PMID:25069801

NCBI chr 3:31,387,892...31,474,415
Ensembl chr 3:31,388,223...31,474,417

G

scavenger receptor class B, member 1

decreases expression

ISO

Rifampin results in decreased expression of SCARB1 mRNA; Rifampin results in decreased expression of SCARB1 protein

NCBI chr12:36,957,302...37,023,982
Ensembl chr12:36,957,496...37,023,980

G

stearoyl-CoA desaturase

increases expression

ISO

Rifampin results in increased expression of SCD1 mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785

G

septin 8

increases expression

ISO

Rifampin results in increased expression of SEPTIN8 mRNA

NCBI chr10:38,185,454...38,214,502
Ensembl chr10:38,185,335...38,214,504

G

serpin family A member 4

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA

NCBI chr 6:128,764,738...128,773,858
Ensembl chr 6:128,764,769...128,776,028

G

serpin family B member 1A

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA

NCBI chr17:31,799,446...31,807,853
Ensembl chr17:31,799,415...31,808,166

G

serpin family B member 8

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA

NCBI chr13:24,141,557...24,164,894
Ensembl chr13:24,129,855...24,166,076

G

serpin family B member 9

multiple interactions
increases expression

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA
Rifampin results in increased expression of SERPINB9 mRNA

PMID:21127053 PMID:24552687

NCBI chr17:31,628,887...31,652,003
Ensembl chr17:31,629,392...31,651,974

G

serpin family E member 1

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA

PMID:21127053 PMID:21224054

NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357

G

sideroflexin 1

decreases expression

ISO

Rifampin results in decreased expression of SFXN1 mRNA

NCBI chr17:10,491,315...10,527,793
Ensembl chr17:10,491,344...10,527,456

G

serum/glucocorticoid regulated kinase 2

multiple interactions
increases expression

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA]
Rifampin results in increased expression of SGK2 mRNA

PMID:21127053 PMID:24204015

NCBI chr 3:172,063,625...172,089,000
Ensembl chr 3:172,063,776...172,089,011

G

salt-inducible kinase 2

decreases expression

ISO

Rifampin results in decreased expression of SIK2 mRNA

NCBI chr 8:60,121,913...60,221,707
Ensembl chr 8:60,121,913...60,221,818

G

solute carrier family 10 member 1

decreases expression
multiple interactions

ISO
EXP

Rifampin results in decreased expression of SLC10A1 mRNA
Rifampin results in decreased expression of SLC10A1 protein
[tanshinone co-treated with Rifampin] results in increased expression of SLC10A1 mRNA; [tanshinone co-treated with Rifampin] results in increased expression of SLC10A1 protein; tanshinone inhibits the reaction [Rifampin results in decreased expression of SLC10A1 protein]
[Rifampin co-treated with Isoniazid] results in decreased expression of SLC10A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1

PMID:16837569 PMID:25886055 PMID:33307820 PMID:35835356

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944

G

solute carrier family 13 member 5

increases expression

ISO

Rifampin results in increased expression of SLC13A5 mRNA; Rifampin results in increased expression of SLC13A5 protein

PMID:25628225 PMID:27199754

NCBI chr10:57,364,806...57,389,500
Ensembl chr10:57,364,806...57,389,516

G

solute carrier family 15 member 1

decreases expression

ISO

Rifampin results in decreased expression of SLC15A1 mRNA

NCBI chr15:104,944,461...104,991,316
Ensembl chr15:104,944,463...104,989,369

G

solute carrier family 16, member 12

increases expression
decreases expression

ISO

Rifampin results in increased expression of SLC16A12 mRNA
Rifampin results in decreased expression of SLC16A12 mRNA

PMID:24552687 PMID:27199754

NCBI chr 1:241,597,165...241,674,821
Ensembl chr 1:241,599,066...241,674,743

G

solute carrier family 17 member 1

decreases expression

ISO

Rifampin results in decreased expression of SLC17A1 mRNA

NCBI chr17:41,647,332...41,683,078
Ensembl chr17:41,649,919...41,681,174

G

solute carrier family 1 member 2

decreases expression

ISO

Rifampin results in decreased expression of SLC1A2 mRNA

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

solute carrier family 20 member 2

decreases expression

ISO

Rifampin results in decreased expression of SLC20A2 mRNA

NCBI chr16:76,163,315...76,253,881
Ensembl chr16:76,162,922...76,253,881

G

solute carrier family 22 member 1

decreases expression
multiple interactions

ISO

Rifampin results in decreased expression of SLC22A1 mRNA; Rifampin results in decreased expression of SLC22A1 protein
[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]

PMID:26920453 PMID:27199754

NCBI chr 1:50,624,339...50,651,437
Ensembl chr 1:50,624,377...50,651,436

G

solute carrier family 22, member 25

decreases expression

ISO

Rifampin results in decreased expression of SLC22A9 mRNA

NCBI chr 1:214,767,837...214,956,535
Ensembl chr 1:214,767,837...214,862,340

G

solute carrier family 22 member 7

decreases expression

ISO

Rifampin results in decreased expression of SLC22A7 mRNA

PMID:16837569 PMID:27199754

NCBI chr 9:22,044,672...22,052,051
Ensembl chr 9:22,045,435...22,051,681

G

solute carrier family 23 member 2

increases expression

ISO

Rifampin results in increased expression of SLC23A2 mRNA

NCBI chr 3:139,755,583...139,913,304
Ensembl chr 3:139,755,584...139,847,343

G

solute carrier family 23, member 3

decreases expression

ISO

Rifampin results in decreased expression of SLC23A3 mRNA

NCBI chr 9:84,071,286...84,081,951
Ensembl chr 9:84,071,471...84,080,037

G

solute carrier family 25 member 22

increases expression

ISO

Rifampin results in increased expression of SLC25A22 mRNA

NCBI chr 1:205,954,713...205,966,188
Ensembl chr 1:205,958,032...205,965,877

G

solute carrier family 25, member 34

decreases expression

ISO

Rifampin results in decreased expression of SLC25A34 mRNA

NCBI chr 5:159,215,120...159,219,892
Ensembl chr 5:159,215,120...159,219,892

G

solute carrier family 25, member 40

decreases expression

ISO

Rifampin results in decreased expression of SLC25A40 mRNA

NCBI chr 4:26,544,288...26,631,439
Ensembl chr 4:26,544,290...26,631,383

G

solute carrier family 26 member 2

decreases expression

ISO

Rifampin results in decreased expression of SLC26A2 mRNA

NCBI chr18:56,918,662...56,937,032
Ensembl chr18:56,923,337...56,937,012

G

solute carrier family 26 member 4

decreases expression

ISO

Rifampin results in decreased expression of SLC26A4 mRNA

NCBI chr 6:53,835,102...53,873,968
Ensembl chr 6:53,835,110...53,873,216

G

solute carrier family 27 member 1

increases expression

ISO

Rifampin results in increased expression of SLC27A1 mRNA

NCBI chr16:18,311,859...18,337,024
Ensembl chr16:18,313,015...18,330,045

G

solute carrier family 27 member 2

increases expression

ISO

Rifampin results in increased expression of SLC27A2 mRNA

NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:134,258,101...134,295,581

G

solute carrier family 27 member 3

decreases expression

ISO

Rifampin results in decreased expression of SLC27A3 mRNA

NCBI chr 2:178,150,835...178,155,503
Ensembl chr 2:178,150,835...178,155,503

G

solute carrier family 27 member 5

increases expression

ISO

Rifampin results in increased expression of SLC27A5 mRNA

NCBI chr 1:82,688,742...82,699,335
Ensembl chr 1:82,688,750...82,699,358

G

solute carrier family 29 member 1

increases expression

ISO

Rifampin results in increased expression of SLC29A1 mRNA

NCBI chr 9:22,897,099...22,911,640
Ensembl chr 9:22,902,471...22,914,620

G

solute carrier family 29 member 4

increases expression

ISO

Rifampin results in increased expression of SLC29A4 mRNA

NCBI chr12:16,967,047...16,998,276
Ensembl chr12:16,967,047...16,988,338

G

solute carrier family 2 member 12

increases expression

ISO

Rifampin results in increased expression of SLC2A12 mRNA

NCBI chr 1:24,623,558...24,683,577
Ensembl chr 1:24,589,707...24,694,290

G

solute carrier family 2 member 2

multiple interactions
decreases expression

ISO

NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein]
Rifampin results in decreased expression of SLC2A2 mRNA; Rifampin results in decreased expression of SLC2A2 protein

PMID:26616219 PMID:27199754 PMID:34689256

NCBI chr 2:113,537,884...113,568,422
Ensembl chr 2:113,537,972...113,568,467

G

solute carrier family 30, member 10

decreases expression

ISO

Rifampin results in decreased expression of SLC30A10 mRNA

NCBI chr13:99,529,664...99,584,442
Ensembl chr13:99,529,790...99,544,213

G

solute carrier family 38, member 2

decreases expression

ISO

Rifampin results in decreased expression of SLC38A2 mRNA

NCBI chr 7:129,730,450...129,742,619
Ensembl chr 7:129,730,450...129,742,619

G

solute carrier family 3 member 1

decreases expression

ISO

Rifampin results in decreased expression of SLC3A1 mRNA

NCBI chr 6:15,361,037...15,396,695
Ensembl chr 6:15,361,046...15,394,775

G

solute carrier family 46, member 3

increases expression

ISO

Rifampin results in increased expression of SLC46A3 mRNA

NCBI chr12:12,176,776...12,193,256
Ensembl chr12:12,176,807...12,193,255

G

solute carrier family 47 member 1

increases expression

ISO

Rifampin results in increased expression of SLC47A1 mRNA

NCBI chr10:46,533,580...46,590,128
Ensembl chr10:46,533,583...46,587,096

G

solute carrier family 51 member A

increases expression

ISO

Rifampin results in increased expression of SLC51A mRNA

NCBI chr11:81,804,141...81,818,539
Ensembl chr11:81,803,972...81,818,539

G

SLC51 subunit beta

increases expression

ISO

Rifampin results in increased expression of SLC51B mRNA

NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109

G

solute carrier family 5 member 11

increases expression

ISO

Rifampin results in increased expression of SLC5A11 mRNA

NCBI chr 1:187,166,609...187,226,291
Ensembl chr 1:187,166,811...187,282,848

G

solute carrier family 5 member 12

increases expression

ISO

Rifampin results in increased expression of SLC5A12 mRNA

NCBI chr 3:117,633,885...117,683,966
Ensembl chr 3:117,633,887...117,682,963

G

solute carrier family 6 member 12

increases expression

ISO

Rifampin results in increased expression of SLC6A12 mRNA

NCBI chr 4:156,257,518...156,275,870
Ensembl chr 4:156,254,208...156,275,879

G

solute carrier family 6 member 20a

increases expression

ISO

Rifampin results in increased expression of SLC6A20 mRNA

NCBI chr 8:132,159,768...132,200,016
Ensembl chr 8:132,158,915...132,200,008

G

solute carrier family 6 member 9

increases expression

ISO

Rifampin results in increased expression of SLC6A9 mRNA

NCBI chr 5:136,660,022...136,694,173
Ensembl chr 5:136,659,948...136,694,172

G

solute carrier family 7 member 11

multiple interactions

EXP

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

solute carrier family 9 member A8

increases expression

ISO

Rifampin results in increased expression of SLC9A8 mRNA

NCBI chr 3:176,559,658...176,617,510
Ensembl chr 3:176,567,124...176,617,511

G

solute carrier organic anion transporter family, member 1a4

multiple interactions
decreases activity

EXP
ISO

Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin]
Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of epyrifenacil metabolite]
Rifampin results in decreased activity of SLCO1A4 protein

PMID:11883641 PMID:34619012

NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816

G

solute carrier organic anion transporter family member 1B2

multiple interactions
decreases activity
decreases expression

ISO

Rifampin inhibits the reaction [SLCO1B3 protein results in increased import of cyanoginosin LR]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Docetaxel]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of epyrifenacil metabolite]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of estradiol-17 beta-glucuronide]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of fexofenadine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Ursodeoxycholic Acid metabolite]
Rifampin inhibits the reaction [SLCO1B2 protein results in increased uptake of epyrifenacil metabolite]
Rifampin results in decreased activity of SLCO1B3 protein
Rifampin results in decreased expression of SLCO1B3 mRNA

PMID:17369605 PMID:18180276 PMID:21256917 PMID:21430235 PMID:27199754 More...

NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083

G

solute carrier organic anion transporter family, member 1c1

decreases activity
multiple interactions

EXP

Rifampin results in decreased activity of SLCO1B1 protein
[Rifampin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate

NCBI chr 4:176,197,736...176,244,401
Ensembl chr 4:176,197,741...176,244,395

G

solute carrier organic anion transporter family, member 2a1

multiple interactions

ISO

Rifampin inhibits the reaction [decitabine results in increased expression of SLCO2A1 mRNA]

NCBI chr 8:112,467,739...112,551,923
Ensembl chr 8:112,467,160...112,551,921

G

solute carrier organic anion transporter family, member 2b1

increases expression
decreases expression
multiple interactions

ISO

Rifampin results in increased expression of SLCO2B1 mRNA
Rifampin results in decreased expression of SLCO2B1 mRNA; Rifampin results in decreased expression of SLCO2B1 protein
Rifampin inhibits the reaction [Dextran Sulfate results in increased expression of SLCO2B1 mRNA]; Rifampin inhibits the reaction [Lipopolysaccharides results in increased expression of SLCO2B1 mRNA]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein]

PMID:21430235 PMID:27199754 PMID:38423481

NCBI chr 1:163,371,410...163,419,412
Ensembl chr 1:163,371,410...163,419,279

G

solute carrier organic anion transporter family, member 4C1

increases expression

ISO

Rifampin results in increased expression of SLCO4C1 mRNA

NCBI chr 9:104,624,802...104,676,462
Ensembl chr 9:104,624,802...104,676,462

G

SMAD family member 9

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA

NCBI chr 2:141,106,668...141,156,477
Ensembl chr 2:141,106,668...141,156,477

G

synuclein alpha

multiple interactions
increases sumoylation

EXP

Rifampin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SNCA protein modified form]; UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein]

PMID:17280646 PMID:28132806

NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:91,026,474...91,126,315

G

small nucleolar RNA, H/ACA box 71C

decreases expression

ISO

Rifampin results in decreased expression of SNORA71C mRNA

NCBI chr 3:167,437,646...167,437,777
Ensembl chr 3:167,437,646...167,437,777

G

suppressor of cytokine signaling 3

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA

NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825

G

sorbin and SH3 domain containing 1

decreases expression

ISO

Rifampin results in decreased expression of SORBS1 mRNA

NCBI chr 1:249,057,324...249,279,703
Ensembl chr 1:249,057,324...249,279,608

G

spectrin, beta, erythrocytic

increases expression

ISO

Rifampin results in increased expression of SPTB mRNA

NCBI chr 6:101,043,512...101,170,389
Ensembl chr 6:101,045,216...101,170,278

G

sequestosome 1

increases expression

ISO

Rifampin results in increased expression of SQSTM1 protein

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

ISO

[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]

NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462

G

signal transducer and activator of transcription 5A

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA

NCBI chr10:86,285,859...86,310,187
Ensembl chr10:86,285,547...86,310,184

G

serine threonine kinase 39

increases expression

ISO

Rifampin results in increased expression of STK39 mRNA

NCBI chr 3:73,321,522...73,588,397
Ensembl chr 3:73,321,522...73,586,740

G

sulfotransferase family 1E member 1

multiple interactions

ISO

[NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]

NCBI chr14:20,700,444...20,718,719
Ensembl chr14:20,700,292...20,718,716

G

sulfotransferase family 2A member 1

multiple interactions

ISO
EXP

[Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]

NCBI chr 1:84,582,011...84,639,001

G

small ubiquitin-like modifier 1

increases expression

EXP

Rifampin results in increased expression of SUMO1 protein

NCBI chr 9:68,572,901...68,602,803
Ensembl chr 9:68,572,911...68,602,890

G

small ubiquitin-like modifier 3

multiple interactions

ISO

Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]

NCBI chr20:11,009,730...11,020,502
Ensembl chr20:11,009,734...11,020,287

G

Sad1 and UNC84 domain containing 1

decreases expression

ISO

Rifampin results in decreased expression of SUN1 mRNA

NCBI chr12:20,510,230...20,555,123
Ensembl chr12:20,490,861...20,555,240

G

thymus, brain and testes associated

decreases expression

ISO

Rifampin results in decreased expression of TBATA mRNA

NCBI chr20:29,660,904...29,677,971
Ensembl chr20:29,660,970...29,677,972

G

transcription factor EC

increases expression

ISO

Rifampin results in increased expression of TFEC mRNA

NCBI chr 4:46,072,093...46,146,200
Ensembl chr 4:46,073,605...46,146,200

G

thrombospondin type 1 domain containing 4

increases expression

ISO

Rifampin results in increased expression of THSD4 mRNA

NCBI chr 8:69,280,397...69,880,144
Ensembl chr 8:69,284,646...69,917,342

G

tight junction protein 1

affects localization
decreases expression

ISO

Rifampin affects the localization of TJP1 protein
Rifampin results in decreased expression of TJP1 mRNA

NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158

G

tight junction protein 2

decreases expression

ISO

Rifampin results in decreased expression of TJP2 mRNA

NCBI chr 1:231,136,218...231,264,750
Ensembl chr 1:231,136,243...231,264,750

G

toll-like receptor 1

increases expression

ISO

Rifampin results in increased expression of TLR1 mRNA

NCBI chr14:43,737,761...43,750,389
Ensembl chr14:43,740,379...43,756,243

G

transmembrane protein 120B

decreases expression

ISO

Rifampin results in decreased expression of TMEM120B mRNA

NCBI chr12:39,108,280...39,148,090
Ensembl chr12:39,108,280...39,148,090

G

transmembrane protein 145

increases expression

ISO

Rifampin results in increased expression of TMEM145 mRNA

NCBI chr 1:90,019,727...90,029,432
Ensembl chr 1:90,019,745...90,029,427

G

transmembrane protein 88

increases expression

ISO

Rifampin results in increased expression of TMEM88 mRNA

NCBI chr10:54,617,554...54,619,309
Ensembl chr10:54,617,630...54,619,438

G

transmembrane serine protease 2

increases expression

EXP

Rifampin results in increased expression of TMPRSS2 mRNA

NCBI chr11:50,403,707...50,443,224
Ensembl chr11:50,398,349...50,443,114

G

tumor necrosis factor

decreases expression

ISO

Rifampin results in decreased expression of TNF protein

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF superfamily member 10

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA

NCBI chr 2:112,136,550...112,155,903

G

TNFRSF1A-associated via death domain

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA

NCBI chr19:50,046,057...50,048,158
Ensembl chr19:50,046,061...50,052,550

G

tsukushi, small leucine rich proteoglycan

increases expression

ISO

Rifampin results in increased expression of TSKU mRNA

PMID:24552687 PMID:27177772

NCBI chr 1:162,071,459...162,082,972
Ensembl chr 1:162,064,126...162,089,272

G

ubiquitin-conjugating enzyme E2I

multiple interactions

EXP

UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein]

NCBI chr10:14,782,245...14,802,911
Ensembl chr10:70,199,041...70,199,866
Ensembl chr10:70,199,041...70,199,866

G

UDP-glucose 6-dehydrogenase

multiple interactions
increases expression

ISO

[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA
Rifampin results in increased expression of UGDH mRNA

NCBI chr14:43,202,480...43,226,002
Ensembl chr14:43,202,356...43,226,629

G

UDP glucuronosyltransferase family 1 member A1

affects expression
increases expression
multiple interactions

ISO

Rifampin affects the expression of UGT1A1 mRNA
Rifampin results in increased expression of UGT1A1 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of UGT1A1 mRNA

PMID:15104253 PMID:15771232 PMID:15849716 PMID:18098064 PMID:22126990 More...

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases expression
multiple interactions

ISO

Rifampin results in increased expression of UGT1A3 mRNA
pimecrolimus inhibits the reaction [Rifampin results in increased expression of UGT1A3 mRNA]

PMID:25313206 PMID:29356861

NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 1 member A6a

increases expression

ISO

Rifampin results in increased expression of UGT1A6 mRNA

NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 1 member A9

increases expression

ISO

Rifampin results in increased expression of UGT1A9 mRNA; Rifampin results in increased expression of UGT1A9 protein

NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 2 member B7

increases expression

ISO

Rifampin results in increased expression of UGT2B7 mRNA

NCBI chr14:21,251,535...21,274,451
Ensembl chr14:21,251,535...21,274,451

G

ubiquitin like with PHD and ring finger domains 2

decreases expression

ISO

Rifampin results in decreased expression of UHRF2 mRNA

NCBI chr 1:237,224,050...237,291,406
Ensembl chr 1:237,228,456...237,292,353

G

uracil-DNA glycosylase

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA

NCBI chr12:48,145,838...48,154,789
Ensembl chr12:48,145,838...48,155,257

G

ubiquitin specific peptidase 17-like a2

decreases expression

ISO

Rifampin results in decreased expression of USP17L2 mRNA

NCBI chr 1:168,563,281...168,567,056

G

vascular endothelial growth factor A

increases expression

EXP

Rifampin results in increased expression of VEGFA protein

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

vascular endothelial growth factor D

multiple interactions

ISO

[Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA

NCBI chr X:33,704,582...33,740,305
Ensembl chr X:33,706,055...33,740,167

G

vitamin K epoxide reductase complex, subunit 1

affects response to substance

ISO

VKORC1 alternative form affects the susceptibility to Rifampin

NCBI chr 1:191,932,969...191,935,490

G

von Willebrand factor A domain containing 1

decreases expression

ISO

Rifampin results in decreased expression of VWA1 mRNA

NCBI chr 5:171,659,694...171,664,880
Ensembl chr 5:171,659,698...171,664,880

G

X-linked inhibitor of apoptosis

increases expression

ISO

Rifampin results in increased expression of XIAP protein

NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978

G

X-ray repair cross complementing 4

multiple interactions

ISO

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA

NCBI chr 2:22,686,506...22,932,929
Ensembl chr 2:22,686,508...22,933,160

G

zinc finger CCHC-type containing 13

decreases expression

ISO

Rifampin results in decreased expression of ZCCHC13 mRNA

NCBI chr X:72,709,319...72,710,422
Ensembl chr X:72,709,152...72,731,030

G

zinc finger protein 11

decreases expression

ISO

Rifampin results in decreased expression of ZNF546 mRNA

NCBI chr12:32,664,312...32,676,940
Ensembl chr12:32,650,373...32,677,739

G

zinc finger protein 451

decreases expression

ISO

Rifampin results in decreased expression of ZNF451 mRNA

NCBI chr 9:43,481,395...43,546,103
Ensembl chr 9:43,481,401...43,516,706

G

zinc finger protein 46

decreases expression

ISO

Rifampin results in decreased expression of ZNF436 mRNA

NCBI chr 5:153,802,887...153,813,388
Ensembl chr 5:153,802,834...153,812,941

G

zinc finger protein 462

decreases expression

ISO

Rifampin results in decreased expression of ZNF462 mRNA

NCBI chr 5:74,465,383...74,606,020
Ensembl chr 5:74,468,643...74,606,020

G

zinc finger protein 658

decreases expression

ISO

Rifampin results in decreased expression of ZNF782 mRNA

NCBI chr 1:103,129,001...103,143,510
Ensembl chr 1:103,129,101...103,142,366

G

zinc finger protein 873

increases expression

ISO

Rifampin results in increased expression of ZNF441 mRNA

NCBI chr 7:8,577,725...8,602,577
Ensembl chr 7:8,577,999...8,602,710

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

ISO

rifamycin SV results in decreased activity of ABCB11 protein

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

C-reactive protein

affects expression

ISO

rifamycin SV affects the expression of CRP protein

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514

G

solute carrier organic anion transporter family, member 1a4

multiple interactions

ISO

rifamycin SV inhibits the reaction [SLCO1A4 protein results in increased uptake of epyrifenacil metabolite]

NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816

G

solute carrier organic anion transporter family member 1B2

multiple interactions
decreases activity

ISO

rifamycin SV inhibits the reaction [SLCO1B3 protein results in increased import of 8-sulfocholecystokinin octapeptide]; rifamycin SV inhibits the reaction [SLCO1B3 protein results in increased uptake of epyrifenacil metabolite]
rifamycin SV inhibits the reaction [SLCO1B2 protein results in increased uptake of epyrifenacil metabolite]
rifamycin SV results in decreased activity of SLCO1B3 protein

PMID:27450509 PMID:31364238 PMID:34619012

NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arylacetamide deacetylase

multiple interactions
decreases acetylation

ISO

AADAC mRNA affects the reaction [rifapentine results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine]

NCBI chr 2:146,293,449...146,351,061
Ensembl chr 2:146,313,279...146,324,525

G

ATP binding cassette subfamily B member 11

decreases activity

ISO

rifapentine results in decreased activity of ABCB11 protein

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

androgen receptor

multiple interactions

ISO

rifapentine binds to and results in decreased activity of AR protein

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases expression

ISO

AADAC mRNA affects the reaction [rifapentine results in increased expression of CYP3A4 mRNA]

PMID:16837568 PMID:21856291

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

estrogen receptor 2

multiple interactions

ISO

rifapentine binds to and results in decreased activity of ESR2 protein

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

ISO

sakuranetin results in decreased activity of CYP19A1 protein

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate aminotransferase

decreases expression

ISO

Thalidomide results in decreased expression of AADAT mRNA

NCBI chr16:34,520,236...34,566,388
Ensembl chr16:34,520,238...34,566,540

G

ATP binding cassette subfamily A member 1

increases response to substance

ISO

ABCA1 gene SNP results in increased susceptibility to Thalidomide

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

ATP binding cassette subfamily B member 1A

decreases expression
decreases activity

ISO

Thalidomide results in decreased expression of ABCB1 mRNA; Thalidomide results in decreased expression of ABCB1 protein
Thalidomide results in decreased activity of ABCB1 protein

PMID:15920492 PMID:19840843

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP-binding cassette, sub-family B member 1B

increases expression
increases activity

EXP

Thalidomide results in increased expression of ABCB1B protein
Thalidomide results in increased activity of ABCB1B protein

NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:26,106,903...26,279,567

G

acid phosphatase 5, tartrate resistant

multiple interactions

ISO

[Thalidomide co-treated with Dexamethasone] results in decreased expression of ACP5 protein

NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:28,939,985...28,943,929

G

actin alpha 2, smooth muscle

multiple interactions
decreases expression

EXP

[Thalidomide co-treated with Dimethylnitrosamine] results in decreased expression of ACTA2 protein; Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]; Thalidomide inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 mRNA]; Thalidomide inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 protein]; Thalidomide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
Thalidomide results in decreased expression of ACTA2 protein

PMID:16604421 PMID:16943688 PMID:17030452 PMID:17174718

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

actinin alpha 2

decreases expression

ISO

Thalidomide results in decreased expression of ACTN2 mRNA

PMID:26006729 PMID:26217789

NCBI chr17:62,835,055...62,902,331
Ensembl chr17:62,812,988...62,903,552

G

actin related protein 6

decreases expression

ISO

Thalidomide results in decreased expression of ACTR6 mRNA

NCBI chr 7:26,037,574...26,058,362
Ensembl chr 7:26,037,574...26,060,604

G

adenylosuccinate synthase 1

decreases expression

ISO

Thalidomide results in decreased expression of ADSS1 mRNA

NCBI chr 6:137,500,549...137,523,087
Ensembl chr 6:137,501,001...137,523,086

G

ALF transcription elongation factor 2

decreases expression

ISO

Thalidomide results in decreased expression of AFF2 mRNA

NCBI chr X:152,972,579...153,477,080
Ensembl chr X:152,972,581...153,477,080

G

AKT serine/threonine kinase 1

decreases phosphorylation
increases phosphorylation
decreases activity

ISO

Thalidomide analog results in decreased phosphorylation of AKT1 protein
Thalidomide analog results in increased phosphorylation of AKT1 protein
Thalidomide results in decreased activity of AKT1 protein

PMID:15067094 PMID:15858615

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aldehyde dehydrogenase 1 family, member A2

decreases expression

ISO

Thalidomide results in decreased expression of ALDH1A2 mRNA

NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883

G

alkaline phosphatase, intestinal

increases expression

ISO

Thalidomide results in increased expression of ALPI mRNA

NCBI chr 9:95,221,314...95,224,780
Ensembl chr 9:95,221,314...95,224,780

G

alpha-methylacyl-CoA racemase

decreases expression

ISO

Thalidomide results in decreased expression of AMACR mRNA

NCBI chr 2:61,673,291...61,685,381
Ensembl chr 2:61,670,475...61,685,379

G

angiopoietin 2

affects expression

ISO

Thalidomide affects the expression of ANGPT2 mRNA

NCBI chr16:77,790,760...77,841,241
Ensembl chr16:77,790,563...77,841,239

G

ankyrin repeat domain 37

decreases expression

ISO

Thalidomide results in decreased expression of ANKRD37 mRNA

NCBI chr16:53,001,487...53,004,545
Ensembl chr16:52,994,740...53,004,545

G

annexin A2

decreases expression

ISO

Thalidomide results in decreased expression of ANXA2 mRNA; Thalidomide results in decreased expression of ANXA2 protein

NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:78,986,242...79,022,631

G

APAF1 interacting protein

decreases expression

ISO

Thalidomide results in decreased expression of APIP mRNA

NCBI chr 3:109,886,919...109,913,295
Ensembl chr 3:109,886,953...109,915,862

G

apelin

decreases expression

ISO

Thalidomide results in decreased expression of APLN mRNA

NCBI chr X:132,058,739...132,091,518
Ensembl chr X:132,081,759...132,091,246

G

aquaporin 4

increases expression

ISO

Thalidomide results in increased expression of AQP4 mRNA

NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098

G

aquaporin 5

increases expression

ISO

Thalidomide results in increased expression of AQP5 mRNA

NCBI chr 7:132,601,528...132,605,060
Ensembl chr 7:132,601,059...132,605,062

G

Rho GDP dissociation inhibitor alpha

increases expression

ISO

Thalidomide results in increased expression of ARHGDIA mRNA

NCBI chr10:106,352,858...106,356,347
Ensembl chr10:106,353,491...106,356,347

G

actin related protein 2/3 complex, subunit 4

decreases expression

ISO

Thalidomide results in decreased expression of ARPC4 mRNA

NCBI chr 4:148,077,799...148,088,427
Ensembl chr 4:148,077,240...148,088,428

G

aristaless related homeobox

increases expression

ISO

Thalidomide results in increased expression of ARX mRNA

NCBI chr X:62,010,097...62,022,009
Ensembl chr X:62,010,097...62,022,002

G

adipocyte-related X-chromosome expressed sequence 1

decreases expression

ISO

Thalidomide results in decreased expression of ARXES1 mRNA

NCBI chr X:103,742,157...103,743,676

G

ankyrin repeat and SOCS box-containing 12

decreases expression

ISO

Thalidomide results in decreased expression of ASB12 mRNA

NCBI chr X:64,338,223...64,487,615
Ensembl chr X:64,338,225...64,425,500

G

activating transcription factor 3

increases expression

ISO

Thalidomide analog results in increased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

aurora kinase A

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of AURKA mRNA

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

EXP

Thalidomide results in increased expression of BAX mRNA
HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of BAX protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of BAX protein]]; Thalidomide inhibits the reaction [Paraquat results in increased expression of BAX protein]

PMID:18291259 PMID:33015978

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

B-cell receptor-associated protein 29

decreases expression

ISO

Thalidomide results in decreased expression of BCAP29 mRNA

NCBI chr 6:53,910,209...53,950,206
Ensembl chr 6:53,910,216...53,949,963

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

ISO
EXP

[oblimersen co-treated with Thalidomide co-treated with Dexamethasone] results in decreased expression of BCL2 mRNA; [oblimersen co-treated with Thalidomide co-treated with Dexamethasone] results in decreased expression of BCL2 protein
Thalidomide results in decreased expression of BCL2 protein
HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]]; Thalidomide inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]

PMID:15867202 PMID:15982930 PMID:33015978

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

decreases expression

ISO

Thalidomide results in decreased expression of BCL2L1 protein

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

bradykinin receptor B1

multiple interactions

ISO

Thalidomide inhibits the reaction [bradykinin, des-Arg(9)- results in increased expression of BDKRB1 protein]

NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:130,275,478...130,280,973

G

beclin 1

multiple interactions

ISO

Thalidomide promotes the reaction [temozolomide results in increased expression of BECN1 protein]

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

BCL2 interacting protein like

increases expression

ISO

Thalidomide results in increased expression of BNIPL mRNA

NCBI chr 2:185,507,591...185,519,415
Ensembl chr 2:185,507,593...185,517,582

G

biorientation of chromosomes in cell division 1

decreases expression

ISO

Thalidomide results in decreased expression of BOD1 mRNA

NCBI chr10:16,497,918...16,504,259
Ensembl chr10:16,497,876...16,504,253

G

bone marrow stromal cell antigen 2

decreases expression

ISO

Thalidomide results in decreased expression of BST2 mRNA

NCBI chr16:18,250,593...18,254,967
Ensembl chr16:18,251,847...18,254,967

G

BUB1 mitotic checkpoint serine/threonine kinase B

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of BUB1B mRNA

NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796

G

complement C3

decreases expression

ISO

Thalidomide results in decreased expression of C3 protein

NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339

G

calcium voltage-gated channel subunit alpha1 C

decreases expression

ISO

Thalidomide results in decreased expression of CACNA1C mRNA

PMID:26006729 PMID:26217789

NCBI chr 4:153,431,169...154,051,932
Ensembl chr 4:153,436,427...154,051,762

G

calcium voltage-gated channel auxiliary subunit beta 4

decreases expression

ISO

Thalidomide results in decreased expression of CACNB4 mRNA

NCBI chr 3:57,315,900...57,578,271
Ensembl chr 3:57,315,900...57,578,220

G

calbindin 1

decreases expression

ISO

Thalidomide results in decreased expression of CALB1 mRNA

NCBI chr 5:34,172,612...34,199,555
Ensembl chr 5:34,172,664...34,200,160

G

caspase 3

decreases activity
increases activity
increases expression

ISO
EXP

Thalidomide results in decreased activity of CASP3 protein
Thalidomide results in increased activity of CASP3 protein
Thalidomide results in increased expression of CASP3 mRNA

PMID:14682394 PMID:15067094 PMID:18291259

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

increases cleavage
decreases expression

ISO

Thalidomide analog results in increased cleavage of CASP8 protein
Thalidomide results in decreased expression of CASP8 mRNA

PMID:15858615 PMID:26217789

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

decreases activity

ISO

Thalidomide results in decreased activity of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

cytosolic arginine sensor for mTORC1 subunit 1

decreases expression

ISO

Thalidomide results in decreased expression of CASTOR1 mRNA

NCBI chr14:83,309,710...83,314,123
Ensembl chr14:83,309,504...83,314,127

G

catalase

multiple interactions

ISO

CAT protein inhibits the reaction [Thalidomide results in decreased activity of MYB protein]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

carbonyl reductase 1

decreases expression

ISO

Thalidomide results in decreased expression of CBR1 mRNA

NCBI chr11:46,346,405...46,348,815
Ensembl chr11:46,378,411...46,381,104
Ensembl chr11:46,378,411...46,381,104

G

coiled-coil domain containing 141

decreases expression

ISO

Thalidomide results in decreased expression of CCDC141 mRNA

NCBI chr 3:82,357,046...82,517,199
Ensembl chr 3:82,357,681...82,517,710

G

C-C motif chemokine ligand 2

decreases expression

ISO

Thalidomide analog results in decreased expression of CCL2 mRNA

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 3

increases expression

EXP

Thalidomide results in increased expression of CCL3 mRNA

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

cyclin A2

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CCNA2 mRNA

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin B1

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CCNB1 mRNA

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin D1

decreases expression

ISO

Thalidomide analog results in decreased expression of CCND1 mRNA

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin O

increases expression

ISO

Thalidomide results in increased expression of CCNO mRNA

NCBI chr 2:46,364,074...46,367,113
Ensembl chr 2:46,350,717...46,367,113

G

CD24 molecule

affects expression

ISO

Thalidomide affects the expression of CD24A mRNA

NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785

G

CD274 molecule

decreases expression
multiple interactions

ISO

Thalidomide results in decreased expression of CD274 protein
FGD5-AS1 inhibits the reaction [Thalidomide results in decreased expression of CD274 protein]

NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:236,496,463...236,549,951

G

cell division cycle 20

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CDC20 mRNA

NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799

G

CDC42 effector protein 5

decreases expression

ISO

Thalidomide results in decreased expression of CDC42EP5 mRNA

PMID:26006729 PMID:26217789

NCBI chr 1:79,108,036...79,110,550

G

cadherin 1

increases expression
multiple interactions

ISO

Thalidomide results in increased expression of CDH1 protein
FGD5-AS1 inhibits the reaction [Thalidomide results in increased expression of CDH1 protein]

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cadherin 10

decreases expression

ISO

Thalidomide results in decreased expression of CDH10 mRNA

NCBI chr 2:70,355,521...70,577,880
Ensembl chr 2:70,357,217...70,578,332

G

cadherin 2

decreases expression
multiple interactions

ISO

Thalidomide results in decreased expression of CDH2 protein
FGD5-AS1 inhibits the reaction [Thalidomide results in decreased expression of CDH2 protein]

NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288

G

cadherin 6

increases expression

ISO

Thalidomide results in increased expression of CDH6 mRNA

NCBI chr 2:63,801,630...63,952,309
Ensembl chr 2:63,806,135...63,952,287

G

cyclin-dependent kinase 1

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CDK1 mRNA

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

centromere protein A

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CENPA mRNA

NCBI chr 6:31,420,062...31,431,703

G

centromere protein F

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CENPF mRNA

NCBI chr13:103,715,344...103,760,931
Ensembl chr13:103,715,344...103,760,886

G

cerberus 1, DAN family BMP antagonist

decreases expression

ISO

Thalidomide results in decreased expression of CER1 mRNA

NCBI chr 5:102,352,364...102,355,720
Ensembl chr 5:102,352,368...102,355,720

G

cripto, FRL-1, cryptic family 1

decreases expression

ISO

Thalidomide results in decreased expression of CFC1 mRNA

NCBI chr 9:44,234,997...44,247,846
Ensembl chr 9:44,235,020...44,247,845

G

CASP8 and FADD-like apoptosis regulator

decreases expression

ISO

Thalidomide results in decreased expression of CFLAR protein

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

EXP

Thalidomide inhibits the reaction [TNF protein results in increased expression of CHUK protein]

NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273

G

churchill domain containing 1

decreases expression

ISO

Thalidomide results in decreased expression of CHURC1 mRNA

NCBI chr 6:101,203,778...101,218,364
Ensembl chr 6:101,203,841...101,237,748

G

claudin 4

increases expression

ISO

Thalidomide results in increased expression of CLDN4 mRNA

NCBI chr12:27,388,160...27,389,958
Ensembl chr12:27,387,981...27,389,958

G

claudin domain containing 1

decreases expression

ISO

Thalidomide results in decreased expression of CLDND1 mRNA

NCBI chr11:55,352,321...55,358,779
Ensembl chr11:55,352,321...55,358,907

G

C-type lectin domain containing 9A

decreases expression

ISO

Thalidomide results in decreased expression of CLEC9A mRNA

NCBI chr 4:164,546,323...164,561,380
Ensembl chr 4:164,546,311...164,561,380

G

collagen type I alpha 1 chain

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in increased expression of COL1A1 mRNA]; Thalidomide inhibits the reaction [Paraquat results in increased expression of COL1A1 protein]

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type I alpha 2 chain

multiple interactions

EXP

Thalidomide inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A2 mRNA]; Thalidomide inhibits the reaction [TNF protein results in increased expression of COL1A2 mRNA]

NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995

G

complexin 3

decreases expression

ISO

Thalidomide results in decreased expression of CPLX3 mRNA

NCBI chr 8:66,899,438...66,906,200
Ensembl chr 8:66,899,438...66,906,200

G

cereblon

multiple interactions
affects binding
affects response to substance

ISO

Thalidomide inhibits the reaction [CRBN protein binds to and results in increased ubiquitination of and results in increased degradation of MEIS2 protein]
Thalidomide binds to [SALL4 protein binds to CRBN protein]; Thalidomide binds to CRBN protein
CRBN gene SNP affects the susceptibility to Thalidomide
Thalidomide binds to [CRBN protein binds to DDB1 protein]

PMID:25043012 PMID:25108355 PMID:27751757 PMID:30067223

NCBI chr 4:141,255,400...141,276,722
Ensembl chr 4:141,257,243...141,276,038

G

cAMP responsive element binding protein 5

decreases expression

ISO

Thalidomide results in decreased expression of CREB5 mRNA

NCBI chr 4:83,723,587...84,124,786
Ensembl chr 4:83,723,194...84,120,793

G

CREB3 regulatory factor

increases expression

ISO

Thalidomide analog results in increased expression of CREBRF mRNA

NCBI chr10:16,903,607...16,967,450
Ensembl chr10:16,903,547...16,966,430

G

cripto, EGF-CFC family member

decreases expression

ISO

Thalidomide results in decreased expression of CRIPTO mRNA

PMID:26006729 PMID:26217789

NCBI chr 8:119,803,182...119,808,714
Ensembl chr 8:119,803,220...119,808,948

G

C-reactive protein

decreases expression

ISO

Thalidomide results in decreased expression of CRP protein

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514

G

colony stimulating factor 2

decreases activity

ISO

Thalidomide results in decreased activity of CSF2 protein

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

colony stimulating factor 3

decreases activity

ISO

Thalidomide results in decreased activity of CSF3 protein

NCBI chr10:84,157,485...84,159,860
Ensembl chr10:84,157,211...84,159,860

G

chondroitin sulfate N-acetylgalactosaminyltransferase 2

decreases expression

ISO

Thalidomide results in decreased expression of CSGALNACT2 mRNA

NCBI chr 4:152,944,154...152,981,237
Ensembl chr 4:152,950,028...152,981,220

G

C-X-C motif chemokine ligand 10

increases expression

ISO

Thalidomide results in increased expression of CXCL10

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

C-X-C motif chemokine receptor 1

decreases expression

ISO

Thalidomide results in decreased expression of CXCR1 protein

NCBI chr 9:83,216,040...83,220,225
Ensembl chr 9:83,215,292...83,226,872

G

C-X-C motif chemokine receptor 2

decreases expression

ISO

Thalidomide results in decreased expression of CXCR2 protein

NCBI chr 9:83,178,645...83,185,017
Ensembl chr 9:83,183,808...83,188,602

G

cytochrome c, somatic

increases expression

ISO

Thalidomide results in increased expression of CYCS protein

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

ISO

Thalidomide results in increased expression of CYP2B6 mRNA

PMID:24460184 PMID:28496040

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases hydroxylation
increases oxidation
multiple interactions

ISO

CYP2C19 protein results in increased hydroxylation of Thalidomide
CYP2C19 protein results in increased oxidation of Thalidomide
[CYP2C19 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5'-hydroxythalidomide; [CYP2C19 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5-hydroxythalidomide; [CYP2C19 protein results in increased oxidation of Thalidomide] which results in increased abundance of 5'-hydroxythalidomide; [CYP2C19 protein results in increased oxidation of Thalidomide] which results in increased abundance of 5-hydroxythalidomide

PMID:20443640 PMID:24350712

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression
increases hydroxylation
multiple interactions
increases metabolic processing

ISO

Thalidomide results in increased expression of CYP3A4 mRNA; Thalidomide results in increased expression of CYP3A4 protein
CYP3A4 protein results in increased hydroxylation of Thalidomide
[CYP3A4 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5-hydroxythalidomide
CYP3A4 protein results in increased metabolism of Thalidomide

PMID:20443640 PMID:24460184 PMID:28496040 PMID:28745489

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions
increases hydroxylation
increases expression
increases metabolic processing

ISO

[CYP3A5 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5-hydroxythalidomide
Thalidomide results in increased expression of CYP3A5 mRNA
CYP3A5 protein results in increased metabolism of Thalidomide

PMID:20443640 PMID:28496040 PMID:28745489

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytohesin 3

decreases expression

ISO

Thalidomide results in decreased expression of CYTH3 mRNA

NCBI chr12:15,953,781...16,076,584
Ensembl chr12:15,953,791...16,047,506

G

dishevelled associated activator of morphogenesis 2

decreases expression

ISO

Thalidomide results in decreased expression of DAAM2 mRNA

NCBI chr 9:18,926,620...19,044,672
Ensembl chr 9:18,926,623...19,044,671

G

dihydrolipoamide branched chain transacylase E2

decreases expression

ISO

Thalidomide results in decreased expression of DBT mRNA

NCBI chr 2:207,166,660...207,195,528
Ensembl chr 2:207,166,652...207,195,525

G

damage-specific DNA binding protein 1

affects binding

ISO

Thalidomide binds to [CRBN protein binds to DDB1 protein]

NCBI chr 1:216,677,810...216,703,605
Ensembl chr 1:216,677,810...216,703,596

G

DNA-damage inducible transcript 3

increases expression

ISO

Thalidomide analog results in increased expression of DDIT3 mRNA

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

defensin beta 15

increases expression

ISO

Thalidomide results in increased expression of DEFB15 mRNA

NCBI chr16:76,843,661...76,846,359
Ensembl chr16:76,843,661...76,846,359

G

desmin

multiple interactions

EXP

Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of DES protein]

NCBI chr 9:84,299,626...84,307,344
Ensembl chr 9:84,298,447...84,307,347

G

Dexi homolog

increases expression

ISO

Thalidomide results in increased expression of DEXI mRNA

NCBI chr10:5,632,400...5,645,653
Ensembl chr10:5,632,961...5,645,648

G

DLG associated protein 5

decreases expression

ISO

Thalidomide results in decreased expression of DLGAP5 mRNA

NCBI chr15:23,113,678...23,144,281
Ensembl chr15:23,113,678...23,144,176

G

delta like non-canonical Notch ligand 1

decreases expression

ISO

Thalidomide results in decreased expression of DLK1 mRNA

NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:134,192,518...134,200,529

G

DnaJ heat shock protein family (Hsp40) member B1

increases expression

ISO

Thalidomide analog results in increased expression of DNAJB1 mRNA

NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416

G

DnaJ heat shock protein family (Hsp40) member B4

increases expression

ISO

Thalidomide analog results in increased expression of DNAJB4 mRNA

NCBI chr 2:243,790,296...243,819,042
Ensembl chr 2:243,790,297...243,819,042

G

DnaJ heat shock protein family (Hsp40) member B9

increases expression

ISO

Thalidomide analog results in increased expression of DNAJB9 mRNA

NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344

G

DnaJ heat shock protein family (Hsp40) member C19

decreases expression

ISO

Thalidomide results in decreased expression of DNAJC19 mRNA

NCBI chr 2:118,851,497...118,875,813
Ensembl chr 2:118,869,413...118,873,781

G

dihydrouridine synthase 4-like

decreases expression

ISO

Thalidomide results in decreased expression of DUS4L mRNA

NCBI chr 6:53,955,609...53,970,050
Ensembl chr 6:53,955,609...53,970,087

G

dual specificity phosphatase 1

increases expression

ISO

Thalidomide analog results in increased expression of DUSP1 mRNA

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

dual specificity phosphatase 10

increases expression

ISO

Thalidomide analog results in increased expression of DUSP10 mRNA

NCBI chr13:98,145,317...98,183,304
Ensembl chr13:98,145,893...98,183,304

G

dual specificity phosphatase 8

increases expression

ISO

Thalidomide analog results in increased expression of DUSP8 mRNA

NCBI chr 1:206,596,912...206,613,728
Ensembl chr 1:206,598,942...206,612,441

G

eukaryotic translation elongation factor 1 epsilon 1

decreases expression

ISO

Thalidomide results in decreased expression of EEF1E1 mRNA

NCBI chr17:26,354,247...26,364,953
Ensembl chr17:26,354,228...26,370,687

G

EF-hand calcium binding domain 2

decreases expression

ISO

Thalidomide results in decreased expression of EFCAB2 mRNA

NCBI chr13:92,683,182...92,769,939
Ensembl chr13:92,684,086...92,782,558

G

eukaryotic translation initiation factor 1B

decreases expression

ISO

Thalidomide results in decreased expression of EIF1B mRNA

NCBI chr 8:129,080,497...129,083,772
Ensembl chr 8:129,078,293...129,083,772
Ensembl chr 5:129,078,293...129,083,772

G

eukaryotic translation initiation factor 4E

decreases expression

EXP

Thalidomide results in decreased expression of EIF4E protein

NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105

G

elastase, neutrophil expressed

multiple interactions

ISO

Thalidomide inhibits the reaction [Lipopolysaccharides results in increased secretion of ELANE protein]; Thalidomide inhibits the reaction [lipoteichoic acid results in increased secretion of ELANE protein]

NCBI chr 7:10,467,877...10,469,725
Ensembl chr 7:10,467,877...10,469,725

G

ER membrane protein complex subunit 8

decreases expression

ISO

Thalidomide results in decreased expression of EMC8 mRNA

NCBI chr19:65,620,365...65,630,328
Ensembl chr19:65,620,375...65,630,235

G

EPH receptor A10

decreases expression

ISO

Thalidomide results in decreased expression of EPHA10 mRNA

NCBI chr 5:142,424,260...142,460,305
Ensembl chr 5:142,424,296...142,460,305

G

Eph receptor B1

decreases expression

ISO

Thalidomide results in decreased expression of EPHB1 mRNA

NCBI chr 8:111,386,432...111,823,759
Ensembl chr 8:111,386,432...111,823,759

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

ISO

[ERBB2 protein co-treated with PIK3CA protein mutant form] results in increased susceptibility to Thalidomide metabolite

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

esterase D

decreases expression

ISO

Thalidomide results in decreased expression of ESD mRNA

NCBI chr15:56,453,082...56,472,582
Ensembl chr15:56,453,044...56,473,508

G

EYA transcriptional coactivator and phosphatase 1

decreases expression

ISO

Thalidomide results in decreased expression of EYA1 mRNA

NCBI chr 5:9,646,599...9,884,609
Ensembl chr 5:9,646,591...9,884,614

G

coagulation factor II (thrombin) receptor

decreases expression

ISO

Thalidomide results in decreased expression of F2R mRNA; Thalidomide results in decreased expression of F2R protein

NCBI chr 2:28,604,066...28,620,579
Ensembl chr 2:28,604,066...28,620,579

G

fatty acid binding protein 5

decreases expression

ISO

Thalidomide results in decreased expression of FABP5 mRNA

NCBI chr 2:93,672,451...93,676,186
Ensembl chr 2:93,672,458...93,676,127

G

fatty acid binding protein 7

affects expression

ISO

Thalidomide affects the expression of FABP7 mRNA

NCBI chr20:37,667,125...37,673,299
Ensembl chr20:37,669,601...37,675,907

G

family with sequence similarity 174, member B

decreases expression

ISO

Thalidomide results in decreased expression of FAM174B mRNA

NCBI chr 1:136,925,162...137,006,082
Ensembl chr 1:136,925,151...137,035,589

G

Fas cell surface death receptor

decreases expression
increases expression

ISO
EXP

Thalidomide results in decreased expression of FAS protein
Thalidomide results in increased expression of FAS mRNA

PMID:16531263 PMID:18291259

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fas ligand

multiple interactions
decreases expression

ISO

Thalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of FASL mRNA]
Thalidomide results in decreased expression of FASLG protein

PMID:16510725 PMID:16531263

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

flap structure-specific endonuclease 1

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of FEN1 mRNA

NCBI chr 1:216,270,016...216,274,873
Ensembl chr 1:216,269,163...216,275,016

G

FYVE, RhoGEF and PH domain containing 3

increases expression

ISO

Thalidomide results in increased expression of FGD3 mRNA

NCBI chr17:15,531,237...15,593,678
Ensembl chr17:15,543,236...15,593,676

G

fibroblast growth factor 2

increases response to substance
affects expression
affects secretion
multiple interactions
decreases activity
decreases expression

ISO
EXP

FGF2 protein results in increased susceptibility to Thalidomide
Thalidomide affects the expression of FGF2 mRNA; Thalidomide affects the expression of FGF2 protein
Thalidomide affects the secretion of FGF2 protein
Thalidomide promotes the reaction [FGF2 protein results in decreased expression of MMP2 protein]
Thalidomide results in decreased activity of FGF2 protein
[Temozolomide co-treated with Thalidomide] results in decreased expression of FGF2 protein; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of FGF2 protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of FGF2 protein]]; Thalidomide inhibits the reaction [Paraquat results in increased expression of FGF2 protein]
Thalidomide results in decreased expression of FGF2 protein

PMID:11555579 PMID:12644816 PMID:14558594 PMID:15863203 PMID:15939924 More...

NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493

G

fibroblast growth factor 8

increases expression

ISO

Thalidomide results in increased expression of FGF8 mRNA

NCBI chr 1:254,533,504...254,539,605
Ensembl chr 1:254,533,504...254,539,605

G

Fibroblast growth factor receptor 1

affects expression

ISO

Thalidomide affects the expression of FGFR1 mRNA

NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855

G

fibroblast growth factor receptor 2

decreases expression

ISO

Thalidomide results in decreased expression of FGFR2 mRNA; Thalidomide results in decreased expression of FGFR2 protein

NCBI chr 1:194,175,703...194,280,914
Ensembl chr 1:194,175,705...194,280,914

G

fibroblast growth factor receptor 3

affects expression

ISO

Thalidomide affects the expression of FGFR3 mRNA

NCBI chr14:81,211,800...81,227,215
Ensembl chr14:81,211,800...81,227,209

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Thalidomide analog results in increased expression of FOS mRNA

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

FosB proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Thalidomide analog results in increased expression of FOSB mRNA

NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477

G

forkhead box C2

decreases expression

ISO

Thalidomide results in decreased expression of FOXC2 mRNA

NCBI chr19:66,094,718...66,097,420
Ensembl chr19:66,094,700...66,153,977

G

FAD-dependent oxidoreductase domain containing 1

decreases expression

ISO

Thalidomide results in decreased expression of FOXRED1 mRNA

NCBI chr 8:41,789,557...41,818,064
Ensembl chr 8:41,808,843...41,817,980

G

frizzled class receptor 8

decreases expression

ISO

Thalidomide results in decreased expression of FZD8 mRNA

NCBI chr17:62,007,849...62,015,485
Ensembl chr17:62,007,627...62,015,961

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

ISO

Thalidomide inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA]

NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718

G

galactose mutarotase

decreases expression

ISO

Thalidomide results in decreased expression of GALM mRNA

NCBI chr 6:20,589,775...20,641,516
Ensembl chr 6:20,589,776...20,644,417

G

GATA binding protein 3

increases expression

EXP

Thalidomide results in increased expression of GATA3 protein

NCBI chr17:73,544,234...73,575,670
Ensembl chr17:73,553,548...73,575,670

G

glucosaminyl (N-acetyl) transferase 2

decreases expression

ISO

Thalidomide results in decreased expression of GCNT2 mRNA

NCBI chr17:24,002,592...24,107,339
Ensembl chr17:24,002,597...24,106,989

G

gem (nuclear organelle) associated protein 2

decreases expression

ISO

Thalidomide results in decreased expression of GEMIN2 mRNA

NCBI chr 6:82,442,419...82,456,050
Ensembl chr 6:82,442,350...82,456,048

G

GDNF family receptor alpha 2

decreases expression

ISO

Thalidomide results in decreased expression of GFRA2 mRNA

NCBI chr15:52,351,499...52,443,369
Ensembl chr15:52,351,514...52,477,782

G

glutamic-oxaloacetic transaminase 1

increases expression

ISO

Thalidomide results in increased expression of GOT1 mRNA

NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871

G

glycoprotein 2

increases expression

ISO

Thalidomide results in increased expression of GP2 mRNA

NCBI chr 1:183,228,395...183,243,954
Ensembl chr 1:183,228,395...183,243,954

G

G patch domain containing 4

decreases expression

ISO

Thalidomide results in decreased expression of GPATCH4 mRNA

NCBI chr 2:175,797,503...175,816,547
Ensembl chr 2:175,807,682...175,817,358

G

glutathione peroxidase 1

multiple interactions

EXP

Thalidomide inhibits the reaction [Carbon Tetrachloride results in decreased activity of GPX1 protein]

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

glutathione peroxidase 8

decreases expression

ISO

Thalidomide results in decreased expression of GPX8 mRNA

NCBI chr 2:46,409,646...46,413,401
Ensembl chr 2:46,409,139...46,413,406

G

glutamate ionotropic receptor AMPA type subunit 3

decreases expression

ISO

Thalidomide results in decreased expression of GRIA3 mRNA

NCBI chr X:125,103,975...125,369,690
Ensembl chr X:125,103,782...125,369,679

G

glutamate ionotropic receptor AMPA type subunit 4

increases expression

ISO

Thalidomide results in increased expression of GRIA4 mRNA

NCBI chr 8:9,845,421...10,320,021
Ensembl chr 8:9,847,052...10,319,881

G

glutamate ionotropic receptor NMDA type subunit 2A

decreases expression

ISO

Thalidomide results in decreased expression of GRIN2A mRNA

NCBI chr10:6,136,458...6,560,003
Ensembl chr10:6,138,037...6,551,378

G

glutamate ionotropic receptor NMDA type subunit 2C

decreases expression

ISO

Thalidomide results in decreased expression of GRIN2C mRNA

NCBI chr10:100,987,410...101,006,064
Ensembl chr10:100,987,513...101,005,409

G

general transcription factor IIE subunit 1

decreases expression

ISO

Thalidomide results in decreased expression of GTF2E1 mRNA

NCBI chr11:76,687,382...76,720,253
Ensembl chr11:76,687,772...76,720,784

G

GULP PTB domain containing engulfment adaptor 1

decreases expression

ISO

Thalidomide results in decreased expression of GULP1 mRNA

NCBI chr 9:54,114,823...54,391,058
Ensembl chr 9:54,114,731...54,397,452

G

H2B clustered histone 12

decreases expression

ISO

Thalidomide results in decreased expression of H2BC12 mRNA

NCBI chr17:47,181,477...47,181,940
Ensembl chr17:47,121,467...47,182,816

G

H2B clustered histone 4

decreases expression

ISO

Thalidomide results in decreased expression of H2BC4 mRNA

NCBI chr17:47,388,085...47,392,349
Ensembl chr17:47,404,375...47,419,020

G

H3 clustered histone 1

decreases expression

ISO

Thalidomide results in decreased expression of H3C1 mRNA

NCBI chr17:41,796,236...41,796,759
Ensembl chr17:41,795,396...41,797,281
Ensembl chr17:41,795,396...41,797,281

G

H4 clustered histone 8

decreases expression

ISO

Thalidomide results in decreased expression of H4C4 mRNA

NCBI chr17:47,176,246...47,180,690
Ensembl chr17:41,797,152...41,806,539
Ensembl chr17:41,797,152...41,806,539
Ensembl chr17:41,797,152...41,806,539
Ensembl chr 4:41,797,152...41,806,539

G

hyperpolarization-activated cyclic nucleotide-gated potassium channel 1

decreases expression

ISO

Thalidomide results in decreased expression of HCN1 mRNA

NCBI chr 2:51,228,710...51,632,806
Ensembl chr 2:51,228,710...51,632,806

G

histone deacetylase 6

multiple interactions

EXP

HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]]; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of BAX protein]]; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of FGF2 protein]]; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 protein]]; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF protein]]; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased phosphorylation of NFKBIA protein]]; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased phosphorylation of RELA protein]]; Thalidomide inhibits the reaction [Paraquat results in increased expression of HDAC6 mRNA]

NCBI chr X:17,222,538...17,244,373
Ensembl chr X:17,222,856...17,244,370

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

ISO

Thalidomide analog results in increased expression of HERPUD1 mRNA

NCBI chr19:10,604,360...10,624,168
Ensembl chr19:10,604,362...10,624,081

G

hepatocyte growth factor

affects expression
decreases activity
affects secretion

ISO

Thalidomide affects the expression of HGF mRNA; Thalidomide affects the expression of HGF protein
Thalidomide results in decreased activity of HGF protein
Thalidomide affects the secretion of HGF protein

PMID:15939924 PMID:17557286

NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851

G

HIRA interacting protein 3

decreases expression

ISO

Thalidomide results in decreased expression of HIRIP3 mRNA

NCBI chr 1:190,903,065...190,905,610
Ensembl chr 1:190,902,593...190,905,607

G

high mobility group nucleosome binding domain 5

decreases expression

ISO

Thalidomide results in decreased expression of HMGN5 mRNA

NCBI chr X:78,161,439...78,170,613
Ensembl chr X:78,161,442...78,169,924

G

homeo box B7

increases expression

ISO

Thalidomide results in increased expression of HOXB7 mRNA

NCBI chr10:81,749,159...81,752,577
Ensembl chr10:81,749,097...81,752,550

G

homeo box B9

increases expression

ISO

Thalidomide results in increased expression of HOXB9 mRNA

NCBI chr10:81,733,857...81,737,363
Ensembl chr10:81,733,658...81,738,872

G

hydroxysteroid 11-beta dehydrogenase 2

decreases expression

ISO

Thalidomide results in decreased expression of HSD11B2 mRNA

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

heat shock transcription factor 1

decreases expression

ISO

Thalidomide results in decreased expression of HSF1 mRNA

PMID:26006729 PMID:26217789

NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665

G

heat shock protein family B (small) member 1

decreases expression

ISO

Thalidomide results in decreased expression of HSPB1 mRNA

NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301

G

heat shock protein family H (Hsp110) member 1

increases expression

ISO

Thalidomide analog results in increased expression of HSPH1 mRNA

NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891

G

intercellular adhesion molecule 1

increases response to substance
decreases expression

ISO
EXP

ICAM1 gene SNP results in increased susceptibility to Thalidomide
Thalidomide results in decreased expression of ICAM1 mRNA; Thalidomide results in decreased expression of ICAM1 protein

PMID:17174718 PMID:21245421

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

Idnk, gluconokinase

decreases expression

ISO

Thalidomide results in decreased expression of IDNK mRNA

NCBI chr17:6,489,397...6,496,520
Ensembl chr17:6,488,982...6,499,822

G

interferon gamma

multiple interactions
affects expression
increases expression
decreases expression

ISO
EXP

[Thalidomide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein
Thalidomide affects the expression of IFNG mRNA
Thalidomide results in increased expression of IFNG; Thalidomide results in increased expression of IFNG protein
Thalidomide inhibits the reaction [irinotecan results in increased expression of IFNG protein]; Thalidomide promotes the reaction [irinotecan results in increased expression of IFNG protein]
Thalidomide results in decreased expression of IFNG protein

PMID:15588918 PMID:16078585 PMID:16454849 PMID:16514283 PMID:16815871 More...

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

intraflagellar transport 27

decreases expression

ISO

Thalidomide results in decreased expression of IFT27 mRNA

PMID:26006729 PMID:26217789

NCBI chr 7:111,619,145...111,635,129
Ensembl chr 7:111,619,077...111,634,936

G

intraflagellar transport 70A1

decreases expression

ISO

Thalidomide results in decreased expression of IFT70A1 mRNA

NCBI chr 3:81,309,158...81,312,612

G

intraflagellar transport 74

decreases expression

ISO

Thalidomide results in decreased expression of IFT74 mRNA

NCBI chr 5:114,576,106...114,679,581
Ensembl chr 5:114,593,397...114,679,581

G

insulin-like growth factor 1

affects expression

ISO

Thalidomide affects the expression of IGF1 mRNA

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor binding protein 3

affects expression
decreases expression

ISO

Thalidomide affects the expression of IGFBP3 mRNA
Thalidomide results in decreased expression of IGFBP3 mRNA

PMID:15939924 PMID:26217789

NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944

G

interleukin 10

affects expression
decreases expression

ISO

Thalidomide affects the expression of IL10 mRNA
Thalidomide results in decreased expression of IL10 protein

PMID:16454849 PMID:16514283

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 12A

multiple interactions

ISO

Thalidomide results in decreased expression of [IL12A protein binds to IL12B protein]

NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997

G

interleukin 12B

multiple interactions

ISO

Thalidomide results in decreased expression of [IL12A protein binds to IL12B protein]
Thalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL12B mRNA]

PMID:11788559 PMID:16510725

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194

G

interleukin 18

increases expression

ISO

Thalidomide results in increased expression of IL18

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 beta

decreases expression
multiple interactions

ISO
EXP

Thalidomide results in decreased expression of IL1B protein
Thalidomide inhibits the reaction [irinotecan results in increased expression of IL1B protein]; Thalidomide promotes the reaction [irinotecan results in increased expression of IL1B protein]
Thalidomide inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased expression of IL1B protein]; Thalidomide inhibits the reaction [Paraquat results in increased expression of IL1B mRNA]

PMID:15863203 PMID:16815871 PMID:23510834 PMID:25478868

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor type 1

decreases expression

ISO

Thalidomide results in decreased expression of IL1R1 mRNA

NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579

G

interleukin 1 receptor antagonist

multiple interactions

ISO

Thalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of IL1RN mRNA]

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732

G

interleukin 2

multiple interactions
decreases expression

ISO
EXP

[Thalidomide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein
Thalidomide results in decreased expression of IL2 protein
Thalidomide inhibits the reaction [irinotecan results in decreased expression of IL2 protein]; Thalidomide promotes the reaction [irinotecan results in decreased expression of IL2 protein]

PMID:15588918 PMID:16815871

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 4

increases expression

EXP

Thalidomide results in increased expression of IL4 protein

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 6

decreases secretion
decreases activity
multiple interactions

ISO
EXP

Thalidomide analog results in decreased secretion of IL6 protein
Thalidomide results in decreased activity of IL6 protein
HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 protein]]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of IL6 protein]; Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 mRNA]; Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 protein]
Thalidomide inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased expression of IL6 protein]; Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 mRNA]

PMID:15858615 PMID:16815871 PMID:17557286 PMID:23510834 PMID:25478868 More...

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 6 cytokine family signal transducer

decreases expression

ISO

Thalidomide results in decreased expression of IL6ST mRNA

NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:45,799,380...45,843,182

G

inhibitor of growth family, member 3

increases expression

ISO

Thalidomide analog results in increased expression of ING3 mRNA

NCBI chr 4:51,439,218...51,469,502
Ensembl chr 4:51,443,763...51,470,951

G

intracisternal A particle-promoted polypeptide

decreases expression

ISO

Thalidomide results in decreased expression of IPP mRNA

NCBI chr 5:135,199,198...135,237,912
Ensembl chr 5:135,180,109...135,238,000

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Thalidomide analog results in increased expression of JUN mRNA

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

kalirin, RhoGEF kinase

decreases expression

ISO

Thalidomide results in decreased expression of KALRN mRNA

NCBI chr11:79,703,345...80,309,210
Ensembl chr11:79,703,366...80,133,329

G

kinase insert domain receptor

multiple interactions

ISO

sphingosine 1-phosphate inhibits the reaction [Thalidomide results in decreased expression of KDR mRNA]

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192

G

kinesin family member 2C

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of KIF2C mRNA

NCBI chr 5:135,873,925...135,899,267
Ensembl chr 5:135,873,925...135,899,212

G

kelch-like family member 4

decreases expression

ISO

Thalidomide results in decreased expression of KLHL4 mRNA

NCBI chr X:83,626,047...83,916,328
Ensembl chr X:83,819,076...83,916,328

G

kallikrein 1

decreases expression

ISO

Thalidomide results in decreased expression of KLK1 mRNA

NCBI chr 1:103,779,152...103,783,270
Ensembl chr 1:103,779,164...103,783,270

G

kallikrein 1-related peptidase C10

decreases expression

ISO

Thalidomide results in decreased expression of KLK3 protein

NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586

G

keratin associated protein 1-1

increases expression

ISO

Thalidomide results in increased expression of KRTAP1-4 mRNA

NCBI chr10:85,041,910...85,042,476
Ensembl chr10:85,041,910...85,042,476

G

large tumor suppressor kinase 2

increases expression

ISO

Thalidomide analog results in increased expression of LATS2 mRNA

NCBI chr15:35,940,632...35,992,225
Ensembl chr15:35,940,632...35,980,842

G

leucine rich repeat protein 1

decreases expression

ISO

Thalidomide results in decreased expression of LRR1 mRNA

NCBI chr 6:93,379,159...93,387,950
Ensembl chr 6:93,379,169...93,387,950

G

lactotransferrin

multiple interactions

ISO

Thalidomide inhibits the reaction [Lipopolysaccharides results in increased secretion of LTF protein]; Thalidomide inhibits the reaction [lipoteichoic acid results in increased secretion of LTF protein]

NCBI chr 8:119,878,344...119,901,189
Ensembl chr 8:119,878,344...119,901,189

G

lymphocyte antigen 96

decreases expression

ISO

Thalidomide results in decreased expression of LY96 mRNA

PMID:26006729 PMID:26217789

NCBI chr 5:7,365,536...7,397,864
Ensembl chr 5:7,365,557...7,395,816

G

LYR motif containing 2

decreases expression

ISO

Thalidomide results in decreased expression of LYRM2 mRNA

NCBI chr 5:51,994,540...51,996,818
Ensembl chr 5:51,994,543...51,997,979

G

LYR motif containing 4

decreases expression

ISO

Thalidomide results in decreased expression of LYRM4 mRNA

NCBI chr17:28,951,912...29,067,300
Ensembl chr17:28,951,924...29,143,177

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

ISO

Thalidomide promotes the reaction [temozolomide results in increased expression of MAP1LC3B protein]

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen activated protein kinase 1

increases phosphorylation

ISO

Thalidomide analog results in increased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 14

increases phosphorylation

ISO

Thalidomide analog results in increased phosphorylation of MAPK14 protein

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294

G

mitogen activated protein kinase 3

increases phosphorylation

ISO

Thalidomide analog results in increased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression

ISO

Thalidomide analog results in decreased expression of MCL1 protein

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

minichromosome maintenance complex component 5

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of MCM5 mRNA

NCBI chr19:13,488,813...13,510,131
Ensembl chr19:13,488,813...13,517,758

G

Meis homeobox 2

multiple interactions

ISO

Thalidomide inhibits the reaction [CRBN protein binds to and results in increased ubiquitination of and results in increased degradation of MEIS2 protein]

NCBI chr 3:123,197,066...123,399,002
Ensembl chr 3:123,197,066...123,397,751

G

mesenchyme homeobox 1

decreases expression

ISO

Thalidomide results in decreased expression of MEOX1 mRNA

NCBI chr10:87,318,668...87,338,169
Ensembl chr10:87,318,695...87,337,976

G

mesoderm posterior bHLH transcription factor 2

decreases expression

ISO

Thalidomide results in decreased expression of MESP2 mRNA

NCBI chr 1:143,165,914...143,168,520
Ensembl chr 1:143,165,849...143,168,511

G

methyltransferase 5, N6-adenosine

decreases expression

ISO

Thalidomide results in decreased expression of METTL5 mRNA

NCBI chr 3:75,033,605...75,046,359
Ensembl chr 3:75,026,861...75,045,831

G

microRNA 126a

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in decreased expression of MIR126]

NCBI chr 3:29,813,150...29,813,267

G

microRNA 141

multiple interactions

EXP

MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of BAX protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of FGF2 protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF protein]]; Thalidomide inhibits the reaction [Paraquat results in decreased expression of MIR141]

NCBI chr 4:159,209,525...159,209,618

G

microRNA 206

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in increased expression of MIR206]

NCBI chr 9:30,590,697...30,590,780
Ensembl chr 9:30,590,697...30,590,780

G

microRNA 21

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in decreased expression of MIR21]

NCBI chr10:71,902,600...71,902,691

G

microRNA 221

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in increased expression of MIR221]

NCBI chr X:6,023,182...6,023,290
Ensembl chr X:6,023,182...6,023,290

G

microRNA 222

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in increased expression of MIR222]

NCBI chr X:6,022,621...6,022,723
Ensembl chr X:6,022,621...6,022,723

G

microRNA 301b

increases expression

ISO

Thalidomide results in increased expression of MIR301B mRNA

NCBI chr11:97,384,033...97,384,110
Ensembl chr11:97,384,033...97,384,110

G

microRNA 30e

decreases expression

ISO

Thalidomide results in decreased expression of MIR30E mRNA

NCBI chr 5:139,637,450...139,637,541
Ensembl chr 5:139,637,450...139,637,541

G

microRNA 338

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in decreased expression of MIR338]

NCBI chr10:105,796,342...105,796,407

G

microRNA 449c

increases expression

ISO

Thalidomide results in increased expression of MIR449C mRNA

NCBI chr 2:46,402,375...46,402,473
Ensembl chr 2:46,402,375...46,402,473

G

Mix paired-like homeobox 1

decreases expression

ISO

Thalidomide results in decreased expression of MIXL1 mRNA

NCBI chr13:94,953,907...94,957,938
Ensembl chr13:94,953,907...94,957,938

G

marker of proliferation Ki-67

multiple interactions
decreases expression

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of MKI67 mRNA
Thalidomide results in decreased expression of MKI67 protein

PMID:18720364 PMID:34520751

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

myeloid leukemia factor 2

decreases expression

ISO

Thalidomide results in decreased expression of MLF2 mRNA

NCBI chr 4:159,425,542...159,430,584
Ensembl chr 4:159,411,732...159,430,571

G

membrane metallo-endopeptidase

decreases expression

ISO

Thalidomide results in decreased expression of MME mRNA

NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:149,872,291...149,953,463

G

matrix metallopeptidase 2

multiple interactions
decreases expression

ISO

Thalidomide promotes the reaction [FGF2 protein results in decreased expression of MMP2 protein]
Thalidomide results in decreased expression of MMP2 protein

PMID:14558594 PMID:15863203

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

decreases expression

ISO

Thalidomide results in decreased expression of MMP9 protein

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

monooxygenase, DBH-like 1

decreases expression

ISO

Thalidomide results in decreased expression of MOXD1 mRNA

NCBI chr 1:22,894,543...22,984,599
Ensembl chr 1:22,894,543...22,984,223

G

myeloperoxidase

multiple interactions

ISO

Thalidomide inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased activity of MPO protein]; Thalidomide inhibits the reaction [Indomethacin results in increased activity of MPO protein]

PMID:15138204 PMID:25478868

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

MAGUK p55 scaffold protein 1

decreases expression

ISO

Thalidomide results in decreased expression of MPP1 mRNA

G

mitochondrial ribosomal protein L32

decreases expression

ISO

Thalidomide results in decreased expression of MRPL32 mRNA

NCBI chr17:55,260,651...55,263,517
Ensembl chr17:55,260,270...55,263,517

G

mitochondrial ribosomal protein L34

decreases expression

ISO

Thalidomide results in decreased expression of MRPL34 mRNA

NCBI chr16:18,186,447...18,187,182
Ensembl chr16:18,185,306...18,187,181

G

mitochondrial ribosomal protein L47

decreases expression

ISO

Thalidomide results in decreased expression of MRPL47 mRNA

NCBI chr 2:117,436,199...117,447,790
Ensembl chr 2:117,428,621...117,447,517

G

mitochondrial ribosomal protein L52

decreases expression

ISO

Thalidomide results in decreased expression of MRPL52 mRNA

NCBI chr15:31,852,927...31,856,160
Ensembl chr15:31,852,760...31,856,162

G

mitochondrial ribosomal protein S21

decreases expression

ISO

Thalidomide results in decreased expression of MRPS21 mRNA

NCBI chr 2:186,095,729...186,103,351
Ensembl chr 2:186,095,732...186,103,351

G

mitochondrial fission regulator 2

decreases expression

ISO

Thalidomide results in decreased expression of MTFR2 mRNA

NCBI chr 1:16,942,814...16,958,218

G

MYB proto-oncogene, transcription factor

multiple interactions
decreases activity
decreases phosphorylation

ISO

CAT protein inhibits the reaction [Thalidomide results in decreased activity of MYB protein]
Thalidomide results in decreased phosphorylation of MYB protein

NCBI chr 1:17,759,309...17,793,306
Ensembl chr 1:17,759,309...17,792,547

G

myosin binding protein C3

decreases expression

ISO

Thalidomide results in decreased expression of MYBPC3 mRNA

PMID:26006729 PMID:26217789

NCBI chr 3:97,550,974...97,569,216
Ensembl chr 3:97,551,061...97,569,216

G

MYD88, innate immune signal transduction adaptor

decreases expression

ISO

Thalidomide results in decreased expression of MYD88 mRNA

PMID:26006729 PMID:26217789

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230

G

myosin heavy chain 6

affects expression

ISO

Thalidomide affects the expression of MYH6 mRNA

PMID:26006729 PMID:26217789

NCBI chr15:32,388,102...32,413,663
Ensembl chr15:32,387,487...32,411,333

G

myosin light chain 3

affects expression
decreases expression

ISO

Thalidomide affects the expression of MYL3 mRNA
Thalidomide results in decreased expression of MYL3 mRNA

PMID:26006729 PMID:26217789

NCBI chr 8:119,617,077...119,623,215
Ensembl chr 8:119,616,868...119,623,216

G

myosin light chain 7

decreases expression

ISO

Thalidomide results in decreased expression of MYL7 mRNA

NCBI chr14:84,994,644...84,997,173
Ensembl chr14:84,993,736...84,997,372

G

myosin light chain kinase

increases expression

ISO

Thalidomide results in increased expression of MYLK mRNA

NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659

G

myomesin 1

decreases expression

ISO

Thalidomide results in decreased expression of MYOM1 mRNA

PMID:26006729 PMID:26217789

NCBI chr 9:118,362,547...118,485,954
Ensembl chr 9:118,362,621...118,485,952

G

N(alpha)-acetyltransferase 20, NatB catalytic subunit

decreases expression

ISO

Thalidomide results in decreased expression of NAA20 mRNA

NCBI chr 3:153,775,351...153,790,129
Ensembl chr 3:153,775,338...153,790,916

G

Nanog homeobox

decreases expression

ISO

Thalidomide results in decreased expression of NANOG mRNA

NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:157,615,687...157,623,061

G

NAD(P)HX epimerase

decreases expression

ISO

Thalidomide results in decreased expression of NAXE mRNA

NCBI chr 2:175,816,824...175,818,903
Ensembl chr 2:175,816,824...175,818,889

G

NADH:ubiquinone oxidoreductase subunit B8

decreases expression

ISO

Thalidomide results in decreased expression of NDUFB8 mRNA

NCBI chr 1:253,357,878...253,362,936
Ensembl chr 1:253,357,841...253,362,936

G

nebulette

decreases expression

ISO

Thalidomide results in decreased expression of NEBL mRNA

NCBI chr17:85,022,953...85,374,848
Ensembl chr17:85,022,963...85,374,172

G

neuronal differentiation 4

increases expression

ISO

Thalidomide results in increased expression of NEUROD4 mRNA

NCBI chr 7:7,740,852...7,828,052
Ensembl chr 7:7,740,852...7,752,824

G

neurogenin 2

increases expression

ISO

Thalidomide results in increased expression of NEUROG2 mRNA

NCBI chr 2:218,767,205...218,769,772
Ensembl chr 2:218,765,949...218,769,784

G

NFE2 like bZIP transcription factor 2

multiple interactions

ISO

Thalidomide promotes the reaction [Paraquat results in increased expression of NFE2L2 mRNA]; Thalidomide promotes the reaction [Paraquat results in increased expression of NFE2L2 protein]

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor kappa B subunit 1

multiple interactions
decreases expression

ISO
EXP

[resveratrol co-treated with Thalidomide] results in decreased activity of [RELA protein binds to NFKB1 protein]
Thalidomide results in decreased expression of NFKB1 protein

PMID:16333628 PMID:17164350

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

NFKB inhibitor alpha

multiple interactions
increases expression

ISO
EXP

Thalidomide inhibits the reaction [TGFB1 protein results in increased degradation of NFKBIA protein]; Thalidomide inhibits the reaction [TGFB1 protein results in increased phosphorylation of NFKBIA protein]; Thalidomide inhibits the reaction [TGFB1 protein results in increased transport of NFKBIA protein]; Thalidomide inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased phosphorylation of NFKBIA protein]]; Thalidomide inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFKBIA protein]; Thalidomide inhibits the reaction [Paraquat results in increased phosphorylation of NFKBIA protein]; Thalidomide inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]
Thalidomide results in increased expression of NFKBIA protein

PMID:15687330 PMID:16288038 PMID:16604421 PMID:16943688 PMID:17174718 More...

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

nescient helix loop helix 1

increases expression

ISO

Thalidomide results in increased expression of NHLH1 mRNA

NCBI chr13:87,049,733...87,054,934
Ensembl chr13:87,049,629...87,055,033

G

neuromedin S

increases expression

ISO

Thalidomide results in increased expression of NMS mRNA

NCBI chr 9:48,665,398...48,676,461
Ensembl chr 9:48,665,398...48,676,461

G

nitric oxide synthase 2

multiple interactions

EXP

Thalidomide inhibits the reaction [Dimethylnitrosamine results in increased expression of NOS2 mRNA]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

natriuretic peptide B

multiple interactions

ISO

[Thalidomide co-treated with Dexamethasone] results in increased expression of NPPB protein

NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

decreases expression

ISO

Thalidomide results in decreased expression of NQO2 mRNA

NCBI chr17:31,114,825...31,144,062
Ensembl chr17:31,114,529...31,143,662

G

nuclear receptor subfamily 1, group I, member 2

increases expression

ISO

Thalidomide results in increased expression of NR1I2 mRNA

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 4, group A, member 1

increases expression

ISO

Thalidomide analog results in increased expression of NR4A1 mRNA

NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041

G

nuclear receptor subfamily 4, group A, member 2

increases expression

ISO

Thalidomide analog results in increased expression of NR4A2 mRNA

NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:62,098,743...62,106,769

G

neuropilin 1

multiple interactions

ISO

sphingosine 1-phosphate inhibits the reaction [Thalidomide results in decreased expression of NRP1 mRNA]

NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702

G

neuropilin 2

multiple interactions

ISO

sphingosine 1-phosphate inhibits the reaction [Thalidomide results in decreased expression of NRP2 mRNA]

NCBI chr 9:71,616,602...71,731,869
Ensembl chr 9:71,616,657...71,731,871

G

neurexin 1

decreases expression

ISO

Thalidomide results in decreased expression of NRXN1 mRNA

NCBI chr 6:8,931,360...10,077,381
Ensembl chr 6:8,935,523...10,077,374

G

5'-nucleotidase, cytosolic IIIA

decreases expression

ISO

Thalidomide results in decreased expression of NT5C3 mRNA

NCBI chr 4:87,491,828...87,534,838
Ensembl chr 4:87,491,828...87,534,838

G

5' nucleotidase, ecto

decreases expression

ISO

Thalidomide results in decreased expression of NT5E mRNA

NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645

G

N-terminal asparagine amidase

decreases expression

ISO

Thalidomide results in decreased expression of NTAN1 mRNA

NCBI chr10:2,618,239...2,633,185
Ensembl chr10:2,618,235...2,633,810

G

nudix hydrolase 14

decreases expression

ISO

Thalidomide results in decreased expression of NUDT14 mRNA

NCBI chr 6:137,831,382...137,838,370
Ensembl chr 6:137,831,373...137,838,370

G

nudix hydrolase 22

decreases expression

ISO

Thalidomide results in decreased expression of NUDT22 mRNA

NCBI chr 1:213,612,008...213,615,626
Ensembl chr 1:213,612,009...213,615,713

G

nucleoporin 62 C-terminal like

decreases expression

ISO

Thalidomide results in decreased expression of NUP62CL mRNA

NCBI chr X:108,457,043...108,513,525
Ensembl chr X:108,457,043...108,512,664

G

nucleolar and spindle associated protein 1

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of NUSAP1 mRNA

NCBI chr 3:127,057,220...127,092,779
Ensembl chr 3:127,057,265...127,087,237

G

2'-5' oligoadenylate synthetase 1A

decreases expression

ISO

Thalidomide results in decreased expression of OAS1G mRNA

NCBI chr12:41,330,423...41,341,130
Ensembl chr12:41,285,211...41,341,128

G

occludin

multiple interactions

ISO

Thalidomide inhibits the reaction [dinitrobenzenesulfonic acid results in decreased expression of OCLN protein]

NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411

G

oligodendrocyte transcription factor 2

increases expression

ISO

Thalidomide results in increased expression of OLIG2 mRNA

NCBI chr11:43,961,585...43,964,961
Ensembl chr11:43,958,940...43,968,634

G

oligodendrocyte transcription factor 3

increases expression

ISO

Thalidomide results in increased expression of OLIG3 mRNA

NCBI chr 1:15,900,881...15,902,953
Ensembl chr 1:15,900,736...15,902,274

G

olfactory receptor family 10 subfamily Q member 1

increases expression

ISO

Thalidomide results in increased expression of OR10Q1 mRNA

NCBI chr 1:220,285,910...220,286,866
Ensembl chr 1:220,285,910...220,286,866

G

olfactory receptor family 1 subfamily D member 2

increases expression

ISO

Thalidomide results in increased expression of OR1D2 mRNA

NCBI chr10:59,711,377...59,712,312
Ensembl chr10:59,711,377...59,712,312

G

olfactory receptor family 2 subfamily AG member 1

increases expression

ISO

Thalidomide results in increased expression of OR2AG1 mRNA

NCBI chr 1:170,095,543...170,096,493
Ensembl chr 1:170,095,543...170,096,493

G

olfactory receptor family 2 subfamily Y member 1I

increases expression

ISO

Thalidomide results in increased expression of OR2Y1 mRNA

NCBI chr10:34,238,313...34,239,242

G

olfactory receptor family 51 subfamily Q member 1D

increases expression

ISO

Thalidomide results in increased expression of OR51Q1 mRNA

NCBI chr 1:167,838,348...167,839,313
Ensembl chr 1:167,838,348...167,839,313

G

olfactory receptor family 5 subfamily I member 1

increases expression

ISO

Thalidomide results in increased expression of OR5I1 mRNA

NCBI chr 3:93,723,884...93,724,828
Ensembl chr 3:93,723,878...93,724,828

G

olfactory receptor family 5 subfamily P member 80

increases expression

ISO

Thalidomide results in increased expression of OR5P80 mRNA

NCBI chr 1:171,942,039...171,942,971
Ensembl chr 1:171,942,039...171,942,971

G

olfactory receptor family 8 subfamily A member 1B

decreases expression

ISO

Thalidomide results in decreased expression of OR8A1B mRNA

NCBI chr 8:45,623,650...45,624,579
Ensembl chr 8:45,623,650...45,624,579

G

olfactory receptor family 9 subfamily K member 2

increases expression

ISO

Thalidomide results in increased expression of OR9K2 mRNA

NCBI chr 7:7,519,060...7,520,019
Ensembl chr 7:7,519,060...7,520,019

G

osteoclast stimulating factor 1

decreases expression

ISO

Thalidomide results in decreased expression of OSTF1 mRNA

NCBI chr 1:225,428,661...225,475,851
Ensembl chr 1:225,428,661...225,541,027

G

PP2A Aalpha (PPP2R1A) and B55A (PPP2R2A) interacting phosphatase regulator 1

decreases expression

ISO

Thalidomide results in decreased expression of PABIR1 mRNA

NCBI chr 1:231,541,411...231,542,717
Ensembl chr 1:231,537,357...231,612,411

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

ISO

[Curcumin co-treated with Thalidomide] results in increased cleavage of PARP1 protein
Thalidomide analog results in increased cleavage of PARP1 protein

PMID:15858615 PMID:19372569

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

paired box 3

decreases expression

ISO

Thalidomide results in decreased expression of PAX3 mRNA

NCBI chr 9:87,015,960...87,112,531
Ensembl chr 9:87,016,999...87,124,141

G

paired box 6

increases expression

ISO

Thalidomide results in increased expression of PAX6 mRNA

NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:112,590,391...112,611,763

G

programmed cell death 10

decreases expression

ISO

Thalidomide results in decreased expression of PDCD10 mRNA

NCBI chr 2:162,602,516...162,644,690
Ensembl chr 2:162,602,516...162,644,612

G

PDZ and LIM domain 3

decreases expression

ISO

Thalidomide results in decreased expression of PDLIM3 mRNA

NCBI chr16:53,085,020...53,116,495
Ensembl chr16:53,085,020...53,116,217

G

platelet and endothelial cell adhesion molecule 1

decreases expression

EXP
ISO

Thalidomide results in decreased expression of PECAM1 protein

PMID:18291259 PMID:34520751

NCBI chr10:92,090,263...92,152,002
Ensembl chr10:92,090,235...92,151,839

G

prefoldin subunit 6

decreases expression

ISO

Thalidomide results in decreased expression of PFDN6 mRNA

NCBI chr20:4,947,844...4,949,318
Ensembl chr20:4,947,844...4,949,318

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

multiple interactions

ISO

[ERBB2 protein co-treated with PIK3CA protein mutant form] results in increased susceptibility to Thalidomide metabolite

NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:117,143,468...117,177,411

G

paired immunoglobin-like type 2 receptor alpha

decreases expression

ISO

Thalidomide results in decreased expression of PILRA mRNA

NCBI chr12:23,452,626...23,464,772

G

Pim-1 proto-oncogene, serine/threonine kinase

decreases expression

ISO

Thalidomide results in decreased expression of PIM1 protein

NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,556,113...7,561,764

G

plasminogen activator, urokinase

decreases expression

ISO

Thalidomide results in decreased expression of PLAU protein

NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030

G

plasminogen activator, urokinase receptor

multiple interactions
decreases expression

ISO

Thalidomide inhibits the reaction [TGFB1 protein results in increased expression of PLAUR mRNA]; Thalidomide inhibits the reaction [TGFB1 protein results in increased expression of PLAUR protein]
Thalidomide results in decreased expression of PLAUR protein

NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130

G

phospholipid transfer protein

decreases expression

ISO

Thalidomide results in decreased expression of PLTP mRNA

NCBI chr 3:173,994,162...174,011,982
Ensembl chr 3:173,994,162...174,012,505

G

RNA polymerase II, I and III subunit K

decreases expression

ISO

Thalidomide results in decreased expression of POLR2K mRNA

NCBI chr 7:69,241,233...69,244,579
Ensembl chr 7:69,232,179...69,244,578

G

popeye domain cAMP effector 2

decreases expression

ISO

Thalidomide results in decreased expression of POPDC2 mRNA

NCBI chr11:75,850,068...75,897,094
Ensembl chr11:75,880,274...75,896,269

G

peroxisome proliferator-activated receptor delta

increases response to substance

ISO

PPARD gene SNP results in increased susceptibility to Thalidomide

NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,352,183...6,365,707

G

protein phosphatase 1, regulatory (inhibitor) subunit 11

decreases expression

ISO

Thalidomide results in decreased expression of PPP1R11 mRNA

NCBI chr20:1,606,583...1,610,090
Ensembl chr20:1,606,577...1,613,212

G

protein phosphatase 1, regulatory subunit 15A

increases expression

ISO

Thalidomide analog results in increased expression of PPP1R15A mRNA

NCBI chr 1:105,136,521...105,139,596
Ensembl chr 1:105,136,525...105,139,774

G

protein phosphatase 1, regulatory (inhibitor) subunit 1A

decreases expression

ISO

Thalidomide results in decreased expression of PPP1R1A mRNA

NCBI chr 7:136,533,031...136,540,687
Ensembl chr 7:136,523,604...136,540,683

G

PRELI domain containing 2

decreases expression

ISO

Thalidomide results in decreased expression of PRELID2 mRNA

NCBI chr18:34,120,989...34,212,699
Ensembl chr18:34,125,373...34,212,167

G

perforin 1

increases expression

ISO

Thalidomide results in increased expression of PRF1

NCBI chr20:29,789,040...29,794,550
Ensembl chr20:29,788,972...29,795,124

G

protein kinase C, delta

decreases expression

ISO

Thalidomide results in decreased expression of PRKCD mRNA

NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,775,681...5,805,839

G

protein kinase cGMP-dependent 1

decreases expression

ISO

Thalidomide results in decreased expression of PRKG1 mRNA

NCBI chr 1:237,818,950...239,052,184
Ensembl chr 1:237,823,053...239,103,005

G

proline rich 5

decreases expression

ISO

Thalidomide results in decreased expression of PRR5 mRNA

NCBI chr 7:117,675,308...117,717,833
Ensembl chr 7:117,675,383...117,717,831

G

peroxiredoxin like 2A

decreases expression

ISO

Thalidomide results in decreased expression of PRXL2A mRNA

NCBI chr16:16,900,697...16,920,521
Ensembl chr16:16,900,699...16,920,561

G

proteasome activator subunit 2

increases expression

ISO

Thalidomide results in increased expression of PSME2 mRNA

NCBI chr15:33,048,452...33,053,055
Ensembl chr15:33,048,457...33,053,102

G

phosphatase and tensin homolog

increases expression

ISO

Thalidomide results in increased expression of PTEN protein

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330

G

prostaglandin-endoperoxide synthase 2

increases degradation
decreases expression
multiple interactions
decreases stability

ISO
EXP

Thalidomide results in increased degradation of PTGS2 protein
Thalidomide results in decreased expression of PTGS2 protein
Thalidomide inhibits the reaction [Ifosfamide results in increased expression of PTGS2 protein]
Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
Thalidomide results in decreased stability of PTGS2 mRNA

PMID:11705847 PMID:15982930 PMID:17638016

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

RAB2B, member RAS oncogene family

decreases expression

ISO

Thalidomide results in decreased expression of RAB2B mRNA

PMID:26006729 PMID:26217789

NCBI chr15:27,441,860...27,462,479
Ensembl chr15:27,442,816...27,462,479

G

RAB8A, member RAS oncogene family

decreases expression

ISO

Thalidomide results in decreased expression of RAB8A mRNA

NCBI chr16:17,688,049...17,709,412
Ensembl chr16:17,688,050...17,709,477

G

RAP1B, member of RAS oncogene family

decreases expression

ISO

Thalidomide results in decreased expression of RAP1B mRNA

NCBI chr 7:55,308,922...55,342,217
Ensembl chr 7:55,308,922...55,342,217

G

Ras association domain family member 9

decreases expression

ISO

Thalidomide results in decreased expression of RASSF9 mRNA

NCBI chr 7:39,486,257...39,518,090
Ensembl chr 7:39,409,870...39,519,675

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
decreases expression

ISO
EXP

[irinotecan co-treated with Thalidomide co-treated with Celecoxib] results in increased expression of RELA protein; [irinotecan co-treated with Thalidomide] results in increased expression of RELA protein; [resveratrol co-treated with Thalidomide] results in decreased activity of [RELA protein binds to NFKB1 protein]; Thalidomide inhibits the reaction [TNF protein results in increased transport of RELA protein]
[Thalidomide co-treated with Dimethylnitrosamine] results in decreased transport of RELA protein; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased phosphorylation of RELA protein]]; Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA mRNA]; Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA protein]; Thalidomide inhibits the reaction [Paraquat results in increased phosphorylation of RELA protein]; Thalidomide inhibits the reaction [TNF protein results in increased expression of RELA mRNA]
Thalidomide results in decreased expression of RELA protein
Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Thalidomide inhibits the reaction [Paraquat affects the localization of RELA protein]

PMID:15687330 PMID:16078585 PMID:16333628 PMID:16604421 PMID:16685529 More...

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

RELB proto-oncogene, NF-kB subunit

increases expression

ISO

Thalidomide analog results in increased expression of RELB mRNA

NCBI chr 1:88,385,717...88,413,380
Ensembl chr 1:88,385,717...88,413,420

G

replication factor C subunit 3

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of RFC3 mRNA

NCBI chr12:5,836,546...5,847,331
Ensembl chr12:5,836,553...5,847,340

G

ras homolog family member A

affects expression

ISO

Thalidomide affects the expression of RHOA mRNA

NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302

G

ribonuclease H2, subunit C

decreases expression

ISO

Thalidomide results in decreased expression of RNASEH2C mRNA

NCBI chr 1:212,323,916...212,325,011
Ensembl chr 1:212,323,939...212,329,571

G

ring finger protein 138

decreases expression

ISO

Thalidomide results in decreased expression of RNF138 mRNA

NCBI chr18:12,558,430...12,590,849
Ensembl chr18:12,566,502...12,590,848

G

ring finger protein 166

multiple interactions

ISO

Thalidomide results in increased degradation of and results in decreased expression of RNF166 protein

NCBI chr19:67,437,974...67,447,814
Ensembl chr19:67,437,974...67,447,814

G

ribosomal protein S15

increases expression

ISO

Thalidomide results in increased expression of RPS15 mRNA

NCBI chr 7:10,066,572...10,068,167
Ensembl chr 7:10,066,677...10,068,123

G

ribosomal protein S6 kinase A2

decreases expression

ISO

Thalidomide results in decreased expression of RPS6KA2 mRNA

NCBI chr 1:55,178,988...55,454,271
Ensembl chr 1:55,179,319...55,454,338

G

RAS related

decreases expression

ISO

Thalidomide results in decreased expression of RRAS mRNA

PMID:26006729 PMID:26217789

NCBI chr 1:104,637,061...104,640,841
Ensembl chr 1:104,634,951...104,640,841

G

ribonucleotide reductase regulatory subunit M2

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of RRM2 mRNA

NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370

G

RT1 class Ia, locus A2

affects expression

ISO

Thalidomide affects the expression of HLA-E mRNA

NCBI chr20:4,872,720...4,876,425

G

RT1 class I, locus CE16

increases expression

ISO

Thalidomide results in increased expression of H2-Q1 mRNA

NCBI chr20:3,261,656...3,265,548

G

reticulon 2

decreases expression

ISO

Thalidomide results in decreased expression of RTN2 mRNA

NCBI chr 1:88,063,124...88,076,082
Ensembl chr 1:88,063,119...88,076,043

G

ryanodine receptor 2

decreases expression

ISO

Thalidomide results in decreased expression of RYR2 mRNA

PMID:26006729 PMID:26217789

NCBI chr17:63,081,527...63,667,141
Ensembl chr17:63,081,527...63,666,705

G

spalt-like transcription factor 4

increases expression
multiple interactions
affects binding

ISO

Thalidomide results in increased expression of SALL4 mRNA
Bortezomib inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein]; pevonedistat inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein]; TAK-243 inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein]; Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein
Thalidomide binds to [SALL4 protein binds to CRBN protein]

NCBI chr 3:177,891,705...177,909,743
Ensembl chr 3:177,891,705...177,909,743

G

Sin3A associated protein 30

decreases expression

ISO

Thalidomide results in decreased expression of SAP30 mRNA

NCBI chr16:37,758,494...37,763,825
Ensembl chr16:37,757,656...37,763,823

G

spermidine/spermine N1-acetyl transferase 1

decreases expression

ISO

Thalidomide results in decreased expression of SAT1 mRNA

NCBI chr X:44,008,089...44,011,376
Ensembl chr X:44,006,781...44,011,374

G

sodium voltage-gated channel alpha subunit 7

decreases expression

ISO

Thalidomide results in decreased expression of SCN7A mRNA

NCBI chr 3:71,743,873...71,846,454
Ensembl chr 3:71,743,873...71,846,284

G

succinate dehydrogenase complex assembly factor 1

decreases expression

ISO

Thalidomide results in decreased expression of SDHAF1 mRNA

NCBI chr 1:94,703,662...94,704,611
Ensembl chr 1:94,702,409...94,706,092

G

succinate dehydrogenase complex subunit C

decreases expression

ISO

Thalidomide results in decreased expression of SDHC mRNA

NCBI chr13:86,077,133...86,098,025
Ensembl chr13:86,077,134...86,098,044

G

selenoprotein S

decreases expression

ISO

Thalidomide results in decreased expression of SELENOS mRNA

NCBI chr 1:129,070,240...129,080,007
Ensembl chr 1:129,070,230...129,077,991

G

selectin L

decreases expression

ISO

Thalidomide results in decreased expression of SELL protein

NCBI chr13:78,950,100...78,969,604
Ensembl chr13:78,950,015...78,969,600

G

serpin family B member 2

increases response to substance

ISO

SERPINB2 gene SNP results in increased susceptibility to Thalidomide

NCBI chr13:24,051,933...24,065,032
Ensembl chr13:24,056,021...24,065,031

G

secreted frizzled-related protein 2

increases expression

ISO

Thalidomide results in increased expression of SFRP2 mRNA

NCBI chr 2:171,387,536...171,395,081
Ensembl chr 2:171,387,385...171,395,079

G

SH3 domain binding glutamate-rich protein

decreases expression

ISO

Thalidomide results in decreased expression of SH3BGR mRNA

NCBI chr11:48,973,033...48,997,328
Ensembl chr11:48,973,097...48,997,326

G

solute carrier family 12, member 6

increases response to substance

ISO

SLC12A6 gene SNP results in increased susceptibility to Thalidomide

NCBI chr 3:119,525,521...119,624,655
Ensembl chr 3:119,526,295...119,624,653

G

solute carrier family 13 member 4

decreases expression

ISO

Thalidomide results in decreased expression of SLC13A4 mRNA

NCBI chr 4:64,910,505...64,955,986
Ensembl chr 4:64,910,507...64,955,986

G

solute carrier family 22 member 2

multiple interactions

ISO

Thalidomide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

solute carrier family 25 member 20

decreases expression

ISO

Thalidomide results in decreased expression of SLC25A20 mRNA

NCBI chr 8:118,243,573...118,265,027
Ensembl chr 8:118,243,519...118,265,027

G

solute carrier family 25, member 30

decreases expression

ISO

Thalidomide results in decreased expression of SLC25A30 mRNA

NCBI chr15:57,486,346...57,508,981
Ensembl chr15:57,486,350...57,502,690

G

solute carrier family 2 member 3

increases expression

ISO

Thalidomide results in increased expression of SLC2A3 mRNA

NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186

G

solute carrier family 44, member 3

decreases expression

ISO

Thalidomide results in decreased expression of SLC44A3 mRNA

NCBI chr 2:212,234,425...212,312,886
Ensembl chr 2:212,236,853...212,312,982

G

solute carrier family 8 member A1

decreases expression

ISO

Thalidomide results in decreased expression of SLC8A1 mRNA

PMID:26006729 PMID:26217789

NCBI chr 6:18,975,498...19,299,704
Ensembl chr 6:18,946,798...19,287,964

G

solute carrier organic anion transporter family, member 4C1

decreases expression

ISO

Thalidomide results in decreased expression of SLCO4C1 mRNA

NCBI chr 9:104,624,802...104,676,462
Ensembl chr 9:104,624,802...104,676,462

G

sphingomyelin phosphodiesterase 2

multiple interactions

ISO

sphingosine 1-phosphate inhibits the reaction [Thalidomide results in increased activity of SMPD2 protein]

NCBI chr20:46,568,627...46,571,741
Ensembl chr20:46,568,629...46,571,741

G

SET and MYND domain containing 1

decreases expression

ISO

Thalidomide results in decreased expression of SMYD1 mRNA

PMID:26006729 PMID:26217789

NCBI chr 4:104,757,281...104,811,307
Ensembl chr 4:104,760,475...104,870,081

G

synaptosome associated protein 25

increases expression

EXP

Thalidomide results in increased expression of SNAP25 mRNA; Thalidomide results in increased expression of SNAP25 protein

NCBI chr 3:144,494,579...144,576,449
Ensembl chr 3:144,494,595...144,576,448

G

small nucleolar RNA, C/D box 104

increases expression

ISO

Thalidomide results in increased expression of SNORD104 mRNA

NCBI chr10:91,935,074...91,935,143
Ensembl chr10:91,935,074...91,935,143

G

small nucleolar RNA, C/D box 111

increases expression

ISO

Thalidomide results in increased expression of SNORD111 mRNA

NCBI chr19:55,721,859...55,721,947
Ensembl chr19:55,721,859...55,721,947

G

small nucleolar RNA, C/D box 123

increases expression

ISO

Thalidomide results in increased expression of SNORD123 mRNA

NCBI chr 2:85,017,799...85,017,868
Ensembl chr 2:85,017,799...85,017,868

G

small nuclear ribonucleoprotein D1 polypeptide

decreases expression

ISO

Thalidomide results in decreased expression of SNRPD1 mRNA

NCBI chr18:1,969,351...1,980,207
Ensembl chr18:1,969,674...1,980,207

G

sorting nexin 16

increases expression

ISO

Thalidomide analog results in increased expression of SNX16 mRNA

NCBI chr 2:93,242,779...93,265,048
Ensembl chr 2:93,243,494...93,265,050

G

sorting nexin 24

decreases expression

ISO

Thalidomide results in decreased expression of SNX24 mRNA

NCBI chr18:48,869,804...49,024,352
Ensembl chr18:48,869,882...49,024,350

G

superoxide dismutase 1

multiple interactions

ISO
EXP

Thalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of FASL mRNA]; Thalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL12B mRNA]; Thalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of TNF mRNA]; Thalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of IL1RN mRNA]; Thalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of TGFB1 mRNA]
Thalidomide inhibits the reaction [Carbon Tetrachloride results in decreased activity of SOD1 protein]

PMID:16510725 PMID:17030452

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

SRY-box transcription factor 1

decreases expression

ISO

Thalidomide results in decreased expression of SOX1 mRNA

NCBI chr16:83,837,689...83,841,703
Ensembl chr16:83,802,160...83,841,775

G

SRY-box transcription factor 17

decreases localization

ISO

Thalidomide results in decreased localization of SOX17 protein

NCBI chr 5:19,814,345...19,819,859
Ensembl chr 5:19,814,360...19,819,854

G

Sp1 transcription factor

decreases activity

ISO

Thalidomide results in decreased activity of SP1 protein

NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:135,420,050...135,450,513

G

Sp5 transcription factor

decreases expression

ISO

Thalidomide results in decreased expression of SP5 mRNA

NCBI chr 3:75,682,677...75,685,479
Ensembl chr 3:75,682,677...75,685,479

G

sperm autoantigenic protein 17

decreases expression

ISO

Thalidomide results in decreased expression of SPA17 mRNA

NCBI chr 8:45,496,175...45,507,262
Ensembl chr 8:45,496,175...45,507,262

G

sperm associated antigen 5

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of SPAG5 mRNA

NCBI chr10:63,693,300...63,714,813
Ensembl chr10:63,696,466...63,714,811

G

SPHK1 interactor, AKAP domain containing

decreases expression

ISO

Thalidomide results in decreased expression of SPHKAP mRNA

NCBI chr 9:91,957,497...92,105,834
Ensembl chr 9:91,957,497...92,105,625

G

SRR1 domain containing

decreases expression

ISO

Thalidomide results in decreased expression of SRRD mRNA

NCBI chr12:49,955,081...49,960,693
Ensembl chr12:49,954,882...49,963,366

G

signal transducer and activator of transcription 3

decreases phosphorylation
multiple interactions

ISO

Thalidomide analog results in decreased phosphorylation of STAT3 protein
[resveratrol co-treated with Thalidomide] results in decreased phosphorylation of STAT3 protein; Thalidomide promotes the reaction [Capsaicin results in decreased phosphorylation of and results in decreased activity of STAT3 protein]

PMID:15858615 PMID:17164350 PMID:17505005

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

stathmin 2

decreases expression

ISO

Thalidomide results in decreased expression of STMN2 mRNA

NCBI chr 2:95,112,017...95,159,642
Ensembl chr 2:95,112,019...95,159,335

G

SWIM-type zinc finger 7 associated protein 1

decreases expression

ISO

Thalidomide results in decreased expression of SWSAP1 mRNA

NCBI chr 8:28,762,753...28,765,281
Ensembl chr 8:28,762,616...28,765,234

G

synaptojanin 2 binding protein

decreases expression

ISO

Thalidomide results in decreased expression of SYNJ2BP mRNA

NCBI chr 6:106,920,970...106,958,653
Ensembl chr 6:106,920,970...106,966,543

G

synaptotagmin 15

decreases expression

ISO

Thalidomide results in decreased expression of SYT15 mRNA

NCBI chr16:9,538,740...9,549,548
Ensembl chr16:9,538,748...9,549,558

G

synaptotagmin 4

increases expression

ISO

Thalidomide results in increased expression of SYT4 mRNA

NCBI chr18:23,311,454...23,320,863
Ensembl chr18:23,312,859...23,320,815

G

tandem C2 domains, nuclear

decreases expression

ISO

Thalidomide results in decreased expression of TC2N mRNA

NCBI chr 6:126,526,006...126,622,163
Ensembl chr 6:126,526,009...126,614,215

G

transcription factor 15

decreases expression

ISO

Thalidomide results in decreased expression of TCF15 mRNA

NCBI chr 3:161,099,301...161,105,083
Ensembl chr 3:161,099,301...161,105,083

G

thymine-DNA glycosylase

decreases expression

ISO

Thalidomide results in decreased expression of TDG mRNA

NCBI chr 7:22,965,388...22,990,311
Ensembl chr 7:22,965,388...22,985,100

G

transcription elongation factor, mitochondrial

decreases expression

ISO

Thalidomide results in decreased expression of TEFM mRNA

NCBI chr10:65,617,547...65,622,042
Ensembl chr10:65,617,550...65,622,042

G

TEK receptor tyrosine kinase

decreases expression

ISO

Thalidomide results in decreased expression of TEK mRNA

NCBI chr 5:114,722,815...114,849,535
Ensembl chr 5:114,723,006...114,849,991

G

testis expressed gene 16

decreases expression

ISO

Thalidomide results in decreased expression of TEX16 mRNA

NCBI chr X:81,132,620...81,509,047
Ensembl chr X:81,139,575...81,509,047

G

transforming growth factor, beta 1

multiple interactions
decreases expression

ISO
EXP

Thalidomide inhibits the reaction [TGFB1 protein results in increased degradation of NFKBIA protein]; Thalidomide inhibits the reaction [TGFB1 protein results in increased expression of PLAUR mRNA]; Thalidomide inhibits the reaction [TGFB1 protein results in increased expression of PLAUR protein]; Thalidomide inhibits the reaction [TGFB1 protein results in increased phosphorylation of NFKBIA protein]; Thalidomide inhibits the reaction [TGFB1 protein results in increased transport of NFKBIA protein]
Thalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of TGFB1 mRNA]
Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; Thalidomide inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]; Thalidomide inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA]; Thalidomide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Thalidomide inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA]
Thalidomide results in decreased expression of TGFB1 mRNA; Thalidomide results in decreased expression of TGFB1 protein

PMID:15464241 PMID:16288038 PMID:16510725 PMID:16549389 PMID:16604421 More...

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta induced

decreases expression

ISO

Thalidomide results in decreased expression of TGFBI mRNA

PMID:26006729 PMID:26217789

NCBI chr17:7,960,885...7,990,234
Ensembl chr17:7,960,516...7,990,471

G

transforming growth factor, beta receptor 1

decreases expression

ISO

Thalidomide results in decreased expression of TGFBR1 mRNA; Thalidomide results in decreased expression of TGFBR1 protein

NCBI chr 5:66,449,348...66,506,371
Ensembl chr 5:66,449,293...66,527,260

G

TIMP metallopeptidase inhibitor 1

multiple interactions

EXP

Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 mRNA]; Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 protein]; Thalidomide inhibits the reaction [Thioacetamide results in increased expression of TIMP1 mRNA]

PMID:15464241 PMID:17030452

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

TIMP metallopeptidase inhibitor 2

multiple interactions

EXP

Thalidomide inhibits the reaction [Thioacetamide results in increased expression of TIMP2 mRNA]

NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214

G

tubulointerstitial nephritis antigen-like 1

decreases expression

ISO

Thalidomide results in decreased expression of TINAGL1 mRNA

NCBI chr 5:147,797,884...147,807,925
Ensembl chr 5:147,797,892...147,807,871

G

tight junction protein 1

multiple interactions

ISO

Thalidomide inhibits the reaction [dinitrobenzenesulfonic acid results in decreased expression of TJP1 protein]

NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158

G

TM2 domain containing 3

decreases expression

ISO

Thalidomide results in decreased expression of TM2D3 mRNA

NCBI chr 1:128,677,680...128,687,580
Ensembl chr 1:128,677,629...128,687,580

G

transmembrane protein 138

decreases expression

ISO

Thalidomide results in decreased expression of TMEM138 mRNA

NCBI chr 1:216,644,047...216,651,091

G

transmembrane protein 176A

decreases expression

ISO

Thalidomide results in decreased expression of TMEM176A mRNA

NCBI chr 4:79,101,946...79,109,499
Ensembl chr 4:79,101,857...79,111,175

G

thymopoietin

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of TMPO mRNA

NCBI chr 7:27,529,977...27,554,980
Ensembl chr 7:27,529,978...27,554,937

G

tumor necrosis factor

multiple interactions
increases expression
decreases expression
increases degradation

ISO
EXP

Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Endotoxins results in increased expression of TNF protein]; Thalidomide inhibits the reaction [lipophosphonoglycan results in increased secretion of TNF protein]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Thalidomide inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Thalidomide inhibits the reaction [TNF protein results in increased expression of CXCL8 protein]; Thalidomide inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Thalidomide inhibits the reaction [TNF protein results in increased transport of RELA protein]
Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Thalidomide inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased expression of TNF protein]; Thalidomide inhibits the reaction [dinitrobenzenesulfonic acid results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [Zymosan results in increased expression of TNF mRNA]; TNF protein affects the reaction [vadimezan affects the metabolism of Thalidomide]
Thalidomide results in increased expression of TNF protein
Thalidomide results in decreased expression of TNF mRNA
HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF protein]]; Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Dimethylnitrosamine results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Thioacetamide results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [TNF protein results in increased expression of CHUK protein]; Thalidomide inhibits the reaction [TNF protein results in increased expression of COL1A2 mRNA]; Thalidomide inhibits the reaction [TNF protein results in increased expression of RELA mRNA]; Thalidomide inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Thalidomide inhibits the reaction [Zymosan results in increased expression of TNF protein]
Thalidomide results in increased expression of TNF mRNA
Thalidomide results in increased degradation of TNF mRNA
Thalidomide results in decreased expression of TNF mRNA; Thalidomide results in decreased expression of TNF protein

PMID:9068814 PMID:9623511 PMID:10496904 PMID:10720640 PMID:11367517 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor superfamily member 10b

decreases expression

ISO

Thalidomide results in decreased expression of TNFRSF10A protein

NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082

G

TNF receptor superfamily member 1A

decreases expression

ISO

Thalidomide results in decreased expression of TNFRSF1A mRNA; Thalidomide results in decreased expression of TNFRSF1A protein

PMID:15618473 PMID:16344495

NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816

G

TNF receptor superfamily member 1B

decreases expression

ISO

Thalidomide results in decreased expression of TNFRSF1B mRNA

NCBI chr 5:162,356,250...162,387,411
Ensembl chr 5:162,353,848...162,387,411

G

TNF superfamily member 10

decreases expression

ISO

Thalidomide results in decreased expression of TNFSF10 protein

NCBI chr 2:112,136,550...112,155,903

G

TNF superfamily member 11

multiple interactions

ISO

[Thalidomide co-treated with Dexamethasone] results in decreased expression of TNFSF11 protein

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479

G

troponin C1, slow skeletal and cardiac type

decreases expression

ISO

Thalidomide results in decreased expression of TNNC1 mRNA

PMID:26006729 PMID:26217789

NCBI chr16:6,408,607...6,412,070
Ensembl chr16:6,408,607...6,412,070

G

DNA topoisomerase II alpha

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of TOP2A mRNA

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366

G

tumor protein p53

increases expression

ISO

Thalidomide analog results in increased expression of TP53 mRNA

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

translocation associated membrane protein 1-like 1

decreases expression

ISO

Thalidomide results in decreased expression of TRAM1L1 mRNA

NCBI chr 2:215,195,665...215,197,846
Ensembl chr 2:215,195,364...215,198,082

G

trafficking protein particle complex subunit 2L

decreases expression

ISO

Thalidomide results in decreased expression of TRAPPC2L mRNA

NCBI chr19:67,570,954...67,574,722

G

tribbles pseudokinase 3

increases expression

ISO

Thalidomide analog results in increased expression of TRIB3 mRNA

NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:161,269,955...161,274,802

G

tripartite motif-containing 55

decreases expression

ISO

Thalidomide results in decreased expression of TRIM55 mRNA

NCBI chr 2:104,016,361...104,058,302
Ensembl chr 2:104,016,368...104,058,301

G

tetraspanin 33

decreases expression

ISO

Thalidomide results in decreased expression of TSPAN33 mRNA

NCBI chr 4:59,270,713...59,294,249
Ensembl chr 4:59,270,703...59,294,249

G

tetratricopeptide repeat domain 32

decreases expression

ISO

Thalidomide results in decreased expression of TTC32 mRNA

NCBI chr 6:37,553,628...37,560,227
Ensembl chr 6:37,553,628...37,561,821

G

Ttk protein kinase

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of TTK mRNA

NCBI chr 8:93,632,678...93,672,664
Ensembl chr 8:93,634,319...93,672,664

G

titin

decreases expression

ISO

Thalidomide results in decreased expression of TTN mRNA

PMID:26006729 PMID:26217789

NCBI chr 3:82,059,648...82,332,130
Ensembl chr 3:82,059,648...82,332,171

G

ubiquitin-conjugating enzyme E2C

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of UBE2C mRNA

NCBI chr 3:173,925,975...173,928,375
Ensembl chr 3:173,925,934...173,932,678

G

UBX domain protein 1

decreases expression

ISO

Thalidomide results in decreased expression of UBXN1 mRNA

NCBI chr 1:215,194,418...215,198,343
Ensembl chr 1:215,174,216...215,198,343

G

ubiquitin C-terminal hydrolase L3

decreases expression

ISO

Thalidomide results in decreased expression of UCHL3 mRNA

NCBI chr15:84,888,847...84,942,095
Ensembl chr15:84,899,806...84,942,095
Ensembl chr 3:84,899,806...84,942,095

G

UNC homeobox

decreases expression

ISO

Thalidomide results in decreased expression of UNCX mRNA

NCBI chr12:20,206,604...20,211,125
Ensembl chr12:20,206,609...20,211,125

G

uridine phosphorylase 1

decreases expression

ISO

Thalidomide results in decreased expression of UPP1 mRNA

NCBI chr14:88,023,155...88,043,036
Ensembl chr14:88,023,351...88,043,034

G

ubiquinol-cytochrome c reductase complex assembly factor 5

decreases expression

ISO

Thalidomide results in decreased expression of UQCC5 mRNA

NCBI chr16:6,323,071...6,326,911
Ensembl chr16:6,292,741...6,326,911

G

vascular cell adhesion molecule 1

decreases expression

EXP

Thalidomide results in decreased expression of VCAM1 mRNA; Thalidomide results in decreased expression of VCAM1 protein

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

vascular endothelial growth factor A

affects expression
affects secretion
decreases secretion
decreases activity
decreases expression
increases expression
multiple interactions

ISO
EXP

Thalidomide affects the expression of VEGFA mRNA; Thalidomide affects the expression of VEGFA protein
Thalidomide affects the secretion of VEGFA protein
Thalidomide analog results in decreased secretion of VEGFA protein
Thalidomide results in decreased activity of VEGFA protein
Thalidomide results in decreased expression of VEGFA mRNA; Thalidomide results in decreased expression of VEGFA protein
Thalidomide results in increased expression of VEGFA protein
[Thalidomide co-treated with Paclitaxel] results in decreased expression of VEGFA mRNA
[temozolomide co-treated with Thalidomide] results in decreased expression of VEGFA protein
[Arsenic Trioxide co-treated with Thalidomide] results in decreased expression of VEGFA mRNA; FGD5-AS1 inhibits the reaction [Thalidomide results in decreased expression of and results in decreased secretion of VEGFA protein]; Thalidomide results in decreased expression of and results in decreased secretion of VEGFA protein

PMID:15858615 PMID:15863203 PMID:15939924 PMID:15982930 PMID:16313753 More...

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

vascular endothelial growth factor B

multiple interactions
decreases expression

ISO

[Arsenic Trioxide co-treated with Thalidomide] results in decreased expression of VEGFB mRNA
Thalidomide results in decreased expression of VEGFB mRNA

NCBI chr 1:213,601,570...213,607,254
Ensembl chr 1:213,600,966...213,607,152

G

vascular endothelial growth factor C

affects expression

ISO

Thalidomide affects the expression of VEGFC mRNA

NCBI chr16:44,445,293...44,560,887
Ensembl chr16:44,445,293...44,560,887

G

vascular endothelial growth factor D

multiple interactions
decreases expression

ISO

[Arsenic Trioxide co-treated with Thalidomide] results in decreased expression of VEGFD mRNA
Thalidomide results in decreased expression of VEGFD mRNA

NCBI chr X:33,704,582...33,740,305
Ensembl chr X:33,706,055...33,740,167

G

vitronectin

decreases expression

ISO

Thalidomide results in decreased expression of VTN mRNA

NCBI chr10:63,892,782...63,895,862
Ensembl chr10:63,892,766...63,895,860

G

Wnt family member 5B

decreases expression

ISO

Thalidomide results in decreased expression of WNT5B mRNA

NCBI chr 4:154,281,852...154,406,081
Ensembl chr 4:154,281,852...154,405,681

G

Wnt family member 8A

decreases expression

ISO

Thalidomide results in decreased expression of WNT8A mRNA

NCBI chr18:26,411,833...26,417,426
Ensembl chr18:26,411,833...26,417,426

G

X-linked inhibitor of apoptosis

decreases expression

ISO

Thalidomide analog results in decreased expression of XIAP protein

NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978

G

YJU2 splicing factor homolog B

decreases expression

ISO

Thalidomide results in decreased expression of YJU2B mRNA

NCBI chr19:40,799,392...40,810,885
Ensembl chr19:40,799,526...40,811,579

G

zinc finger CCHC-type containing 17

increases expression

ISO

Thalidomide results in increased expression of ZCCHC17 mRNA

NCBI chr 5:147,942,789...147,984,596
Ensembl chr 5:147,942,789...147,984,584

G

zinc finger E-box binding homeobox 1

multiple interactions
decreases expression

ISO

FGD5-AS1 inhibits the reaction [Thalidomide results in decreased expression of ZEB1 protein]

NCBI chr17:56,644,397...56,811,155
Ensembl chr17:56,644,397...56,810,745

G

zinc finger protein 692

multiple interactions

ISO

Thalidomide results in increased degradation of and results in decreased expression of ZNF692 protein

NCBI chr10:42,988,946...42,997,009
Ensembl chr10:42,988,938...42,997,015

G

zinc finger protein 758

decreases expression

ISO

Thalidomide results in decreased expression of ZFP758 mRNA

NCBI chr 1:70,614,167...70,662,261
Ensembl chr 1:70,614,268...70,662,143

G

zinc finger protein-like 1

decreases expression

ISO

Thalidomide results in decreased expression of ZFPL1 mRNA

NCBI chr 1:212,803,790...212,807,803
Ensembl chr 1:212,803,794...212,807,289

G

zinc finger with KRAB and SCAN domains 5

decreases expression

ISO

Thalidomide results in decreased expression of ZKSCAN5 mRNA

NCBI chr12:14,498,342...14,519,537
Ensembl chr12:14,498,342...14,519,537

G

zinc finger, matrin type 5

decreases expression

ISO

Thalidomide results in decreased expression of ZMAT5 mRNA

NCBI chr14:83,791,005...83,823,095
Ensembl chr14:83,792,262...83,823,095

G

zinc finger protein 780B

decreases expression

ISO

Thalidomide results in decreased expression of ZFP780B mRNA

NCBI chr 1:92,136,761...92,159,076

G

zinc ribbon domain containing 2

decreases expression

ISO

Thalidomide results in decreased expression of ZNRD2 mRNA

NCBI chr 1:212,447,010...212,448,793
Ensembl chr 1:212,447,010...212,448,793

G

zinc finger and SCAN domain containing 12

decreases expression

ISO

Thalidomide results in decreased expression of ZSCAN12 mRNA

NCBI chr17:47,942,976...47,948,930
Ensembl chr17:47,942,977...47,964,605

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activating transcription factor 3

increases expression

ISO

undecanal analog results in increased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

DnaJ heat shock protein family (Hsp40) member B4

increases expression

ISO

undecanal analog results in increased expression of DNAJB4 mRNA

NCBI chr 2:243,790,296...243,819,042
Ensembl chr 2:243,790,297...243,819,042

G

glutamate cysteine ligase, modifier subunit

increases expression

ISO

undecanal analog results in increased expression of GCLM mRNA

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

olfactory receptor family 1 subfamily D member 2

multiple interactions

ISO

undecanal inhibits the reaction [bourgeonal binds to and results in increased activity of OR1D2 protein]

NCBI chr10:59,711,377...59,712,312
Ensembl chr10:59,711,377...59,712,312

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	20874
role	20844
biological role	20831
antimicrobial agent	18216
antibacterial agent	15366
antibacterial drug	7524
antimycobacterial drug	1265
1-(2-hydroxy-4-methoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)propane	0
3,4'-dimethylkaempferol	0
3-nitropropanoic acid	73
5alpha-epoxyalantolactone	0
antitubercular agent +	845
azadiradione	4
bauhinoxepin A	0
bauhinoxepin B	0
bauhinoxepin F	0
bauhinoxepin I	0
bauhinoxepin J	0
canthin-6-one	0
caseargrewiin A	0
caseargrewiin B	0
caseargrewiin C	0
caseargrewiin D	0
cordyol C	0
dehydrocostus lactone	9
ergosterol peroxide	1
hirsutellide A	0
leprostatic drug +	824
linsitinib	0
mollicellin K	0
nothramicin	0
physalin D	0
sakuranetin	1
scleropyric acid	0
tetrahydroxysqualene	0
undecanal	4
viridiflorol	0
Path 2
Term	Annotations
CHEBI ontology	20874
role	20844
application	20572
pharmaceutical	20359
drug	20359
antiinfective agent	15471
antimicrobial drug	11282
antibacterial drug	7524
antimycobacterial drug	1265
1-(2-hydroxy-4-methoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)propane	0
3,4'-dimethylkaempferol	0
3-nitropropanoic acid	73
5alpha-epoxyalantolactone	0
antitubercular agent +	845
azadiradione	4
bauhinoxepin A	0
bauhinoxepin B	0
bauhinoxepin F	0
bauhinoxepin I	0
bauhinoxepin J	0
canthin-6-one	0
caseargrewiin A	0
caseargrewiin B	0
caseargrewiin C	0
caseargrewiin D	0
cordyol C	0
dehydrocostus lactone	9
ergosterol peroxide	1
hirsutellide A	0
leprostatic drug +	824
linsitinib	0
mollicellin K	0
nothramicin	0
physalin D	0
sakuranetin	1
scleropyric acid	0
tetrahydroxysqualene	0
undecanal	4
viridiflorol	0

paths to the root